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ABSTRACT
Understanding the mechanisms through which proteins acquire their three
dimensional structure is currently one of the most challenging tasks in
structural biology. The formation of native disulfide bonds is an important
step in the post-translational modification and folding of many proteins,
helping to stabilise their structure. Protein disulfide isomerase (PDI) is a
folding enzyme that catalyses thiol-disulfide exchange. As well as forming
disulfide bonds in newly synthesised proteins, PDI also catalyses the
rearrangement of intramolecular disulfides. The mechanisms through which
PDI binds to substrate proteins are still not well understood.
In this study, interactions are examined between PDI and a model substrate
protein, bovine pancreatic trypsin inhibitor (BPTI). Since PDI functions
primarily as a folding enzyme its natural substrates will be unfolded or partly
folded proteins. Here, recombinant BPTI constructs were prepared that
represented different stages along the folding pathway of this small protein:
unfolded, partly folded and natively folded BPTI.
A variety of biophysical techniques were then used to characterise each
BPTI construct, both in isolation and in the presence of PDI. NMR spectra
obtained at 5°C, including hydrogen deuterium exchange experiments,
demonstrated the unfolded, partly folded and natively folded nature of each
construct at low temperatures. The addition of PDI to each BPTI construct
showed that, even at sub-stoichiometric concentrations, both the unfolded
and partly-folded substrate proteins showed line broadening. In contrast, line
broadening of natively folded BPTI required much higher concentrations of
PDI.
NMR was also used to observe the effects of differently folded BPTI
substrates binding to PDI. Focus was on the key bb’x binding region of PDI.
Perturbations were observed even at low concentrations of unfolded and
partly-folded substrate, whereas much larger concentrations were required
for the natively folded protein. However, detailed investigations into the
specific regions of binding suggest that the same key sites were involved at
all stages of folding. Contrary to expectations, this small full length protein
showed little binding to regions beyond the key b’ domain.
The binding affinities between PDI and each BPTI substrate were estimated
using surface plasmon resonance (SPR). As expected, PDI has a greater
binding affinity to unfolded BPTI compared to the partly folded construct, with
least affinity to the natively folded protein. However, the difference in affinity
between unfolded and partly folded constructs was relatively small.
This is the first study to investigate the structural interaction of PDI with a
partly folded, full length protein substrate. It is hoped that the findings of this
study will contribute to a general understanding of oxidative protein folding in
the endoplasmic reticulum (ER).
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Chapter 1. Introduction
This chapter introduces some general concepts involved in the study of protein
folding, with an emphasis on the machinery used to facilitate folding in the
endoplasmic reticulum (ER). The processes of oxidation and isomerisation of
disulfide bonds are introduced along with protein disulfide isomerase (PDI), an
important enzyme in catalysing these processes. As well as its function in
catalysing thiol-disulfide exchange, an outline of the other functions of PDI is
given. Different domains of PDI play interdependent roles in the structure and
function of PDI. Current understanding of each domain is discussed.
PDI is the archetypal member of the PDI family of proteins. Current
understanding of this family is introduced together with many of its member
proteins. This family is part of the wider thioredoxin superfamily, which is also
briefly introduced.
As well as PDI, the process of oxidative folding in the ER involves other proteins
and chemicals used to deal with oxidising equivalents. The pathways involved
are not clearly understood, but recent studies in this area are introduced.
Bovine pancreatic trypsin inhibitor (BPTI) is a model substrate protein for
studies of PDI activity. This small protein is introduced along with its well
characterised folding pathway. Previous studies involving PDI/BPTI interaction
are reviewed.
The main biophysical technologies used in this study were NMR spectroscopy
and surface plasmon resonance. The use of these techniques for studying
protein structures and binding interactions are outlined.
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Finally, the aims and scope of this study will be outlined, indicating the manner
in which PDI/BPTI interactions will be studied using these technologies.
1.1. The Protein Folding Energy Landscape
In order to function correctly, most proteins require a specific three dimensional
structure. Some of the earliest studies into folding showed that the polypeptide
chain contains all the necessary information to specify its three dimensional
conformation (Anfinsen 1973). However, despite an incredibly large number of
possible conformations, proteins manage to achieve their natively folded state in
an incredibly short timescale (Kubelka, Hofrichter et al. 2004). It has been
demonstrated that many newly synthesised proteins require assistance to reach
their folded states within a biologically relevant timescale (Hartl 1996). The
mechanism by which they achieve this has been an immensely difficult problem,
spanning many decades of study (Fersht 2008).
The folding of proteins is often described by a funnelling energy landscape,
whereby they seek a conformational state that minimises their free energy,
thereby increasing their stability (Bryngelson, Onuchic et al. 1995; Onuchic and
Wolynes 2004), Figure 1.1. The ruggedness of the energy landscape arises due
to the fact that protein structures are stabilised by thousands of weak
interactions that cannot all be satisfied simultaneously during folding (Bartlett
and Radford 2009).
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Figure 1.1: Schematic representation of a protein folding funnel energy landscape,
modified from (Bartlett and Radford 2009). Nascent chain polypeptides can initially
explore a wide range of conformations. Certain conformations occupy a lower energy
state and are more stable, representing intermediates in the folding pathway. Often
intermediates create an energy barrier that must be overcome before folding can proceed
(e.g. some localised unfolding). The native state is usually the lowest energy and most
stable state.
During the folding process, many metastable intermediates often include non-
native interactions, which need to be overcome before the native state can be
achieved (Hartl and Hayer-Hartl 2009). Although small single chain proteins can
show distinct intermediates during protein folding (Creighton 1992), intermediate
states are even more relevant to large proteins, which have a greater tendency
to collapse into non-native conformations due to exposure of hydrophobic
regions in an aqueous environment (Brockwell and Radford 2007).
Chapter 1: Introduction
4
In a cell folding occurs in a crowded environment, so unfolded or partly folded
proteins are much more likely to aggregate compared to the relatively dilute
conditions of most in vitro studies (Ellis and Minton 2006). However, the cellular
environment also includes many molecular chaperones, which serve to prevent
protein misfolding or aggregation (Ellis 2001; Saibil 2008).
Recent studies suggest that during the protein folding process molecular
crowding appears to favour compact rather than expanded conformations
(Charlton, Barnes et al. 2008; Engel, Westphal et al. 2008; Zhou, Rivas et al.
2008). To facilitate our understanding, molecular dynamic simulations of protein
folding have recently begun to use bulk solvents that account for the
macromolecular environment of the cell, including parameters of spatial
confinement and molecular interactions (Cheung and Thirumalai 2007; Mittal
and Best 2008; Echeverria and Kapral 2010).
1.2. Protein Folding in the Endoplasmic Reticulum
In eukaryotic cells, proteins destined for surface membranes or secretion must
first enter the endoplasmic reticulum (ER) in an unfolded state and only exit
once they have correctly folded and assembled. This process is performed for
an estimated 33% of all human proteins (Chen, Zhang et al. 2005).
The main function of the ER is to perform post-translational modifications and
folding of proteins. These processes are highly regulated, with the ER
containing a wide variety of catalysts for both post-translational modifications,
such as N-glycosylation (Helenius and Aebi 2004), and for protein folding, such
as disulfide bond formation (Sevier and Kaiser 2002).
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Figure 1.2: Schematic of protein folding and degradation pathways in the endoplasmic
reticulum (Ma and Hendershot 2004). a) Secretory proteins are translocated into the ER
lumen co-translationally through translocons in the ER membrane. b) Chaperones such
as BiP and calnexin bind to nascent chain proteins, preventing misfolding or aggregation
while monitoring glycosylation. Protein disulfide isomerase (PDI) facilitates the formation
of disulfide bonds to stabilise the folded protein. c) Natively folded proteins exit the ER
through transport vesicles. d) If a protein becomes misfolded, it will be targeted for
degradation by the proteasome. e) If unfolded proteins accumulate, the unfolded protein
response (UPR) is initiated by ER-stress sensors (IRE1, PERK, ATF6). SRP, signal-
recognition particle; PERK, PKR-like ER kinase.
First, proteins are translated on membrane-bound polysomes and translocated
in an extended, unfolded state through the translocon, a proteinaceous channel
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in the ER membrane (Ma and Hendershot 2004), Figure 1.2a. These newly
synthesised protein molecules are not immediately physiologically functional;
they require folding into their native state.
Immediately as proteins are synthesised they begin to fold co-translationally in
the ER, with folding being completed post-translationally. This combination has
been shown to enhance the folding efficiency of proteins, particularly with multi-
domain proteins (Netzer and Hartl 1997).
Unfolded or partially folded proteins in the ER have exposed hydrophobic
regions, so are prone to aggregation. Small aggregates are potentially cytotoxic,
so a quality control method preventing their accumulation is essential (Ellgaard
and Helenius 2003). Chaperones are able to recognise proteins in this state,
interact with them and prevent their aggregation (Fewell, Travers et al. 2001). A
chaperone system exists in the ER that associates with the newly synthesised
proteins to prevent their aggregation and help them fold and assemble correctly
(Ellgaard, Molinari et al. 1999; Ma and Hendershot 2004), Figure 1.2b. The ER
is also an oxidising and Ca2+-rich environment, which facilitates the addition of
N-linked glycans and disulfide bonds to proteins during their maturation
(Ellgaard and Helenius 2001).
One set of chaperones are the lectin proteins calnexin (CNX) and calreticulin
(CRT). Calnexin is a transmembrane protein whereas calreticulin is a soluble
luminal protein (Jessop, Tavender et al. 2008). Lectins interact with
glycoproteins, but CNX and CRT only specifically interact with glycoproteins that
have monoglucosylated N-glycans (Hammond and Helenius 1994). They
function to retain non-natively folded glycoproteins in the ER via a quality control
system known as the calnexin/calreticulin cycle. This cycle is a multifunctional
system, responsible for promoting the folding of glycoproteins, retaining non-
native glycoproteins in the ER until they are correctly folded and targeting
misfolded glycoproteins for degradation (Helenius and Aebi 2004).
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When some nascent polypeptide chains enter the ER lumen, a process of N-
linked glycosylation occurs via transfer of a triglucosylated, branched core
oligosaccharide (Ellgaard and Helenius 2001). The calnexin/calreticulin cycle is
initiated by the removal of two glucose residues by the sequential action of
glucosidases I and II, generating a monoglucosylated glycoprotein. The
remaining glucose effectively acts as a selective tag for incompletely folded
proteins. The monoglucosylated glycoprotein then interacts with calnexin and
calreticulin (Ellgaard and Helenius 2003). If disulfide bond formation is required,
both chaperones can associate with the PDI family protein ERp57, via an
extended domain known as the P domain (Solda, Garbi et al. 2006). The
remaining glucose is cleaved by glucosidase II, which results in dissociation of
calnexin and calreticulin. If natively folded, glycoproteins can exit the ER.
However, non-native glycoproteins become substrates of UDP-
glucose:glycoprotein glucosyltransferase (UGGT), which places a single
glucose back on the glycan. This again targets the glycoprotein as a substrate
for calnexin and calreticulin. UGGT effectively acts as a sensor of glycoprotein
conformations. The deglucosylation-reglucosylation cycle continues until proper
folding is achieved (Parodi 2000). A protein can only exit the cycle when UGGT
fails to re-glucosylate it, either when its native conformation has been achieved
or if the glycoprotein becomes targeted for degradation (Ellgaard and Helenius
2003). Overall, CRT and CNX together with glucosidase II and UGGT cooperate
to increase the folding efficiency, to prevent premature oligomeric assembly and
to prevent the export of misfolded glycoproteins from the ER (Ellgaard and
Helenius 2001).
Another ER chaperone known as BiP belongs to the Hsp70 family of proteins
(Flynn, Pohl et al. 1991). These proteins use ATP and ADP to regulate the
binding and release of nascent proteins in an ATPase cycle (Bukau and
Horwich 1998). During these cycles of binding and release, aggregation or
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inappropriate interactions are prevented by BiP binding, whereas protein folding
occurs during release (Hendershot, Wei et al. 1996).
The formation of native disulfide bonds is carried out by the ubiquitously
expressed protein disulfide isomerase (PDI). Disulfide bonds in proteins are
formed as covalent bonds between the thiol groups of two cysteine residues.
Their main function is to stabilise protein structure. The formation of disulfide
bonds requires an oxidising environment. Although precise figures vary, it is
known that the ER is much more oxidising than the cytosol and provides an
environment suitable for creating disulfide bonds (Raines 1997). By catalysing
the oxidation and isomerisation of disulfide bonds, PDI can increase the rate of
native disulfide bond formation by a factor of between 1000 to 6000 (Freedman,
Hirst et al. 1994).
If the secretory protein is correctly folded, then it is transported out of the ER via
transport vesicles and continues on the secretory pathway via the Golgi, Figure
1.2c. Alternatively, proteins that do not mature properly are removed from the
folding pathway and targeted to the ER-associated degradation (ERAD)
pathway, Figure 1.2d. This involves translocation to the cytosol for degradation
by the proteasome, which requires both ER and cytosolic chaperones (Brodsky,
Werner et al. 1999).
Alterations in any aspect of the ER environment can lead to the accumulation of
unfolded proteins, which are prone to aggregation, and could interfere with the
normal functioning of the ER (Lee 1992). When adverse physiological conditions
that impact on protein folding are encountered in the ER, a signal-transduction
cascade is activated, known as the unfolded protein response (UPR), Figure
1.2e. This serves to limit the accumulation of unfolded proteins and preserve the
solubility of those that are present so that they can be targeted for degradation
(Ma and Hendershot 2004). This coordinated response is an efficient method of
maintaining a careful balance between retaining and degrading harmful proteins
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while continuing the export of biologically active and essential proteins (Sitia and
Braakman 2003).
Prolonged activation of the UPR, if failing to clear the ER of a high concentration
of harmful mis-folded or mis-assembled proteins, results in the activation of
apoptosis, which can serve to protect the host organism (Otomo, Ito et al. 1999).
1.3. Thiol Oxidation and Isomerisation of Disulfide Bonds
A vital step in the protein folding process is the formation of disulfide bonds
between cysteine residue side chains. It occurs in the periplasm of Gram-
negative bacteria and in the ER of eukaryotic cells. Figure 1.3 illustrates the
initial oxidation of cysteine thiol groups to form disulfide bonds in a polypeptide
chain, followed by a subsequent thiol-disulfide interchange (isomerisation)
resulting in a different disulfide bonding configuration.
Figure 1.3: Thiol oxidation and isomerisation of disulfide bonds (Sevier and Kaiser 2002).
Early research into protein folding revealed that disulfide bond formation could
occur spontaneously (Anfinsen 1973). However, disulfide bond formation
occurred much more slowly in vitro compared to the environment of the cell.
This suggested that enzymes may be involved in catalysing oxidative protein
folding.
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1.4. Protein Disulfide Isomerase
Protein disulfide isomerase (PDI) (E.C. 5.3.4.1, Swiss-Prot accession number
P07237) is a multifunctional protein, able to catalyze disulfide bond formation,
breakage, and rearrangement in all studied non-native protein and peptide
substrates. Human PDI is encoded by the P4HB (prolyl 4-hydroxylase, beta
polypeptide) gene (GeneID 5034). It is an ER localised protein with a KDEL ER
retrieval motif (Pelham 1990). It is present in high concentrations (Lambert and
Freedman 1985) and highly expressed in secretory tissues such as the liver and
pancreas. In addition to its role in disulfide bond formation, PDI acts as a
molecular chaperone (Cai, Wang et al. 1994) and forms the β-subunit of prolyl-
4-hydroxylase (Koivu, Myllyla et al. 1987) and microsomal triglyceride transfer
protein (Wetterau, Combs et al. 1991).
Christian Anfinsen and his group first identified the enzymatic acceleration of
protein reactivation from reduced protein in 1963 (Goldberger, Epstein et al.
1963). They were later able to demonstrate that these enzymes could catalyse
thiol-disulfide exchange reactions (Givol, Goldberger et al. 1964; Goldberger,
Epstein et al. 1964; Givol, Delorenzo et al. 1965). Independently, another group
also discovered the role of enzymes in disulfide bond formation (Venetianer and
Straub 1963). PDI was purified from beef liver and confirmed as an enzyme
which catalysed sulfhydryl-disulfide interchange in proteins (De Lorenzo,
Goldberger et al. 1966), making it the first identified catalyst of protein folding.
However, its current name was not used until 1975 (Hawkins and Freedman
1975). Later, PDI localisation to the ER was confirmed (Lambert and Freedman
1985) and was shown to exist in high concentrations (Hillson, Lambert et al.
1984). The sequence of rat PDI suggested a high degree of homology to the
thioredoxin protein (Edman, Ellis et al. 1985; Creighton 1995a).
PDI degrades insulin by cleavage of the disulfide bonds using glutathione as a
reducing agent and therefore was also known as glutathione-insulin
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transhydrogenase (Noiva, Kimura et al. 1991). This function was originally
thought to be performed by a separate enzyme (Hillson and Freedman 1980),
but later glutathione-insulin transhydrogenase and PDI were identified as being
the same protein (Bjelland, Wallevik et al. 1983).
1.4.1. PDI Catalysis of Thiol-disulfide Exchange
The principal function of PDI is as a thiol-disulfide oxidoreductase. PDI can
catalyse three types of thiol-disulfide exchange reactions: oxidation, reduction
and isomerisation, illustrated in Figure 1.4. These reactions involve the active
sites of either the a or a’ domains of PDI, which are defined by the amino acid
sequence CGHC.
The oxidation of a substrate by PDI converts a substrate dithiol to a disulfide
state (Figure 1.4A). The N-terminal active site cysteine thiolates are more
reactive, so tend to form the mixed disulfides with the substrate. To complete
the catalytic cycle, PDI needs to be reoxidised, e.g. using oxidised glutathione.
The reduction of a substrate by PDI converts a substrate disulfide bond into the
dithiol state (Figure 1.4B). This reaction also involves an intermediate mixed
disulfide between PDI and the substrate. The process oxidises PDI and to
complete the catalytic cycle PDI needs to be returned to its reduced state, e.g.
using reduced glutathione.
The isomerisation of a substrate by PDI involves the rearrangement of disulfides
and thiols resulting in a substrate with a different configuration of disulfide bonds
(Figure 1.4C). This can be achieved either via a single mixed disulfide (direct
isomerisation), or via a combination of reduction and oxidation reactions by PDI.
The isomerisation of disulfide bonds is an especially important role for PDI,
since this process is often the rate limiting factor in protein folding (Huth, Perini
et al. 1993; Land, Zonneveld et al. 2003).
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Figure 1.4: Schematics of the thiol-disulfide exchange reactions catalysed by PDI,
modified from (Hatahet and Ruddock 2009). A) PDI oxidation of a peptide dithiol (reaction
1). Oxidised glutathione can then act as an electron acceptor to re-oxidise PDI (reaction
2). B) PDI reduction of a peptide disulfide. Reduced glutathione or NADPH (catalysed by
thioredoxin reductase) can act as electron acceptors to reduce PDI. C) PDI isomerisation
of peptide disulfide bonds. Isomerisation can take place either directly or via reduction-
oxidation cycles. Thiol species are shown in their predominant ionisation state.
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1.5. The Thioredoxin Superfamily
PDI contains four domains with the thioredoxin structural motif, and as such is
classified as being a member of the thioredoxin superfamily (Appenzeller-
Herzog and Ellgaard 2008). The thioredoxin fold consists of a four stranded β-
sheet surrounded by three α-helices in a βαβαββα configuration (Martin 1995),
Figure 1.5A. The protein of the same name consists of the thioredoxin fold, with
an additional N-terminal βα, resulting in a βαβαβαββα configuration, Figure 1.5B
(Weichsel, Gasdaska et al. 1996). The thioredoxin protein is a small 12 kDa
protein found in all species (Powis and Montfort 2001). It is common to many
protein families associated with sulfur-based redox reactions, including PDI,
glutaredoxin and DsbA. Most of these enzymes contain a conserved active site
motif of the form Cys-X-X-Cys, with the two intervening residues of the motif
varying between families (Eklund, Gleason et al. 1991). There are also several
charged residues surrounding the active site motif which are thought to
influence its reactivity (Gruber, Cemazar et al. 2006).
Figure 1.5: The thioredoxin fold in the protein thioredoxin. A) structure of the thioredoxin
fold, illustrating its βαβαββα configuration, modified from (Gruber, Cemazar et al. 2006);
B) structure of the reduced human thioredoxin protein, which consists of the thioredoxin
fold plus an additional βα at the N-terminus, PDB ID 1ERT (Weichsel, Gasdaska et al.
1996).
A B
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1.6. Domain Architecture of PDI
The cDNA of PDI was first sequenced in 1985 from rat liver (Edman, Ellis et al.
1985). It encoded a total of 508 amino acids, which includes an N-terminal ER
signal sequence and a C-terminal ER retention sequence. The mature protein is
491 amino acids long.
The current multi-domain architecture of PDI has been proposed using a
combination of sequence similarities, comparing with superfamily members (e.g.
thioredoxin) and experimental data, including proteolysis and expression of
putative domains and domain combinations (Freedman, Gane et al. 1998;
Alanen, Salo et al. 2003). The model has four distinct structural domains, a, b, b’,
and a’, a highly acidic C-terminal extension and a 19 amino acid flexible
interdomain region between the b’ and a’ domains, known as the x linker
(Kemmink, Darby et al. 1997; Freedman, Gane et al. 1998), Figure 1.6. The
catalytic activity of PDI depends on the CGHC motif in the a and a’ domains.
The catalytic a and a’ domains are separated by two non-catalytic b and b’
domains as well as the x-region.
Figure 1.6: Human PDI domain architecture. Numbers indicate domain boundaries, with
residue numbers representing mature human PDI (Sidhu 2008).
Despite intense efforts, no high resolution structure of full length human PDI has
been achieved, although low resolution data has been achieved through small
angle X-ray scattering of PDI in solution (Li, Hong et al. 2006). However, the
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structures of isolated domains and domain combinations have been solved.
These include the a domain, PDB ID 1MEK (Kemmink, Darby et al. 1996); the a’
domain, PDB ID 1X5C (Tochio, Koshiba et al. Unpublished); the b domain, PDB
ID 2BJX (Kemmink, Darby et al. 1997); the b’x construct, PDB ID 3BJ5 (Nguyen,
Wallis et al. 2008); the bb’ construct, PDB ID 2K18 (Denisov, Maattanen et al.
2009).
The solved structures of all four structural domains show that they each contain
a thioredoxin fold. Hence, it has been postulated that these domains evolved
from internal gene duplication, which have since lost sequence similarity but
retained the overall domain fold. Studies on the molecular evolution of PDI
suggested that it evolved from an ancestral thioredoxin-like double domain
protein (Kanai, Toh et al. 1998; McArthur, Knodler et al. 2001).
A crystal structure for yeast PDI (Pdi1p) was recently published at 2.4 Å
resolution, PDB ID 2B5E (Tian, Xiang et al. 2006), Figure 1.7. This has helped
to establish a more detailed picture of the structure of human PDI. The structure
contained one molecule of Pdi1p occupying the putative substrate-binding site
of another molecule. It shows the four domains in a twisted U shape.
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Figure 1.7: Ribbon diagram of Pdi1p, from PDB ID 2B5E (Tian, Xiang et al. 2006),
illustrating its ‘twisted U’ structure. Each domain is labelled, along with the interdomain x
linker.
In Pdi1p, the a and a’ domains form the outstretched arms, with their catalytic
sites facing one another across the cleft. The b and b’ domains lie between the
two catalytic domains, with the b domain displaced perpendicular to the plane of
the molecule. The contact areas between the catalytic and non-catalytic
domains (surface area ~200 Å2) are small compared to the large contact area
formed between the two non-catalytic domains (surface area ~700 Å2). This
provides a model whereby the two catalytic domains are flexible around a more
rigid base formed by the b and b’ domains (Tian, Xiang et al. 2006).
The catalytic a and a’ domains contain hydrophobic patches surrounding the
active sites, which appear to form internal hydrophobic surfaces lining the
interior, suggesting sites for substrate binding. The yeast PDI structure also
shows a hydrophobic pocket in the b’ domain facing the catalytic sites (Tian,
Xiang et al. 2006). These hydrophobic regions are illustrated in Figure 1.8.
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Figure 1.8: Surface diagram of Pdi1p, highlighting electrostatic potentials, from PDB
2B5E (Tian, Xiang et al. 2006). Red, acidic regions; blue, basic regions, yellow, non-polar
regions. The top image has the same orientation as the ribbon diagram in Figure 1.7, with
domains labelled; the bottom image has been rotated through 90°. A large non-polar
region in the b’ domain indicates the hydrophobic pocket thought to act as the main
substrate binding region. Smaller non-polar regions in the a and a’ domains indicate the
hydrophobic patches surrounding the active sites.
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1.6.1. The Catalytic Thioredoxin Domains of PDI
The catalytic a and a’ domains share 36.8% identity with each other. They also
have significant similarity with thioredoxin, 41% sequence similarity with the a
domain and 32% with the a’ domain. However, they have little similarity to the b
and b’ domains.
Using a redox assay with short peptide substrates, both the isolated a and a’
domains were shown to have redox properties lying between a strong reductant
(e.g. thioredoxin) and strong oxidant (e.g. DsbA) (Darby and Creighton 1995).
These individual domains could act as either a reductant or oxidant, depending
on the substrate and redox environment.
Both catalytic domains of human PDI have a CGHC active site motif. The active
sites lie in such a way that the N-terminal active-site cysteine is more exposed,
whereas the C-terminal active-site cysteine has limited solvent exposure.
During the process of disulfide bond formation, cysteines in the deprotonated
state act as much better nucleophiles than when protonated. Hence, the pKa
values of cysteine residues are important in understanding catalysed disulfide
bond formation (Karala, Lappi et al. 2010).
Studies have revealed that the pKa of the N-terminal cysteine is in the range 4.4
to 6.7 (Hawkins and Freedman 1991; Kortemme, Darby et al. 1996; Ruddock,
Hirst et al. 1996), considerably lower than the normal pKa of a protein cysteine
thiol, which averages around 8.3 (Bulaj, Kortemme et al. 1998). This results in
the active thiolate state predominating at physiological pH. In contrast, the C-
terminal active-site cysteine reportedly has a high pKa (Hawkins and Freedman
1991; Nelson and Creighton 1994), resulting in the less active thiol state
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predominating at physiological pH. Overall, this leads to less stable disulfide
bonds being formed in PDI than in thioredoxin, which may explain the more
oxidative nature of PDI. A recent study revealed that the side chains of Arg120,
close to the a domain active site, and the corresponding Arg461, close to the a’
domain active site, provide mechanisms to modulate the pKa of the C-terminal
active site cysteines (Karala, Lappi et al. 2010). It is believed that this has
evolved to enable PDI to efficiently catalyse both oxidation and isomerisation
reactions.
Activity observed using full length PDI on larger substrates, which require
complex isomerisation, was not observed with individual a or a’ domains,
leading to the conclusion that other domains of PDI are required for these
complex reactions (Darby and Creighton 1995).
1.6.2. The Non-Catalytic Thioredoxin Domains of PDI
Unlike the a and a’ domains, the b and b’ domains do not have the conserved
thioredoxin–like active site residues. Therefore, these domains do not have
oxidoreductase capability.
Structural alignment shows that the b and b’ domains have only 19.3% identity
to each other. It also reveals only 13% sequence identity between the a and b
domains (Hatahet and Ruddock 2009). Despite showing only 27% sequence
similarity to thioredoxin, the structure of the b domain indicates a thioredoxin-like
fold (Kemmink, Dijkstra et al. 1999) and although the b’ domain shows little
sequence similarity with either the a or b domains, it too has a thioredoxin-like
fold (Nguyen, Wallis et al. 2008).
The b’ domain has been proposed as the main site of peptide binding for some
time (Klappa, Ruddock et al. 1998). More recently, residues within the b’ domain
Chapter 1: Introduction
20
of PDI were found to form a hydrophobic pocket involved in substrate binding
(Byrne, Sidhu et al. 2009). This conserved binding pocket is also the primary
region for substrate binding in other PDI family members (Ellgaard and Ruddock
2005) and is highlighted in the structure of yeast PDI (Pdi1p) in Figure 1.8. In
contrast, the b domain has a much less direct role in substrate binding and is
thought to have a mainly structural function, helping to stabilise and orientate
the other domains.
Several studies have revealed that although the b’ domain is essential for
binding small peptides, other domains are required to bind larger substrates
(Klappa, Ruddock et al. 1998; Wang, Wang et al. 2008).
1.6.3. Interdependence of PDI Thioredoxin Domains
In isolation, the catalytic a and a’ domains are capable of catalysing simple thiol-
disulfide exchange reactions, but show greatly reduced isomerase activity
compared to the full length protein. For isomerisation reactions, it has been
shown that the non-catalytic domains are also required. The b’ domain in
particular has been shown to be very important for isomerisation activity (Darby,
Penka et al. 1998). The PDI fragment b’a’c was shown to be the minimum
domain combination required that is able to catalyse disulfide bond
rearrangement (Wang, Wang et al. 2008), illustrating the importance of the b’
domain to the isomerase function of PDI. Furthermore, it was found that
complex isomerisation reactions required all four PDI domains but did not
require the C-terminal extension. This indicates a synergic relationship between
all the thioredoxin domains of PDI in order to perform complex dithiol-disulfide
oxidoreductase activity (Freedman, Klappa et al. 2002).
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1.6.4. The x Region
The 19 residue x region of PDI provides a flexible link between the b’ domain
and the a’ domain, making it the longest region between the four thioredoxin
domains (Freedman, Gane et al. 1998). A recent study showed that the x region
allowed PDI to adopt two distinct conformations (Byrne, Sidhu et al. 2009). In
one conformation, known as the “capped” conformer, the x region covers the
substrate binding site; in the other conformation, known as the “uncapped”
conformer, the x region moves to expose the binding site (for illustration see
Figure 6.3 in Section 6.2.4). A similar dynamic conformational exchange has
been suggested for other PDI family members (Wang, Wang et al. 2008).
Peptide ligands were shown to compete with x for binding, suggesting that x
functions to gate access to the principal ligand-binding site of the b’ domain
(Byrne, Sidhu et al. 2009). The change in conformation also leads to a
significant movement between the a’ and b’ domains, which could assist in
inducing conformational changes in substrate proteins (Hatahet and Ruddock
2009).
1.6.5. The C-terminal Extension
The C-terminal extension of PDI forms an α-helix consisting of 29 residues,
many of which are either glutamate or aspartate (Pihlajaniemi, Helaakoski et al.
1987). The functional importance of this acidic extension is not known, but it has
been reported to have a low-affinity, high capacity calcium ion binding site
(Macer and Koch 1988). The extension also contains the amino acid sequence
KDEL, which is essential to retain PDI within the ER lumen. The isomerisation
function of PDI does not require the C-terminal extension (Klappa, Ruddock et
al. 1998). However, it is thought to stabilise the conformation of the a’ domain
through hydrophobic contacts (Tian, Xiang et al. 2006).
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1.7. The PDI Family
For some time the PDI protein was considered to be the only enzymatic catalyst
of thiol-disulfide exchange reactions in the ER. However, it is now known that
PDI is just one protein in an ever-growing family. The PDI family, as it became
known, is named after its archetypal and most abundant member, the PDI
protein (Hatahet and Ruddock 2009). The PDI family of proteins are a subfamily
of the thioredoxin superfamily.
PDI family members are believed to be the only enzymes which catalyse
complex rate limiting isomerisation reactions (Weissman and Kim 1993).
Proteins are classified as members of the family based on their structure,
sequence similarity and ER localisation, rather than by physiological function. All
contain at least one domain with a thioredoxin-like fold, which can be catalytic or
non-catalytic in function. They also contain a cleavable N-terminal ER targeting
signal sequence. Most PDI family members are ER localised with the aid of a C-
terminal KDEL ER retention signal, or a similar variant of this motif. Since all
PDI family members have distinct features and differing tissue distribution, they
are all likely to have distinct physiological functions, although these may partially
overlap (Hatahet and Ruddock 2009). This is supported by evidence that yeast
PDI family members are not functionally interchangeable (Norgaard, Westphal
et al. 2001).
Different organisms have different subfamilies of PDI. Whilst some clearly have
functions similar to orthologs in other species, such as human PDI and yeast
Pdi1p, many appear to be unique to a subset of organisms. Only 5 PDI family
members have been identified in S. cerevisiae, whereas 20 have currently been
defined in humans (Hatahet and Ruddock 2009), see Figure 1.9.
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Figure 1.9: Illustration of human PDI family members. Yellow, catalytic domains likely to
have a thioredoxin-like fold, with their active-site sequence inset; blue, non-catalytic
domains likely to have a thioredoxin-like fold; red, transmembrane regions (Hatahet and
Ruddock 2009).
Although detailed characterisation has yet to be undertaken on many PDI family
members, it appears that only a small subset combine a generalised substrate
binding domain with a catalytic domain, a combination that has been shown to
be essential for efficient isomerisation by PDI (Darby, Penka et al. 1998). Indeed,
many members of the PDI family (e.g. ERp27) do not have any active sites
(Alanen, Williamson et al. 2006). Hence, perhaps the classification or
nomenclature of this family of ER resident folding catalysts needs to be re-
evaluated.
The only two human PDI family members that show the same domain
architecture as PDI, i.e. abb’a’c, are ERp57 and PDIp. They all have two
catalytically active a and a’ domains with similar active site residues, see Figure
1.9. Other than PDI itself, ERp57 is the most characterised of all the PDI family
members (Ferrari and Soling 1999).
Most PDI family proteins show a broad distribution of expression. However, two
notable exceptions in humans are PDIp and PDILT. PDIp was reported to be
expressed solely in acinar cells of the pancreas (DeSilva, Lu et al. 1996;
Chapter 1: Introduction
24
DeSilva, Notkins et al. 1997), while PDILT expression is highly specific to the
testes after puberty and is the only PDI family member to show developmental
control (van Lith, Hartigan et al. 2005; van Lith, Karala et al. 2007).
An interesting subset of the PDI family is the thioredoxin-related transmembrane
proteins, which span the membrane of the ER. Five human transmembrane PDI
family members have been proposed and their transmembrane regions
identified, see Figure 1.9 (named with TMX prefix). All have type I
transmembrane protein ER localisation signals (Appenzeller-Herzog and
Ellgaard 2008), although only three of these have been published: TMX (Matsuo,
Akiyama et al. 2001), TMX2 (Meng, Zhang et al. 2003) and TMX3 (Haugstetter,
Blicher et al. 2005). Hence, there is a lot of scope to increase understanding of
these ER resident, membrane bound proteins.
Another interesting human PDI family member is ERdj5. It is the only family
member to contain a DnaJ domain (labelled J domain in Figure 1.9) (Cunnea,
Miranda-Vizuete et al. 2003). This domain associates with BiP (an Hsp70
chaperone), thus implying a role for ERdj5 in ER-associated degradation (ERAD)
(Hosoda, Kimata et al. 2003). Recent studies have revealed details of this role,
which requires both the DnaJ domain and the redox activity of the catalytic
domains for reductase activity of misfolded ER proteins (Dong, Bridges et al.
2008; Ushioda, Hoseki et al. 2008).
Until 2006, calsequestrin was the closest protein to PDI to have a full three
dimensional structure (Wang, Trumble et al. 1998). It is a 40 kDa protein
consisting of three thioredoxin-like domains and is involved in the regulation of
Ca2+ ion channels in the sarcoplasmic reticulum of muscle cells (Kawasaki and
Kasai 1994).
Although no structure for full length human PDI has been achieved, a full length
structure of PDI from Saccharomyces cerevisiae (yeast) has been solved by X-
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ray crystallography (Tian, Xiang et al. 2006). Like human PDI, yeast PDI (Pdi1p)
incorporates all four thioredoxin domains, see Figure 1.10.
Figure 1.10: Alignment of human and yeast PDI domains. a) Domains showing boundary
residues and residue numbers for mature human PDI, aligned with the homologous
regions of yeast PDI. Residues flanking the active sites in the a and a’ domains are
highlighted. b) Crystal structure of yeast PDI (Pdi1p), PDB ID 2B5E. Active sites are
highlighted green. Figure from (Gruber, Cemazar et al. 2006).
Sequence similarity between PDI and Pdi1p is high, so the structure has
provided valuable insight into its human ortholog. The hydrophobic cleft is
speculated to be large enough to accommodate a folded protein of
approximately 100 residues, a figure which is important to consider when
studying the interaction of PDI and substrate proteins (Tian, Xiang et al. 2006).
More recently, three crystal structures of human PDI family members have been
solved. The small ERp29 protein (also known as ERp28) was resolved to 2.9 Å
resolution (Barak, Neumann et al. 2009). ERp29 is an exceptional member of
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the human PDI family in that as well as having a non-catalytic thioredoxin-like
domain it also has a non-thioredoxin, entirely helical domain at its C-terminus,
termed the D-domain (Liepinsh, Baryshev et al. 2001). It is very similar in
structure and function to its ortholog Wind protein, a PDI-related protein found in
Drosophila melanogaster (Lippert, Diao et al. 2007).
A crystal structure of ERp57 was recently solved in a complex with the substrate
protein tapasin, to a 2.6 Å resolution (Dong, Wearsch et al. 2009). This is
particularly interesting, given that ERp57 is a human PDI family member that
shares the same domain architecture as PDI. Since its structure is solved with a
bound natural substrate, this provides useful information about the nature of
enzyme-substrate binding for all PDI family members. ERp57 is known to act in
a complex to catalyse disulfide bond isomerisation specifically in N-glycosylated
protein substrates (Russell, Ruddock et al. 2004). A knockout of ERp57 was
found to be lethal in embryonic mice (Garbi, Tanaka et al. 2006). However,
knockout of ERp57 in individual cells showed that very few proteins were
affected (Solda, Garbi et al. 2006), indicating that ERp57 is involved in the
folding of very few proteins or that other PDI family members are able to
compensate for it.
A crystal structure of ERp44 was recently solved to 2.6 Å resolution (Wang,
Wang et al. 2008). The protein consists of three thioredoxin-like domains (a, b
and b’), with a C-terminal extension (Figure 1.9). The structure shows that the
three thioredoxin domains form a clover shape, with the C-terminal extension
occluding the substrate binding site and partially shielding the active site. It is
thought that the C-terminus may act to mediate substrate access to the enzyme
(Wang, Wang et al. 2008). ERp44 was initially identified as a ER-located binding
partner for Ero1 (Anelli, Alessio et al. 2002). However, despite having a RDEL
ER retention motif (Raykhel, Alanen et al. 2007), ERp44 is an unusual PDI
family member in that it has since been reported to be co-localised to the ER,
ER-Golgi intermediate compartment and cis-Golgi (Gilchrist, Au et al. 2006).
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Interestingly, its only active site has an unusual motif, CRFS, since it lacks the
C-terminal cysteine. It has been proposed that the absence of a second
cysteine allows mixed disulfides between ERp44 and its substrate to persist for
much longer, thus facilitating its proposed function to assist non-native protein
transport from the ER (Anelli, Ceppi et al. 2007).
The only structural data available from full length human PDI comes from low
resolution small angle X-ray scattering (SAXS) (Li, Hong et al. 2006). More
recently, the same technique was used to characterise ERp72 (Kozlov,
Maattanen et al. 2009).
Many PDI family proteins interact with their substrate primarily through a
conserved binding pocket located in the non-catalytic b’ domain (Ellgaard and
Ruddock 2005). In some of these proteins, the binding site may have become
specialised for the binding of particular substrates. For example, ERp57 is a PDI
family member that forms a complex with either of the chaperone proteins
calnexin or calreticulin (Russell, Ruddock et al. 2004). This complex then acts to
catalyse disulfide bond isomerisation specifically in N-glycosylated protein
substrates (Coe and Michalak 2010). The b domain seems to have a less
crucial role in substrate binding and is thought to play a mainly structural role in
multi-domain PDI proteins.
1.8. PDI Chaperone Function
Molecular chaperones are a functional class of proteins that assist the correct
non-covalent assembly of other polypeptide-containing structures in vivo, but
are not components of these final structures (Ellis 1993).
As well as its role in catalysis of thiol-disulfide exchange reactions, PDI can also
exhibit molecular chaperone activity, i.e. it shows ability to prevent the
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aggregation of substrate molecules, thus preventing them from following a non-
productive folding pathway (Wang and Tsou 1993). In essence, PDI has two
separate but related functions in the ER: an isomerase and a chaperone.
The chaperone function of PDI was first demonstrated using a protein that has
no disulfide bonds, D-glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
by showing that PDI prevents aggregation of this substrate (Cai, Wang et al.
1994). This anti-aggregation ability was also demonstrated using rhodanese as
the substrate protein (Song and Wang 1995). Since these substrates contain no
disulfide bonds, the chaperone activity was clearly independent of PDI’s
redox/isomerase function.
However, PDI chaperone activity has also been demonstrated during folding of
proteins that contain disulfide bonds (Puig and Gilbert 1994; Yao, Zhou et al.
1997; Winter, Klappa et al. 2002). In studying of the refolding of proinsulin, the
redox activity was found to be independent from the chaperone activity of PDI,
since mutation of active site residues did not affect its chaperone activity (Winter,
Klappa et al. 2002). A study of reduced and denatured acidic phospholipase A2
(APLA2) used alkylated PDI, which effectively prevents thiol-disulfide exchange,
to show that the substrate could still become reactivated in the presence of both
the alkylated PDI and a redox buffer (Yao, Zhou et al. 1997).
Some attempts have been made to identify the substrate binding site for PDI
chaperone activity. It was found that PDI chaperone activity does not depend on
the catalytic domain active sites, but it is inhibited by the presence of a peptide
substrate for the b’ domain (Quan, Fan et al. 1995). A similar study found that
although the b’ domain was necessary, other domains contributed to chaperone
activity of PDI (Winter, Klappa et al. 2002). Likewise, domain combinations of ab
and b’a’c of PDI were shown to lack chaperone function and this was
speculated to result from the lack of protein substrate binding, thus more than
just the b’ domain was required (Sun, Dai et al. 2000).
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When studying PDI-substrate interactions, it is important to consider the
chaperone function of PDI, since this may influence the binding of substrates,
especially those not considered candidates for thiol-disulfide exchange by PDI.
However, since the action of PDI as a protein folding catalyst requires it to bind
to non-native proteins, molecular chaperone like activity may be intrinsic to its
function as a protein folding catalyst (Hatahet and Ruddock 2009). Certainly the
literature seems to suggest that the regions required for substrate binding of
chaperone activity correlate strongly with the regions required for substrate
binding of protein thiol-disulfide exchange reactions.
1.9. PDI as a Subunit of Larger Protein Complexes
PDI is most commonly referred to in the context of its function in the oxidation,
reduction and isomerisation of disulfide bonds. All of these disulfide related
activities take place with PDI as a single peptide in a monomeric state. However,
PDI is a multifunctional polypeptide that can also play a role within larger protein
complexes. PDI serves as the β-subunit of both prolyl-4-hydroxylase, involved in
the synthesis of collagens (Koivu, Myllyla et al. 1987), and microsomal
triglyceride transfer protein, essential for the assembly of certain lipoproteins
(Wetterau, Combs et al. 1991).
The main function of PDI in both of these protein complexes seems to be to
maintain the highly insoluble α-subunits in a catalytically active, non-aggregated
conformation (Lamberg, Jauhiainen et al. 1996; Kivirikko and Pihlajaniemi 1998).
This function relates to the peptide binding and chaperone functions of PDI. It
does not require the catalytic site cysteine residues (Vuori, Pihlajaniemi et al.
1992b; Lamberg, Jauhiainen et al. 1996).
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1.9.1. Collagen Prolyl 4-Hydroxylase
Collagen prolyl 4-hydroxylase (P4-H) catalyses the formation of 4-
hydroxyproline by hydroxylation of prolines (Kivirikko, Myllyla et al. 1989). This
catalysis is essential in the formation of procollagen polypeptide chains into
triple helical molecules.
P4-H has an approximate molecular weight of 240 kDa (Tuderman, Kuutti et al.
1975). It consists of two α-subunits of 63 kDa each (Pankalainen, Aro et al.
1970) and two β-subunits of 55 kDa each. The β-subunit was discovered to be
PDI (Koivu, Myllyla et al. 1987). The α-subunit has been known to exist in two
isomers (Annunen, Helaakoski et al. 1997), but more recently a third form was
identified (van den Diepstraten, Papay et al. 2003). All α-subunits contained
cysteine residues that form intrachain disulfide bonds required to maintain
structure and enable tetramer assembly (Kivirikko, Myllyla et al. 1989).
Although PDI was identified as the β-subunit, it was found that PDI activity was
not essential for tetramer assembly or P4-H enzyme activity (Vuori, Pihlajaniemi
et al. 1992b). However, the solubility of the α-subunit is dependent upon its
association with PDI (John, Grant et al. 1993). Hence, it is PDI’s function as a
molecular chaperone that ensures P4-H maintains its catalytic activity (Vuori,
Pihlajaniemi et al. 1992a). This was supported by evidence that a PDI construct
spanning from b’ to a’ domains (now known as b’xa’) was sufficient for assembly
of active P4-H (Pirneskoski, Ruddock et al. 2001). In addition, the C-terminal
domain of PDI contains an ER retention signal, which is thought to be important
in retaining P4-H within the ER (Vuori, Pihlajaniemi et al. 1992b).
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1.9.2. Microsomal Triglyceride-transfer Protein
Microsomal triglyceride transfer protein (MTP) enhances the transport of
triglycerides, cholesteryl esters and phospholipids between membrane vesicles
via a shuttle mechanism (Atzel and Wetterau 1993; Wetterau, Lin et al. 1997).
MTP is also involved in the assembly of some lipoproteins (Gordon and Jamil
2000; Hussain, Shi et al. 2003); the genetic disease abetalipoproteinemia, which
results in a lack of apolipoprotein b (apoB) and triglycerides in blood plasma,
arises from a mutation in the MTP gene (Wetterau, Aggerbeck et al. 1992). MTP
is localised to the ER and Golgi apparatus (Swift, Zhu et al. 2003).
MTP is a 150 kDa protein (Wetterau, Aggerbeck et al. 1991), composed of two
subunits, a 97 kDa α-subunit and a 55 kDa β-subunit (Wetterau and Zilversmit
1986). The β-subunit was identified as PDI (Wetterau, Combs et al. 1990). PDI
is inactive with respect to its isomerase activity in the MTP complex (Wetterau,
Combs et al. 1990; Wetterau, Combs et al. 1991). Moreover, the isomerase
activity is not essential for its association with the larger α-subunit and for MTP
activity, since PDI mutants lacking enzyme activity are fully functional in lipid
transfer activity within the MTP complex (Lamberg, Jauhiainen et al. 1996).
Lipoproteins were found to bind to MTP but not to PDI alone (Hussain, Shi et al.
2003). However, the PDI β-subunit of MTP is known to be vital to ensuring a
soluble complex, since dissociated α-subunits formed inactive insoluble protein
aggregates (Lamberg, Jauhiainen et al. 1996). Recently, a novel splice variant
of MTP was identified that predominantly exists in adipocytes (fat cells) and are
specifically localised to the Golgi apparatus of these cells (Mohler, Zhu et al.
2007).
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1.10. Other Functions of PDI
It has been proposed that interaction with PDI is necessary for the export of
misfolded secretory proteins via the ER-associated degradation (ERAD)
pathway (Gillece, Luz et al. 1999), even for cysteine free proteins. This suggests
that PDI, in its function as a chaperone, may act as a part of the ER quality
control machinery, recognising terminally misfolded secretory proteins. This is
supported by a recent study that suggests PDI is a component of the SPP-
mediated ERAD machinery (Lee, Cho et al. 2010).
PDI has also been reported to be involved in many biological functions outside
the ER, including cell adhesion (Turano, Coppari et al. 2002), although the
mechanisms for PDI escaping the ER are unclear.
1.11. Other Processes Involved in Oxidative Folding
The PDI family are not the only ER resident proteins involved in the oxidation
and isomerisation of disulfide bonds. Other substances are involved in either
direct thiol-disulfide exchange of substrate proteins or in the transfer of oxidising
equivalents to maintain the homeostasis of the ER. The manner in which these
components interoperate is currently poorly understood.
1.11.1. Ero1
One enzyme known to be involved in the flow of oxidising equivalents for
disulfide bond formation is Ero1 (endoplasmic reticulum oxidoreductin 1). Ero1
is a 65 kDa flavoenzyme localised to the ER membrane. Some studies suggest
that PDI is an important intermediate in the transfer of disulfide bonds between
Ero1 and substrate proteins (Frand and Kaiser 1999). Ero1 is thought to oxidise
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reduced PDI via one internal pair of cysteines, with this pair in turn being re-
oxidised by internal dithiol-disulfide exchange with another pair of cysteines
within Ero1 (Frand, Cuozzo et al. 2000). A flavin adenine dinucleotide (FAD)
cofactor is believed to be involved in the subsequent transfer of electrons,
resulting in molecular oxygen being converted to hydrogen peroxide (Sevier and
Kaiser 2008).
One model for disulfide formation is the flow of oxidising equivalents from
molecular oxygen to Ero1, then to PDI before finally to the substrate protein.
This model produces one molecule of hydrogen peroxide per disulfide bond
made (Karala, Lappi et al. 2009). It was previously believed that the hydrogen
peroxide produced would be highly toxic to the cell, but a recent study provided
evidence that the hydrogen peroxide may be recycled and used as a substrate
for disulfide bond formation. At physiological pH, the natively folded state is
obtained more efficiently using peroxide than by the use of a glutathione redox
buffer (Karala, Lappi et al. 2009).
1.11.2. Glutathione
Glutathione is a glutamate–cysteine–glycine tripeptide. It is the most abundant
thiol-disulfide component of the eukaryotic cell and plays an active role in the
process of protein disulfide bond formation (Bass, Ruddock et al. 2004).
Glutathione is the principal redox buffer in the ER lumen, with the ratio of
reduced and oxidised glutathione defining the redox potential. The ratio of
reduced (GSH) to oxidised (GSSG) glutathione in the ER has been estimated to
be between 1:1 and 3:1 (Bass, Ruddock et al. 2004). This is considerably more
oxidising than the cytosolic ratio, estimated to be 30:1–100:1 (Hwang, Sinskey
et al. 1992). GSH can be regenerated from GSSG by the enzyme glutathione
reductase. A study of glutathione transport indicates there is a preferential
transport of reduced glutathione into the ER lumen (Banhegyi, Lusini et al.
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1999). It has also been demonstrated that Ero1 contributes to the oxidation of
glutathione, suggesting a role for glutathione in buffering the ER against
hyperoxidising conditions (Cuozzo and Kaiser 1999).
Glutathione can oxidise protein substrates directly and a recent study showed
more than half of the microsomal glutathione was found to be present in mixed
disulfides with protein (Bass, Ruddock et al. 2004). However, it has been shown
that disulfide bond formation can still take place even in the absence of
glutathione (Frand and Kaiser 1998), indicating the involvement of other
chemicals and adding to the complexity of the system. Although cells lacking
glutathione would be able to produce disulfide-bonded proteins via Ero1 and
PDI alone, they would lack the ability to adapt rapidly to changes in disulfide-
bond protein production and to other changes in redox conditions (Hatahet and
Ruddock 2009).
There appears to be some functional cross-talk between PDI, Ero1 and
glutathione pathways which is not yet fully understood (Frand, Cuozzo et al.
2000) and it seems likely that disulfide bonds are formed by complex
interdependent pathways within the endoplasmic reticulum (Karala, Lappi et al.
2009). The strongly interconnected roles of PDI, Ero1, glutathione, hydrogen
peroxide and molecular oxygen are currently areas of intense research.
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1.12. Bovine Pancreatic Trypsin Inhibitor
Bovine pancreatic trypsin inhibitor (BPTI), also known as aprotinin, is a small
monomeric single chain globular protein. The mature protein is 58 amino acids
long with a molecular weight of 6.5 kDa. It was first isolated from bovine
pancreas in 1936 (Kunitz and Northrop 1936). It is also known more generally
as basic pancreatic trypsin inhibitor when from a non-bovine source, since it has
10 positively charged but only 4 negatively charged side chains, making it a
strongly basic protein.
Physiologically, BPTI is known to inhibit digestive enzymes in the gut, known as
serine proteases, including trypsin, chymotrypsin, plasmin and kallikrein (Mahdy
and Webster 2004). It became the archetypal member of the Kunitz-type family
of serine protease inhibitors. Kunitz-type inhibitors are protease inhibitors that
work using a classic lock and key mechanism.
BPTI secondary structure is 18% helical and 25% β-sheet, with a large
proportion retaining a coil structure (Kabsch and Sander 1983). The core of the
protein contains an anti-parallel β-sheet, with two β-strands connected by a β-
turn and a third, shorter β-strand in close proximity, together forming in a twisted
hairpin. A surface exposed α-helix lies at the C-terminus with a short 310 helix
near the N-terminus, Figure 1.11A. The basic side chains of Lys15 and Arg16
on the exposed loop are thought to bind tightly to the active site of trypsin,
inhibiting its enzymatic activity (Scheidig, Hynes et al. 1997).
An attractive feature of BPTI in the study of protein folding is that the mature
protein has six cysteine residues, which are used to form three disulfide bonds
in the native state, Figure 1.11B. The (30-51) disulfide binds a β-strand to the C-
terminal α-helix, stabilising the protein core. The (5-55) disulfide binds the
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helices at either end of the protein, while the (14-38) disulfide stabilises less
structured regions of the protein.
Figure 1.11: Mature BPTI. A) Primary and secondary structure elements. Red, helix; blue,
β-strand; gold, β-turn; black, random coil. Cysteines are highlighted yellow in the primary
sequence, with disulfide bonds indicated with green dotted lines. B) Ribbon diagram of
native BPTI. Disulfide bonds are highlighted as ball and stick, labelled with the sequence
numbers of the cysteines involved. Sequence numbers refer to mature BPTI. Based on
PDB ID 1PIT.
Medicinally, BPTI has been used during surgical procedures to reduce bleeding,
by slowing the breakdown of blood clots (fibrinolysis). It was shown to result in a
reduction of 39% of requirements for blood transfusion during coronary artery
A
B
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bypass graft surgery (Sedrakyan, Treasure et al. 2004). However, there have
been concerns about its safety (Mahdy and Webster 2004), resulting in it being
withdrawn from use. The debate about BPTI safety in surgical procedures is still
ongoing (Dietrich 2009; Karkouti, Wijeysundera et al. 2010).
BPTI was one of the earliest protein crystal structures solved (Huber, Kukla et al.
1970), with a high resolution structure emerging a few years later (Deisenhofer
and Steigemann 1975). Since this structure was available, BPTI became the
first biological macromolecule to be modelled using molecular dynamics
simulations (McCammon, Gelin et al. 1977).
BPTI was used as a model protein in the early days of the development of NMR
to study biological molecules (Wuthrich and Wagner 1975; Brown, Demarco et
al. 1978; Kumar, Ernst et al. 1980; Wuthrich, Wagner et al. 1980), becoming the
first protein to have its NMR structure determined (Wagner and Wuthrich 1982;
Havel and Wuthrich 1985). It was later used to develop NMR as a probe for
investigating protein hydration (Otting, Liepinsh et al. 1991a) and to develop
techniques for hydrogen deuterium exchange (Otting, Liepinsh et al. 1991b),
resulting in a high quality NMR structure (Berndt, Guntert et al. 1992). It was
further used as a model protein for identifying regions of internal mobility (Smith,
Vanschaik et al. 1995).
In the context of this study, it is the folding pathway of BPTI that is of most
interest. In particular, the mechanisms through which the protein forms its native
disulfide bonds. During protein folding, the trapping of BPTI with a specific
configuration of disulfide bonds is akin to trapping a clearly defined folding
intermediate for this protein.
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1.12.1. BPTI Folding Pathway
The folding pathway of BPTI, in terms of the combinations of disulfide bonds
formed during folding, has been studied extensively. Early studies of folding
intermediates were performed by Thomas Creighton in the 1970s (Creighton
1975), around the same time as Anfinsen and colleagues were developing
some of the fundamental principles governing polypeptide self-assembly and
protein folding (Anfinsen 1973; Anfinsen and Scheraga 1975). Meanwhile, a
high resolution crystal structure of BPTI was revealed (Deisenhofer and
Steigemann 1975). Different in vitro conditions effecting BPTI folding and
unfolding were explored, including the use of denaturing agents (Creighton 1977;
Creighton 1978; Creighton 1979; Creighton 1980) and the role that PDI may
have in its folding was first explored (Creighton, Hillson et al. 1980). Throughout
the 1980s, various biophysical techniques were used to characterise native
BPTI and various conformations thought to be key to its folding pathway (Kosen,
Creighton et al. 1980; Kosen, Creighton et al. 1981), showing that disulfide
bonds can be used as effective probes for studying protein folding (Creighton
1986). This led to exploration of the folding pathway of other small proteins
(Kaderbhai and Austen 1985; Pace and Creighton 1986). With well
characterised intermediates now in place, attention turned to the kinetics of
BPTI folding, in an attempt to establish the rate at which intermediates were
formed (Goldenberg 1988). Other, less populated intermediate species of BPTI
folding were also being investigated (Vanmierlo, Darby et al. 1991a). By this
stage, a folding pathway for BPTI had been well established, with relative rates
for each step in the process being estimated, Figure 1.12. It indicated that the
optimum folding pathway necessitated the creation of non-native disulfide bonds
and that isomerisation of these species was rate-limiting to establish the native
structure.
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Figure 1.12: Model of the productive BPTI folding pathway, showing major disulfide
intermediates in their approximate conformations (Darby, Morin et al. 1995). The non-
productive quasi-native species (5-55, 14-38) has been omitted. The relative rate of each
step is indicated by the thickness of the appropriate arrowhead; the wider the arrowhead,
the greater the rate in that direction.
Meanwhile another group was independently studying intermediates of BPTI
folding (Oas and Kim 1988). Controversially, they proposed an alternative
folding pathway model, suggesting that only native disulfide bonds were
predominant (Weissman and Kim 1991), Figure 1.13.
The discrepancies between the two models arise due to the manner in which
kinetic folding intermediates are trapped by quenching. Whilst Creighton and
colleagues used chemical quenchers, which may be inaccessible to buried
thiols, Weissman and colleagues used an acid quenching technique. The
controversy over the predominance of native disulfide species came to a head
in a review article by Creighton and associated response by Weissman and Kim
(Creighton 1992; Weissman and Kim 1992b). It should be noted that the
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formation of non-native disulfides was never under dispute; rather, it was a
debate about the dominant or transient nature of the non-native disulfide bonds
in the BPTI folding pathway.
Figure 1.13: Alternative BPTI folding pathway model, emphasising the predominance of
native disulfide bonds (Weissman and Kim 1991). The relative conversion rates between
disulfide species are labelled. R is fully reduced BPTI; N is natively folded; N* is a
kinetically trapped intermediate. Less populated species, including non-native
intermediates, are not shown but are still required in transitions to the (30-51, 5-55)
species.
Meanwhile, further characterisation of the conformational properties of
intermediates involved the use of both one and two dimensional 1H NMR
(Vanmierlo, Darby et al. 1991a; Vanmierlo, Darby et al. 1991b; Darby,
Vanmierlo et al. 1992; Staley and Kim 1992; Vanmierlo, Darby et al. 1992) and
an X-ray crystal structure (Eigenbrot, Randal et al. 1992). These revealed that
many intermediates have a native-like structure, which perhaps contributes to
the difficulty of sequential native disulfide formation, due to steric hindrance of
buried cysteines (Goldenberg 1992). The effects of other ER resident proteins
on the folding of BPTI was investigated (Zapun, Creighton et al. 1992; Creighton,
Bagley et al. 1993), showing the influence that PDI may have on the rate limiting
steps of the process (see below). Further NMR studies focused on the influence
of side chains on both the folding and structure of BPTI, revealing the
importance of some aromatic rings (Kemmink and Creighton 1993; Kemmink,
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Vanmierlo et al. 1993; Mendoza, Jarstfer et al. 1994; Yu, Weissman et al. 1995;
Zhang and Goldenberg 1997).
Evidence of (30-51) as the most stable first disulfide bond in BPTI folding was
revealed (Darby and Creighton 1993). The structure and dynamics of this critical
one disulfide intermediate was further refined with the use of 1H-15N HSQC
NMR of isotopically labelled intermediates (Vanmierlo, Darby et al. 1993). This,
together with an independent NMR study of the same intermediate (Staley and
Kim 1994), showed clear evidence that, despite only one disulfide being present,
a large proportion of the protein showed native-like structure, with the first 14 N-
terminal residues remaining unfolded. However, structure was only observed at
low temperatures. Likewise, very similar structures were identified for both the
(30-51, 5-14) and (30-51, 5-38) non-native intermediates using 1H NMR
(Vanmierlo, Kemmink et al. 1994). Interestingly, NMR of fully reduced and
unfolded BPTI suggested that it retained some structure (Pan, Barbar et al.
1995). Structural studies of BPTI mutants using 13C NMR were also performed
(Hansen, Lauritzen et al. 1995).
Reviews comparing the folding pathways of several different proteins reveal
common features in the formation of native disulfide bonds (Creighton, Zapun et
al. 1995; Creighton 1995a; Creighton 1995b). A more recent comparison is
available that relates these folding pathways to current understanding of the in
vivo apparatus of prokaryotic and eukaryotic thiol-disulfide exchange
(Mamathambika and Bardwell 2008).
1.13. PDI / BPTI Interaction Studies
Although a wide variety of peptides and proteins have been used as substrates
for the study of PDI folding, BPTI has been a particularly popular candidate. As
well as being a natural substrate for bovine PDI, it has the advantage of being a
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small single domain protein containing three disulfide bonds. Furthermore, since
the folding pathway of BPTI has been extensively characterised, the
identification of soluble intermediates can be used to quantify the rate by which
protein folding has been catalysed by PDI. It should be noted that bovine and
human PDI are extremely similar (94.9% identity), as are BPTI and its human
ortholog, so it is reasonable to consider BPTI a good model substrate for studies
with human PDI.
PDI was first confirmed to catalyse the refolding of mature BPTI in vitro in 1980
(Creighton, Hillson et al. 1980). The study showed that the rate of those steps in
the folding pathway that involved disulfide bond formation, reduction or
isomerisation were significantly increased if they involved substantial
conformational change of the substrate. Interestingly, even in this early study it
was postulated that the intramolecular rearrangement of disulfides observed in
BPTI folding alone would not be so prominent when PDI is present, since PDI
bypasses the intramolecular disulfide rearrangement process by forming
transient mixed disulfides with BPTI. Thus, intermediates involving non-native
disulfides in the folding of BPTI may be replaced by complexes involving
intermolecular disulfides with PDI (Creighton, Hillson et al. 1980). Another study
showed that other components of the ER, including ATP and Ca2+, did not add
to or replace the increased rate of BPTI folding by PDI, indicating that such
chemical additives were not involved in this catalytic process (Zapun, Creighton
et al. 1992). Under certain conditions in vitro, one study found that the refolding
of BPTI was reduced from several hours to about two minutes with the addition
of PDI (Creighton, Bagley et al. 1993); a similar study reported a 3,500- to
6,000-fold increase in rates for the rate-limiting steps (Weissman and Kim 1993),
which are both within the range for PDI catalysis now generally accepted
(Freedman, Hirst et al. 1994). A much more recent study used BPTI to compare
the catalytic activity of PDI with two other human PDI family proteins, ERp57
(referred to as ERp61) and ERp72 (Satoh, Shimada et al. 2005). They found
that ERp57 and ERp72 accelerated the initial steps of BPTI folding more
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efficiently than PDI. However, the rate limiting steps at the later stages of BPTI
folding were catalysed less efficiently. Interestingly, they suggest that PDI and
ERp72 can work cooperatively to catalyse BPTI folding more efficiently than
with either enzyme alone (Satoh, Shimada et al. 2005). Another recent study
used BPTI as a model substrate to show that the ability of PDI to act as a
catalyst for disulfide bond formation or isomerisation was dependent on the pKa
of its active site cysteines, and that this pKa could be altered by nearby arginine
side chains (Karala, Lappi et al. 2010).
As well as using BPTI as a substrate for full length mature PDI, it has also been
used in studies with various domain combinations of PDI, to identify how each
domain contributes to the activities of PDI. One key study used BPTI to show
that all the thioredoxin domains of PDI contributed to efficient thiol-disulfide
exchange reactions of the enzyme, not just the catalytic domains (Darby, Penka
et al. 1998).
As an alternative to human PDI, BPTI has also been used as a substrate in
studies of yeast PDI. For example, the activity of various yeast PDI mutants was
investigated by following the refolding of BPTI in vitro to identify the relative
importance of the a and a’ domains in the catalytic activity of the enzyme
(Westphal, Darby et al. 1999).
There has been a lot of interest in the pathways involved in the transfer of
oxidising equivalents to maintain homeostasis in the ER during protein folding. A
recent study used BPTI as a substrate in investigating the role of hydrogen
peroxide in this process (Karala, Lappi et al. 2009). They found that, at
physiological pH, peroxide-mediated oxidation was much faster than that
mediated by a glutathione redox buffer, showing that it can be used as a
substrate for disulfide bond formation.
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All of the above studies use the interaction of PDI with BPTI to elucidate either
the effect of PDI on the kinetics of the BPTI folding pathway or to identify the
functional significance of components of PDI to its catalytic activity. However, no
previous studies have used BPTI or its folding intermediates to investigate the
structural aspects of its binding to PDI.
1.14. Protein NMR Spectroscopy
1.14.1. Observing Nuclear Spin Frequencies
Spin is a fundamental property of atomic nuclei and elementary particles.
Nuclear magnetic resonance (NMR) can be applied to atomic nuclei that have
spin > 0, but it is most commonly applied to nuclei where spin = ½. The most
common nuclei in biological molecules are 1H, 12C, 14N and 16O. Of these,
however, only 1H has a spin = ½. In order to observe other atoms, labelling with
an isotope with spin = ½ is usually required. For studying recombinant proteins,
this is usually achieved by growing cells in a minimal medium using isotopically
labelled substances, e.g. 15N labelled ammonium sulphate.
NMR active nuclei can be aligned to an external magnetic field. They precess
with angular momentum around the external field at close to an angular
frequency known as the Larmor frequency, which is unique for each isotope.
Larmor frequencies are within the radio frequencies of the electromagnetic
spectrum. In NMR, the different Larmor frequencies can be exploited to obtain
different types of information about the biological molecule. A short radio
frequency pulse is applied close to the Larmor frequency of the nuclear spins of
interest, usually at 90o to the external field, producing a transverse
magnetisation of spins. A transient NMR signal, known as free induction decay
(FID), can then be detected as the transverse spins relax towards equilibrium.
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Although the resonance frequency will be close to the Larmor frequency of an
isotope of interest, the precise frequency observed shifts depending on the
chemical environment of the nucleus. This difference is known as a chemical
shift and is influenced mainly by the electronic environment of the nucleus.
1.14.2. Converting FID to Frequency Signal
The free induction decay (FID) signal is very difficult to interpret in its raw state.
Instead, the signal is Fourier transformed from the time domain signal of the FID
to a frequency domain signal. Since the chemical shifts are very small
compared to the resonance frequencies of the observed nuclei, the signal is
normalised so that the differences in resonance frequencies between chemical
environments, the chemical shifts, are highlighted. This is done by subtracting
the frequency domain from a reference molecule, typically TMS
(tetramethylsilane) or DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid).
Chemical shifts are typically in the order of a millionth of the resonance
frequency of the observed nuclei, so are reported in parts per million (ppm)
(Pascal 2008). This normalisation also means that chemical shift is independent
of magnetic field (a chemical shift of 10 ppm is equivalent to 4 kHz on a 400
MHz spectrometer but 7 kHz on a 700 MHz spectrometer). In 2D NMR spectra,
chemical shifts are typically displayed in ppm frequency with axes labelled ω1
and ω2.
1.14.3. Protein Structure from Frequency Signals
When using NMR to determine protein structure, one aspect of the chemical
environment of nuclei that is utilised is their interactions with neighbouring nuclei.
Each nucleus acts as a magnetic dipole and interactions between nuclei are
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referred to as dipole-dipole interactions. These interactions can be transmitted
either directly through space or indirectly through bonding electrons.
The atomic structure of small molecules can be identified using simple one
dimensional NMR experiments. However, for large macromolecular structures
such as proteins this produces many overlapping peaks that are impossible to
resolve. Increasing dimensionality reduces the number of overlapping peaks.
Multidimensional NMR relies on correlating multiple resonances. These are
identified by cross-peaks in the NMR spectrum and provide information about
their interaction. The cross-peaks between different 1H atoms of amino acids
tend to lie in different regions of certain NMR spectra, Figure 1.14. Using a
variety of multidimensional NMR combining both through bond and through
space experiments, the resonances associated with each amino acid in a
protein sequence can be assigned.
Figure 1.14: Spectral regions for two dimensional TOCSY and NOESY experiments,
modified from (Birkbeck 2009).
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1.14.4. Through Bond NMR Observations
Scalar coupling (J-coupling) is the coupling between two nuclear spins due to
the influence of bonding electrons on the magnetic field running between the
two nuclei. Hence it is a through-bond magnetic interaction between nuclei via
paired electrons. NMR techniques such as COSY (correlation spectroscopy)
use the resulting correlations to detect atoms that are linked by up to three
chemical bonds. One benefit of this technique is that even when relatively
insensitive heteronuclei are present bonding between atoms can still be inferred
by transferring magnetisation via nearby sensitive 1H nuclei.
A related technique, known as TOCSY (total correlation spectroscopy),
magnetisation is dispersed over successive scalar couplings. This dispersion
allows detection of nuclei over more than three bonds. Hence, it can show
correlations between all protons within any amino acid residue, referred to as a
spin system. A characteristic pattern of signals often enables the type of amino
acid to be identified. However, some amino acids have almost identical spin
systems.
1.14.5. Through Space NMR Observations
Through space interactions occur due to dipolar interactions between nuclei.
Dipolar coupling is the direct interaction between two magnetic dipoles. It
depends on the inverse cube of the internuclear distance. Since dipolar
couplings are anisotropic interactions, in solution they average to zero as a
result of rotational diffusion. However, the effect also causes the fluctuating local
magnetic fields experienced by both nuclei to become correlated as the spins
relax, a phenomenon known as cross relaxation. The resulting transfer of spin
polarisations results in a measurable nuclear Overhauser effect (NOE). The
NMR NOESY (Nuclear Overhauser Effect Spectroscopy) technique can be used
Chapter 1: Introduction
48
to measure NOEs in proteins. The cross-peaks in a resulting spectrum can be
used to connect resonances from spins that are spatially close. NOESY spectra
from large biomolecules can often be assigned using sequential walking
(sequential assignment). Correlations may also be observed between nuclei that
are close in three dimensional space but far apart in the primary sequence.
NOEs are not normally observed for protons separated by more than 6 Å.
1.14.6. Heteronuclear Single Quantum Correlation
Heteronuclear Single Quantum Correlation (HSQC) is a two dimensional NMR
experiment that detects correlations between 1H nuclei and those of other NMR
active nuclei, typically 15N (Maudsley and Ernst 1977). The technique detects
the transfer of magnetisation from each amide proton to its attached 15N nucleus
and back (Pascal 2008). The decoupled HSQC spectrum produces one peak for
each 1H-15N pair. The resulting spectrum has a proton axis and a 15N axis, with
a single peak for each amino acid (excluding prolines). Additional peaks will be
present from the side chains of amino acids that contain amine groups.
1.14.7. Hydrogen Deuterium Exchange
Hydrogen deuterium (H/D) exchange is a chemical reaction in which a
covalently bonded hydrogen atom is replaced by a deuterium atom. Usually the
protons being examined are the amides in the backbone of a protein. The
protein sample is solubilised in a deuterium oxide solution. Using NMR
observations, the method gives information about the solvent accessibility of
various parts of the molecule, and thus the three dimensional surface of the
protein. In particular, H/D exchange can provide insight into protein dynamics
caused by structural fluctuations in the protein (Englander and Kallenbach 1983).
HSQC spectra are recorded at a series of time points while the hydrogen is
exchanging with the deuterium in the solvent. Since only the proton signal is
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detected, the signal will decay as protons are exchanged for deuterium atoms.
An amide buried in the hydrophobic core of a protein will exchange slowly, while
an amide on the surface will exchange rapidly. Freely exposed amide
hydrogens have been reported to exchange in about 1 s at pH 7 and 0°C.
However, the protecting structure surrounding most backbone amides slow
these rates down and spread them over many orders of magnitude, placing
them on a convenient laboratory time scale (Krishna, Hoang et al. 2004). The
precise rates of these exchanges can be informative about the dynamics of
different parts of the protein. This can be particularly useful in studies of protein
folding, since the extent to which different intermediates have folded can be
elucidated from how solvent exposed they are (Wuthrich, Wagner et al. 1980).
Furthermore, H/D exchange can aid in identifying which components of each
intermediate protein have folded, thus identify detailed steps involved in
establishing the native structure (Englander and Kallenbach 1983). The kinetics
of the exchange process are dependent on environmental conditions such as
pH and temperature (Woodward, Simon et al. 1982). A ten-fold change in
exchange rate can be obtained by a change of one pH unit, or about 22°C in
temperature (Krishna, Hoang et al. 2004).
1.14.8. Chemical Shift Mapping
Chemical shift mapping is a technique used to compare subtle differences
between two NMR spectra. It is often used to compare a reference spectrum of
a sample in controlled conditions with a spectrum where the sample conditions
have been altered. For example, a chemical shift map can be produced to
highlight the changes that occur in the HSQC spectrum of an enzyme after the
addition of a substrate (Rajagopal, Waygood et al. 1997). The map identifies
chemical shift perturbations for each assigned residue, thus indicating the extent
to which they have been affected by the environmental change. In the case of
substrate binding, the largest perturbations would be expected to occur at the
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binding interface. When combined with other NMR techniques, detailed
structural information about protein-protein interactions can be obtained
(Schumann, Riepl et al. 2007).
Chemical shift mapping can be performed even when only one of the spectra
being compared have been assigned. This is referred to as minimal shift
mapping and involves mapping from each assigned peak in the source
spectrum to the nearest peak in the target spectrum. It is convenient when
comparing one reference spectrum with multiple spectra where the environment
of the sample has been altered, e.g. comparing the HSQC spectrum of an
enzyme alone with the HSQC spectra of the enzyme in the presence of different
substrates.
1.14.9. Use of NMR Spectroscopy to Investigate Binding to PDI
The two most powerful biophysical techniques for investigating protein
structures are X-ray crystallography and NMR spectroscopy. They are both
regularly used to provide high resolution structures of biological molecules at
atomic resolution.
Since NMR uses molecules in solution, it is not limited to those proteins that
crystallise. Many attempts have been made to crystallise human PDI, but these
have been unsuccessful, mainly due to its inherent flexibility, which makes
crystal formation difficult. Even when successful, the crystallisation process
often causes packing effects, whereas solution state NMR can observe a
protein structure closer its native structure in the cell. NMR has a further
advantage of being able to study dynamic properties such as protein flexibility
and ligand binding (Baldwin and Kay 2009). This includes observations on a
wide variety of timescales, including conformational change, chemical exchange
and internal mobility (Mittermaier and Kay 2006). One major drawback of NMR
Chapter 1: Introduction
51
is the size limit of molecules that can be studied. In the case of PDI, this means
that experiments are restricted to truncated versions of the enzyme; X-ray
crystallography has no such limitation. Another major drawback of NMR is that
data analysis tends to take much longer compared to crystallography data.
1.15. Studying Protein Interactions using Biosensors
A biosensor is an analytical device for the detection of a biological analyte that
combines a biological component with a physicochemical transducer. Interaction
between the target analyte (e.g. a substrate protein) and the biological material
(e.g. an enzyme) produces a physicochemical change detected by the
transducer, usually resulting in a signal proportional to the concentration of
interacting analyte (Schasfoort and Tudos 2008). The most prominent example
is the glucose biosensor, which uses enzyme-electrodes for the rapid self-
diagnosis of blood glucose levels by diabetes sufferers (Barredo 2005).
1.15.1. Surface Plasmon Resonance as a Biosensor
One form of real-time biosensor is based on the phenomenon of surface
plasmon resonance (SPR). It enables accurate analysis of protein binding
specificity, kinetics and affinity. SPR biosensors work by immobilising one
interacting partner to a surface before passing a liquid sample containing
another interaction partner over the surface. Where interaction occurs, binding
of molecules to the surface generates a response which is proportional to the
bound mass. Sensors use optical techniques to detect a change in refractive
index near the surface due to the interaction of the biological partners (Clow,
Fraser et al. 2008). The application of SPR based sensors to monitoring
biological interactions was first demonstrated in 1983 (Liedberg, Nylander et al.
1983). Recent publications offer good introductions into the theoretical and
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practical use of SPR as a biosensor (Schasfoort and Tudos 2008; de Mol and
Fischer 2010).
SPR biosensors can be used to determine a range of interaction characteristics,
including the kinetics and affinity of an interaction and the concentration of
interacting molecules present in a sample. Affinity analysis can provide
quantitative data about the strength of binding between two interacting
molecules in terms of a dissociation constant. Modern SPR biosensors can
detect affinity binding events in the μM to sub-nM range (de Mol and Fischer
2010). The affinity of an interaction is calculated based on either rates of
association and dissociation or the equilibrium level of binding. Kinetic analysis
of binding can establish the rate of association or dissociation of an interaction.
kon and koff rates can be ascertained using various concentrations of an analyte,
after careful analysis of the time curves produced using various interaction
models.
Although many applications use purified proteins, binding interactions with crude
mixtures including nucleic acids, lipids, carbohydrates or even whole cells can
be measured as they pass over the sensor. In such circumstances, the
concentration of the actively binding molecule can be estimated from the
response levels obtained.
One of the key advantages of SPR biosensors is that there is no need to label
molecules with fluorescent or radioactive tags, thus avoiding the possibility that
labels may change the native conformation of the molecule and affect its activity.
Compared to other biophysical techniques, SPR biosensors require relatively
small volumes of sample. Furthermore, the analyte is not destroyed during
analysis and is often recovered for identification by mass spectrometry
(Natsume, Nakayama et al. 2000; Williams and Addona 2000).
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Despite all of the potential advantages of using SPR biosensors, some inherent
disadvantages of this technology should be highlighted. The most obvious is the
requirement of one of the interacting molecules to be immobilised to a surface,
which could potentially cause steric hindrances that effect the interaction of
binding partners. A variety of immobilisation strategies can be explored to
minimise these effects. Another issue is that molecules can bind non-specifically
to the surface, although appropriate controls should account for this. Mass
transport effects can occur due to multiple binding of a single analyte molecule
to many immobilised molecules; using appropriate flow rates for the analyte
should avoid this effect. In order to get reproducible results, it is essential that
the analyte can be removed from the surface without affecting the immobilised
protein, a process known as regeneration. For some interactions, this
regeneration can be very problematic.
1.15.2. Components of SPR Biosensors
All SPR instruments comprise three essential units integrated into one system:
an optical unit, a liquid handling unit and a sensor surface. All configurations
directly measure refractive index changes at the sensor surface in real-time
(Schasfoort and Tudos 2008). The changes are usually due to binding events
and are proportional to the change in mass at the chip surface.
Plasmons result from the oscillation of ionised gas and play a large role in the
optical properties of metals. They are often confined to surfaces (surface
plasmons) and interact strongly with light. Surface plasmons can be thought of
as charged density waves propagating along the interface of a metal and an
insulating media (de Mol and Fischer 2010). Generally, gold is used as the
metal surface in sensor chips, since it combines favourable SPR characteristics
with inertness in biomolecular interactions (Biacore 2003).
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In the presence of an appropriate medium (e.g. a prism), polarised light striking
a surface plasmon at a particular angle of incidence will become totally internally
reflected. Despite being internally reflected, some of the photons of polarised
light interact (resonate) with the free electrons of the metal surface, penetrating
a short distance into a medium of a lower refractive index, thereby creating a
type of wave known as an evanescent wave. This is a standing wave exhibiting
exponential decay with distance. Resonance energy is transferred between the
evanescent wave and the surface plasmons, causing a reduction in light
intensity (Schasfoort and Tudos 2008). This allows the phenomenon of surface
plasmon resonance to be observed.
In a typical SPR biosensor setup, a sensor chip is coated with a film of gold.
During operation, one surface contains a prism and provides a surface for
plasmon resonance to take place. On the other side of the gold film, where an
evanescent wave will penetrate, molecules (e.g. proteins) are immobilised and
an analyte is allowed to flow past in a controlled manner, Figure 1.15.
Figure 1.15: Schematic illustrating the principles of detection of a surface plasmon
resonance signal (Paulo 2006).
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The angle at which the maximum loss of the reflected light intensity occurs (the
resonance angle) is dependent on the refractive indices of the media at both
sides of the gold film. The refractive index of the prism never changes. However,
on the other side the refractive index in the vicinity of the metal surface will
change when accumulated mass (e.g. the analyte) bind to it (Schasfoort and
Tudos 2008). Only refractive index changes very close to the surface affect the
SPR signal, since the effective penetration depth of the evanescent wave is
typically around 150 nm (Biacore 2003).
A linear relationship is found between resonance energy and mass
concentration of biological molecules, such as proteins. Therefore, the SPR
signal, expressed in resonance units, is effectively a measure of mass
concentration at the sensor chip surface. This means that association and
dissociation between the immobilised molecules and the analyte can be
observed. Hence, rate constants and equilibrium constants can be calculated
(de Mol and Fischer 2010).
1.15.3. The SPR Sensor Surface
In most commercial products, the sensor surface of a SPR biosensor is
provided by a chip consisting of a glass surface coated with a thin layer of gold,
onto which a range of functional groups can be attached. Thus, a sensor chip
provides the physical conditions necessary to generate an SPR signal, with
interactions being studied on the chip surface.
For interactions to take place, the sensor chip surface needs to be modified to
immobilise molecules such that they can selectively capture the target analytes,
but should not be prone to adsorbing other components present in the sample
or buffer media (Schasfoort and Tudos 2008).
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The most common sensor chips consist of a carboxymethylated dextran matrix
covalently attached to the gold surface (Clow, Fraser et al. 2008). The molecule
targeted for immobilisation needs to be chemically bonded to the dextran matrix
so to provide a reproducible chip surface after extensive washing. The
immobilisation must be done so that the analyte can access and bind to the
immobilised molecule efficiently (Clow, Fraser et al. 2008).
Figure 1.16: Immobilisation of protein (ligand) onto carboxymethylated sensor chip
surface. A) Activation of chip surface using EDC and NHS; B) Ligand immobilisation onto
EDC/NHS activated sensor chip via amine coupling (Biacore 2003).
The established procedure for immobilisation of a protein links amine groups in
the protein to derivatised carboxyl groups, provided by the dextran, on the
sensor chip surface (Johnsson, Lofas et al. 1991). This can be achieved in a
two step process, Figure 1.16. First, the carboxyl activating agent EDC (1-Ethyl-
3-(3-dimethylaminopropyl)carbodiimide) is bond to the carboxyl groups of
dextran. A second activating agent, NHS (N-hydroxysuccinimide), is then bound
to the EDC, Figure 1.16A. This provides a succinimide ester that can react with
the amine groups of protein ligands in a process known as amine coupling,
Figure 1.16B. The optimum pH for amine coupling can vary between proteins,
so a process of pH scouting is often performed prior to immobilisation to identify
A
B
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the most desirable pH. The amount of protein that has been immobilised is
identified by the change in response units before and after immobilisation.
Amine coupling is only one mechanism of immobilising proteins. One potential
issue is that amine coupling could bind proteins in a way that would affect the
binding of substrates. A more uniform alignment to a chip surface could be
achieved by site specific immobilisation via an affinity tag, e.g. using the His-tag
of appropriate fusion proteins (Schmid, Keller et al. 1997). However, a
disadvantage of the His-tag system is that metal dependent non-specific protein
adsorption can occur (Clow, Fraser et al. 2008).
1.15.4. Detecting Binding of Analyte
Figure 1.17: Schematic of the direct detection of analyte flowing over the sensor chip
surface with bound protein (ligand). The analyte is captured by the ligand immobilised on
the sensor surface. Accumulation of the analyte results in a refractive index change in
the evanescent field shifting the SPR angle (Schasfoort and Tudos 2008).
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When molecules in the analyte solution bind to the immobilised molecule on the
surface the mass increases; when they dissociate the mass falls, Figure 1.17.
When binding occurs biomolecules accumulate within the aqueous layer,
changing the sensor surface, thus changing the refractive index (Schasfoort and
Tudos 2008). This allows continuous, real-time monitoring of the association
and dissociation of the interacting molecules (Paulo 2006), which is shown as a
plot of resonance signal against time, known as a sensorgram, Figure 1.18.
Changes in the amount of analyte bound can be detected down to
concentrations corresponding to the picomolar to nanomolar range of analyte in
the sample solution (Biacore 2003). After a set time of analyte associating with
the immobilised protein, a buffer without analyte is used to dissociate bound
analyte. If tightly bound, some analyte may remain bound to the immobilised
protein. A regeneration buffer (e.g. 50 mM NaOH) is used to dissociate any
remaining analyte, Figure 1.18. It is essential that the analyte can be removed
from the sensor chip surface without affecting the immobilised protein. This
makes binding analysis reproducible.
Figure 1.18: Typical sensorgram showing the association, dissociation and regeneration
phases of analyte binding to an immobilised ligand (Paulo 2006).
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1.16. Aims of this Study
This chapter has introduced general concepts of protein folding and
mechanisms involved in protein folding in the endoplasmic reticulum. Disulfide
bonds play a key role in the folding of many proteins, with oxidoreductase
enzymes involved in catalysing their oxidation, reduction and isomerisation.
Protein disulfide isomerase (PDI) is the most abundant and well studied of these
enzymes, but represents only one member of the PDI family of proteins.
This study aims to learn more about the mechanisms through which PDI binds
to substrate proteins by studying its interaction with a classic model protein,
bovine pancreatic trypsin inhibitor (BPTI). The BPTI folding pathway has been
studied extensively, with disulfide bonded intermediate states well characterised.
The pathway includes intermediates with non-native as well as native disulfide
bonds, making isomerisation necessary. This makes BPTI a good candidate for
studying PDI activity, since the enzyme strongly catalyses these rate limiting
steps.
This study aims to investigate the interaction between PDI and BPTI substrates
using the technologies introduced in this chapter as well as other biophysical
techniques. The aims can be broken down as follows:
 Create recombinant proteins representative of different stages of the
folding pathway of BPTI.
 Characterise each BPTI construct using a variety of biophysical
techniques. NMR will be used to identify which regions within each
folding intermediate are folded and which remain unfolded. Hydrogen
deuterium exchange will enable details to be elucidated about solvent
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exposed regions of each BPTI construct, with a timecourse revealing the
flexibility of each construct.
 The effects of titrating the PDI enzyme into solutions of each BPTI
construct will be observed by NMR. What concentrations of PDI are
necessary to observe perturbations in the BPTI spectra? Can regions of
interaction be identified?
 The entire PDI enzyme is too large to be observed by NMR. However,
the bb’x region of PDI is known to include the main binding regions of the
enzyme. This construct has recently been studied by NMR and its
structure is now well characterised. Thus, this study will add the various
BPTI constructs to bb’x and observe any perturbations to the known
spectrum. Does bb’x bind more strongly to one construct compared to
another? Does binding occur in different parts of the binding region with
different BPTI constructs? How do the observations of BPTI binding
compare with binding of other substrates to PDI constructs from previous
studies?
 Estimate the binding affinity between PDI and each BPTI substrate. How
does the binding differ between substrates at different stages along the
folding pathway of BPTI? How do these compare to binding by other PDI
substrates studied previously?
It is hoped that the combination of approaches described above will facilitate
understanding of the mechanisms of substrate binding to PDI and contribute to
an overall understanding of the processes involved in oxidative protein folding in
the endoplasmic reticulum.
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Chapter 2. Materials and Methods
2.1. Wild Type BPTI and PDI Constructs
All proteins were expressed from a vector derived from pET-23b from Novagen,
kindly provided by Dr. L Ruddock. This vector includes a T7 RNA polymerase
promoter. Constructs were made by cloning the open reading frame (ORF) and
inserting into the NdeI and BamHI sites of the multiple cloning site of the pET-
23b vector.
Recombinant BPTI was expressed with a leading methionine, used as a start
codon, but the wild type was otherwise identical to mature BPTI. PDI expression
vectors included a hexa-histidine tag (His-tag), sequence MHHHHHHM, to
facilitate purification. The His-tag was not removed after purification, but showed
no evidence of affecting our observations of protein behaviour. All recombinant
proteins were expressed in E. coli BL21 (DE3) pLysS strains.
2.2. Site Directed Mutagenesis of BPTI
Single point mutations were performed by site directed mutagenesis, mutating
guanine to cytosine such that codon changes would be TGCTCC or
TGTTCT. This would lead to the expression of serine instead of cysteine.
Each of the desired mutant forms of BPTI required different combinations of
single point mutations. However, many of the single point mutations were
common to several of the desired constructs (e.g. C14S). A strategy was
employed whereby the most common single point mutations would be
performed first. These products were then used as templates to introduce
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further single point mutations. Both forward and reverse primers were designed
to incorporate mutations at each desired position, as listed below:
C5SForward : 5'-CGT CCG GAT TTT TCC CTG GAA CCA CCG TAT ACC-3'
C5SReverse : 5'-GGT ATA CGG TGG TTC CAG GGA AAA ATC CGG ACG-3'
C14SForward: 5'-CCG TAT ACC GGC CCT TCT AAA GCG CGG ATC ATT-3'
C14SReverse: 5'-AAT GAT CCG CGC TTT AGA AGG GCC GGT ATA CGG-3'
C38SForward: 5'-GTG TAC GGC GGT TCT CGA GCG AAA CGT AAT AAC-3'
C38SReverse: 5'-GTT ATT ACG TTT CGC TCG AGA ACC GCC GTA CAC-3'
C55SForward: 5'-GAC TGC ATG CGT ACC TCT GGT GGC GCT TAA TAA-3'
C55SReverse: 5'-TTA TTA AGC GCC ACC AGA GGT ACG CAT GCA GTC-3'
For each site directed mutagenesis, polymerase chain reaction (PCR) was
performed using PfuUltra High-Fidelity DNA Polymerase (Agilent) to amplify the
entire vector. 50 μl reactions were set up following manufacturers guidelines,
which included 1.0 μl each primer at 100 ng/μl and 1.0 μl of DNA template at
100 ng/μl. The PCR cycling parameters were optimised such that parent DNA
was denatured at 95°C for 30 s, followed by 30 cycles of 95°C for 30 s, 55°C for
1 minute to anneal primers, then 68°C for 4 minutes to extend primers.
Reactions were incubated at 68°C for a further 10 minutes to ensure complete
primer extension. After every mutagenesis, the desired mutation was confirmed
by DNA sequencing.
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2.3. Protein Expression
2.3.1. Expression of Unlabelled Protein
Ampicillin and chloramphenicol antibiotics were added to an LB agar plate.
Frozen glycerol stocks of the appropriate construct were used to streak out cells
onto an agar plate and grown overnight at 37°C. A single colony was used to
inoculate 50 ml of LB in a 250 ml conical flask containing the appropriate
antibiotics. This was incubated overnight at 37°C shaking at 180 rpm. The
optical density (OD) of the overnight culture was measured at 600 nm and the
appropriate volume used to inoculate a larger culture, typically six two litre flasks
containing 400 ml LB each, such that the starting OD600 = 0.05. The culture was
incubated at 37°C shaking at 180 rpm until OD600 = 0.4 (for BPTI) or OD600 = 0.5
(for PDI). Overexpression of the recombinant protein was induced with the
addition of 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). The culture was
incubated for a further 4 hours at 37°C shaking at 180 rpm. Cells were then
harvested by centrifugation at 6000 x g using a Beckman JLA-8.1000 rotor for
12 min at 4°C.
2.3.2. Expression of 15N Labelled Protein
Whenever 15N isotope labelling of samples was required, the expression
protocol was identical except that LB was replaced by minimal medium as
defined in Table 2.1.
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Table 2.1: Minimal medium nutrients added to 1 litre of sterile water. For 15N labelling of
recombinant proteins, (15NH4)2SO4 was used, which consisted of 99% 15N isotope
(Cambridge Isotope Labs).
Nutrient Amount (mg)
(NH4)2SO4 1000
Glucose 4000
Na2HPO4 6800
KH2HPO4 3000
NaCl 500
Na2SO4 42
EDTA 50
MnCl2 16
FeCl3 5
ZnCl2 0.5
CuCl2 0.1
CoCl2 0.1
H3BO3 0.1
MgSO4 0.25
CaCl2 44
d-Biotin 1
Thiamine 1
2.3.3. Lysis of Cell Culture
The cell pellet was resuspended in 1/10th culture volume 20 mM sodium
phosphate, 10 μg/ml DNase, pH 7.3. Cells were initially lysed by freezing
overnight, then thawing in a water bath at room temperature. Further lysis
occurred by sonication. A Bandelin Sonoplus HD 2070 sonicator was used to
apply three bursts of 30 seconds sonication at 70% power with 90 second
intervals, while keeping the culture on ice to prevent overheating.
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2.4. Purification and Refolding of BPTI Constructs
2.4.1. Isolation of Inclusion Bodies
Lysed cells were centrifuged at 30000 x g for 12 min to pellet all insoluble cell
debris. The pellet was resuspended in ¼ volume of inclusion body wash buffer
(50 mM Tris-HCl, 10 mM EDTA, 0.5% Triton-X 100, pH 8.0) to break up and
solubilise lipid membranes and membrane proteins. Centrifugation and
resuspension of the pellet in the wash buffer were repeated, followed by a
further centrifugation to pellet the inclusion bodies. The pellet was resuspended
in the same volume of water and centrifuged once again. This was repeated to
ensure all detergent and EDTA was removed. Inclusion body pellets could then
be stored at -20°C if necessary.
2.4.2. Solubilisation of Inclusion Bodies
Inclusion bodies were solubilised by resuspending the pellet in solubilisation
buffer (5 M guanidine hydrochloride, 50 mM tris-HCl, 20 mM DTT, pH 8.7) using
1/200th volume of the total cell culture (i.e. 2400 ml culture resuspend in 12 ml
solubilisation buffer). DTT was added to the buffer just before use to prevent air
oxidation. The mixture was incubated at room temperature for 45 min. This
reduced and denatured the protein molecules, causing the inclusion bodies to
break up into monomeric BPTI.
2.4.3. Desalting of Solubilised Inclusion Bodies
The denaturant and reducing agent were removed from the BPTI solution using
desalting columns. 5 ml HiTrap desalting columns (GE Healthcare) contain a
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Superdex g-25 Superfine matrix and were used to effectively remove all small
molecular weight substances. Columns were attached to an ÄKTApurifier 100
FPLC. Typically, four columns were attached in series to allow a larger volume
of protein to be injected. The solvent used for desalting was 10 mM HCl, so that
the protein remained in a reduced state at a low pH after elution. The columns
were equilibrated with 3 CV of solvent. The solubilised inclusion body sample
was centrifuged to pellet any remaining precipitate. 3 ml of supernatant was
then loaded onto a 5 ml loop before being injected onto the column. Typically, a
flow rate of 1.5 ml/min was used, ensuring that the maximum pressure (0.3 MPa)
was not exceeded. The absorbances at 280 nm and 254 nm were recorded
along with the conductance. The eluted material was collected in 1 ml fractions.
Fractions correlating to observed peaks at 280 nm were analysed by SDS-
PAGE to identify the BPTI protein. If required, the process was repeated,
loading 3 ml of sample on each occasion. Separate HiTrap columns were
maintained for each BPTI construct, to avoid cross-contamination.
2.4.4. Oxidation and Refolding of BPTI
Reduced BPTI was refolded to its fullest extent via an oxidation reaction. In the
case of wild type BPTI, this generated the native protein. In the case of other
BPTI constructs, the extent to which the protein proceeded through the folding
pathway was determined by the combination of cysteines present, see Figure
1.12. Each sample was diluted such that the final concentration of protein would
be 50 μM (0.3 mg/ml) after later addition of the refolding buffer containing
oxidising and reducing agents. To prevent aggregation of the protein, it was
important to dilute the BPTI before addition of the refolding agents. Separately,
the following components were added together, such that the final
concentrations (after later addition of BPTI) were as follows:
 Refolding buffer, 0.1 M Tris-HCl + 1mM EDTA, pH 8.7
 Oxidising agent, 0.5 mM glutathione disulfide (GSSG)
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 Reducing agent, 2 mM glutathione GSH
Note that as well as using GSSG as the oxidising agent, reducing GSH is also
added to facilitate the isomerisation of incorrectly paired disulfide bonds. Once
prepared, the reagents were used immediately since they deteriorate rapidly.
The protein was then added gradually to the refolding buffer while stirring. The
reaction was incubated overnight at 4°C while stirring gently. The reaction
mixture was centrifuged at 75,000 x g to pellet any aggregated protein.
2.4.5. Post-refolding Purification using Solid Phase Extraction
Once refolding was complete, the diluted protein was concentrated and the
refolding buffer and agents were removed. This was achieved using solid phase
extraction (SPE). Pre-packed 3 ml Grace Vydac SPE columns were used,
containing reverse phase C-18 bonded to 13 μm silica beads with a 300 Å pore
diameter. The relatively large pore size was essential for use with
macromolecules such as proteins. Optimisation of experimental conditions
indicated that these columns have a maximum binding capacity of 3.0 mg for
BPTI. Protein samples were prepared by adding ¼ volume of sample buffer
(20% acetonitrile, 2% TFA). The column was activated with 3 ml 50%
acteonitrile, then equilibrated with 3 ml equilibration buffer (5% acetonitrile, 0.5%
TFA). The sample was applied to the column either manually by syringe or by
gravity flow overnight at 4°C, depending on the sample volume. The column
was rinsed with 3 x 3 ml 5% acetonitrile to wash off weakly bound protein and to
ensure all TFA was removed. Protein was eluted in 2 x 3 ml 50% acetonitrile.
2.4.6. Vacuum Evaporation and Lyophilisation
The sample eluted from SPE in 50% acetonitrile was put into a Duran vacuum
desiccator (Schott), which was attached to a diaphragm pump and run under
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vacuum overnight to evaporate off the volatile acetonitrile, leaving the protein in
water. This was then frozen in liquid nitrogen and the water was sublimated by
lyophilisation for 4-6 hours until only a white powder remained. The lyophilised
protein was stored at -20°C.
2.5. Purification of PDI Constructs
2.5.1. Immobilised Metal Affinity Chromatography (IMAC)
Lysed cells were centrifuged at 30,000 x g for 12 min to pellet all insoluble cell
debris. Initial purification of PDI constructs from the soluble portion of the cell
lysate was performed using an IMAC column, whereby the His-tag of the
recombinant protein binds to the nickel bound to a sepharose resin. IMAC
columns were produced by adding Chelating Sepharose Fast Flow resin (GE
Healthcare) to a syringe to produce a column volume (CV) of 5 ml. The column
was rinsed with 10 CVs of water before adding 2 ml of 0.2 M nickel chloride.
After rinsing with 5 CVs of water, 5 CVs of 20 mM sodium acetate, 0.5 M NaCl
pH 3.0 was added to rinse out any weakly bound nickel. The column was
equilibrated with 5 CVs of 20 mM sodium phosphate pH 7.3. The crude protein
sample (total soluble portion of cell lysate) was then loaded onto the column.
Loosely bound impurities were removed using 2 CVs of a low imidazole wash
(25 mM imidazole, 0.5 M sodium chloride, 20 mM sodium phosphate, pH 7.3).
This was followed by 5 CVs of a low salt solution (20 mM sodium phosphate pH
7.3). PDI was then eluted using 5 CVs of 50 mM EDTA, 20 mM sodium
phosphate, pH 7.3.
Chapter 2: Materials and Methods
69
2.5.2. Buffer Exchange by Dialysis
Dialysis was used to buffer exchange the eluted samples from the IMAC
purification to remove the nickel and EDTA. Dialysis membrane with a molecular
weight cut-off (MWCO) of 12-14 kDa (Medicell International) was used to buffer
exchange into 20 mM sodium phosphate, pH 7.3.
2.5.3. Ion Exchange Chromatography
Further purification of the protein was performed using anion exchange
chromatography. A 10 ml Source 30Q column (GE Healthcare) provided a resin
with a strong positive charge. This was connected to an ÄKTApurifier 100 fast
protein liquid chromatography (FPLC) system (GE Healthcare). The column was
rinsed and equilibrated in 20 mM sodium phosphate, pH 7.3 (Buffer A). The
protein sample was loaded onto the column via an injection loop. A gradient
from 0-100% of 20 mM sodium phosphate, 0.5 M NaCl, pH 7.3 (Buffer B) was
used to elute the protein over 10 CVs. 2 ml fractions were collected. Those
corresponding to a peak in the chromatogram were analysed by SDS-PAGE to
identify the desired protein.
2.5.4. Size Exclusion Chromatography
For preparations of the bb’x construct of PDI, size exclusion chromatography
was used to separate the monomer from the dimer. A Superdex 75 10/300 GL
gel filtration column (GE Healthcare) was connected to an ÄKTApurifier 100
FPLC (GE Healthcare). 20 mM sodium phosphate, 150 mM NaCl, pH 7.3 was
used as the buffer. The column was equilibrated using 2 CVs of buffer (CV =
300 ml). Samples were concentrated using Centricon filter columns (10 kDa
MWCO) to a volume of 1 ml. The sample was injected via a 2 ml injection loop
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and buffer was consumed at a flow rate of 2.0 ml per minute. Protein elution
was monitored at A280 and 5 ml fractions collected. Fractions showing
absorbance peaks were analysed by native PAGE to verify monomer and dimer
states.
2.6. Estimating Protein Concentration
Protein concentration was determined by measurement of the UV absorbance
at 280 nm (A280) using a Jenway 6305 spectrophotometer. The extinction
coefficient (ε280), expressed in M-1cm-1, for each protein was calculated by
submitting the sequence of the mature protein (including His-tag, where
appropriate) to the ProtParam tool of the Expasy Proteomics Server (available
at http://www.expasy.ch/tools/protparam.html). The protein concentration was
then calculated based on the Beer-Lambert law:
Protein Concentration (M) = A280 / (ε280 x path length of cuvette (cm))
2.7. Alkylation using Iodoacetamide
Successful oxidation of wild type BPTI and BPTI mutants can be judged by the
number of free thiols groups remaining. Free thiol groups can be alkylated by a
carboxyamidomethylation reaction with iodoacetamide. When analysed by mass
spectrometry, an additional 57.1 Da will be added to the mass of the protein for
each free thiol group. 2.2 M iodoacetamide was prepared from powder into 100
mM sodium phosphate pH 7.0. Iodoacetamide is light sensitive, so was kept in
the dark at all times by covering with aluminium foil. To fully dissolve, the
iodoacetamide was kept at 65°C. BPTI samples were prepared by dilution to
make 50 μl of 50 μM in 100 mM sodium phosphate pH 7.0 and kept on ice.
Samples were used immediately to avoid air oxidation. The iodoacetamide was
removed from the heat for 90 seconds to cool. The protein sample was added
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and incubated at room temperature for exactly 30 seconds. Iodoacetamide,
while binding preferentially to free thiol groups, will also show some binding to
other amino acid side chains, so it was important not to let the reaction proceed
for too long. The reaction was quenched by adding 33 μl of 20% acetonitrile, 2%
TFA. This will quench the reaction by reducing the pH. The sample was frozen
immediately in liquid nitrogen and stored at -80°C.
2.7.1. Alkylation to Trap Reduced Wild Type BPTI
The iodoacetamide reaction can also be used to stabilise the fully reduced wild
type BPTI, if performed before the oxidation reaction. This fully reduced BPTI
effectively represents a protein at the beginning of the folding pathway. As such,
its structural interaction with PDI could be very informative. The protocol of
alkylation to trap fully reduced BPTI was essentially as described above, but on
a preparative scale. To reduce the amount of iodoacetamide required, the
reaction used only 50 mM iodoacetamide, but the reaction was allowed to
proceed for 20 min. Aliquots of the fully reduced protein were analysed by mass
spectrometry to verify that alkylation was successful. As with fully folded BPTI,
the reduced protein was further purified using solid phase extraction, see
Section 2.4.5.
2.8. ESI Mass Spectrometry
2.8.1. Sample Preparation
All mass spectrometry samples of BPTI were prepared to a concentration of 50
μM in 50 μl of 50% acetonitrile. Normally, concentrating and buffer exchange of
the sample was required. This was achieved by applying the sample to a
PepClean C-18 Spin Column (Pierce). This contains a porous C-18 reversed-
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phase resin that the protein can bind to during centrifugation in an aqueous
buffer. The protein was then eluted by centrifugation with 50% acteonitrile.
2.8.2. Data Acquisition
Mass spectrometry was performed on a Bruker mircOTOF electrospray
ionisation (ESI) time of flight (TOF) instrument. The control software was used
to observe a window between 500 and 2500 mass/charge ratio (m/z). Each
sample was injected via a syringe at a flow rate of 240 μl/h. Signals were
recorded over 1.5 mins and an averaged spectrum was acquired. A
mass/charge ruler facilitated the identification of the dominant mass species in
various charge states. This was used to deconvolute the spectrum to mass
versus intensity, independent of the charged state.
2.9. Electrophoresis Analysis
2.9.1. SDS-PAGE
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was
used to analyse protein samples under denaturing and reducing conditions.
2.9.1.1. SDS-PAGE for Analysis of BPTI Constructs
In order to achieve good resolution of bands near to the small molecular weight
of BPTI (6.6 kDa), pre-cast gels were used for SDS-PAGE analysis. 12%
NuPAGE Novex Bis-Tris Mini Gels (Invitrogen) were run using a 2-(N-
morpholino)ethanesulfonic acid (MES) running buffer. Gels were typically run at
200 V for 35 min. SeeBlue Plus 2 Pre-Stained Standard (Invitrogen) provided
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protein markers with a suitable range of molecular weights, including
commercial pancreatic trypsin inhibitor (also known as aprotinin).
2.9.1.2. SDS-PAGE for Analysis of PDI Constructs
SDS-PAGE of PDI constructs were carried out according to the Tris-Glycine
buffer system (Laemmli 1970). Discontinuous gels were cast consisting of a
resolving gel at pH 8.8 and a stacking gel at pH 6.8. Typically, 12% acrylamide
was used in the resolving gel. Gels were cast using the Mini Protean II gel kit
(Bio-Rad). Samples were reduced with the addition of 10% β-mercaptoethanol
to the sample loading buffer (1 M Tris-HCl pH 6.8, 40% glycerol, 0.8% SDS,
0.1% w/v bromophenol blue). A low molecular weight marker from Amersham
GE Healthcare was used to estimate the molecular weight of each band. Gels
were run at 60 V through the stacking gel, then at 200 V until the dye front ran
off the gel (typically 60 min). Gels were stained using Coomassie Blue R250 dye.
2.9.2. Native PAGE
To distinguish between monomeric and dimeric states of various PDI constructs,
PAGE was run under native conditions. The method was identical to SDS-
PAGE of PDI constructs, except that SDS and β-mercaptoethanol were omitted
from the gels, the loading buffer and the running buffer.
2.10. Circular Dichroism
Far-UV circular dichroism (CD) was performed on BPTI samples using a Jasco
J-815 CD spectropolarimeter at 25°C, unless stated otherwise. Lyophilised
samples were resuspended in 10 mM sodium phosphate, pH 7.3 to a
concentration of 0.1 mg/ml (15 μM). Spectra were recorded between 260 nm
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and 190 nm, averaged over 16 scans per sample and baseline corrected using
buffer only. CD spectra were analysed using Dichroweb (Whitmore and Wallace
2008).
2.11. Surface Plasmon Resonance
Surface plasmon resonance was performed on a Biacore 2000 instrument from
GE Healthcare. All experiments used a CM5 sensor chip, which contains a
carboxymethyl dextran surface, onto which proteins were immobilised. All
chemicals were supplied by GE Healthcare specifically for use with Biacore
instruments. HBS-EP, a HEPES buffer containing EDTA and Surfactant P20,
was used as a running buffer. The temperature was varied as described in the
results.
2.11.1. Protein Immobilisation by Amine Coupling
All proteins were immobilised to the chip surface by amine coupling, whereby
succinimide esters react spontaneously with primary amine groups to link
covalently to the dextran matrix. Binding may occur at NH2 of amino acid side
chains as well as the N-terminus of the protein. Prior to immobilisation of the
desired protein, pH scouting was performed to establish the most effective pH,
which turned out to be pH 5.0 for all immobilised proteins.
Preparing the dextran surface of the CM5 sensor chip for amine coupling first
requires reactions with 0.2 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC) and 0.05 M N-hydroxysuccinimide (NHS). This activates the carboxyl
groups on the surface to give reactive succinimide esters. The succinimide
esters react spontaneously with amine groups, allowing direct immobilisation of
molecules. The protein was prepared to a concentration of 50 μg/ml in HBS-EP
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buffer. The standard protocol for amine coupling was followed using the
manufacturer’s instructions. Once the protein immobilisation was complete, 1 M
ethanolamine was used to deactivate excess reactive groups.
2.11.2. Binding Analysis
All protein samples used as analyte for binding analysis were prepared in HBS-
EP running buffer to a volume of 370 μl for 2 replications. Prior to analysis, all
flow cells were normalised using 40% glycerol to compensate for variations in
the reflectance characteristics between individual sensor chips. The procedure
followed the manufacture’s instructions. Analyte was injected at a flow rate of 50
μl/min, which was fast enough to prevent mass transport effects. Regeneration
of the chip after each analysis was performed using 400 μl of 50 mM NaOH.
2.11.3. Analysis of Biacore Data
BIAevaluation version 3.1 was used to process and analyse the raw sensorgram
data. Sensorgrams were baseline corrected using the Y-transform function, by
zeroing the signal in a region before the start of injection. Only the association
and dissociation phases of each sensorgram were used for binding analysis. All
curve fitting used simultaneous ka/kd calculations.
Fitting simultaneous ka/kd models to experimental data involves both generation
of the rate equations for the model used and finding the values for parameters in
the rate equations that best fit the experimental data.
During curve fitting calculations, differences are calculated between the
experimental data points and the calculated points of the model, known as
residuals. Using BIAevaluation, curve fitting optimises parameter values by
minimising the sum of the squared residuals, which is performed by the
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Marquardt-Levenberg algorithm. The algorithm starts with the initial values
given for each parameter in the model, then iterates to minimise the sum of
squared residuals (Biacore 1997).
The most appropriate fit of experimental data to a model is influenced by both
the ability of the fitting algorithm to converge towards the true minimum in the
sum of squared residuals function and by the number of parameters that can be
varied in the model.
It is important to bear in mind that as the complexity of a model increases the
ability to fit the equations to the experimental data improves, since the number
of parameters involved increase and hence the degrees of freedom in the model
increase. The simplest model that fits the data should always be regarded as
the most appropriate.
For the data analysed in this study, many different models were tried. However,
the two predefined BIAevaluation models that were examined closely were the
1:1 (Langmuir) Binding model and the Heterogeneous Ligand (Parallel
Reactions) model. Use of these models for curve fitting to PDI/BPTI interaction
sensorgrams and optimisation of the parameters for each model are discussed
in section 7.4.
2.11.3.1. Definition of 1:1 (Langmuir) Binding Model
The 1:1 (Lamgmuir) Binding model is the simplest model, which assumes a 1:1
interaction between the analyte (A) and the immobilised ligand (B), forming the
complex (AB).
Reaction: A + B↔ AB
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Parameters:
tOn – Sample injection start time (s), constant.
tOff – Sample injection end time (s), constant.
Conc – analyte concentration (M), constant.
Rmax – Maximum analyte binding capacity (Response Units), fit globally.
ka – Association rate constant (M-1s-1), fit globally.
kd – Dissociation rate constant (s-1), fit globally.
RI – Bulk refractive index contribution (Response Units), fit locally.
Rate Equations:
A = Conc
B[0] = Rmax
dB/dt = - (ka*A*B - kd*AB)
AB[0] = 0
dAB/dt = (ka*A*B - kd*AB)
Total response:
AB + RI
Calculated Report Parameters:
KA (1/M) = ka/kd. Equilibrium binding (affinity) constant, global.
KD (M) = kd/ka. Equilibrium dissociation constant, global.
Req (Response Units) = ka*Conc*Rmax*/(ka*Conc+kd). Steady state binding level,
local.
kobs (1/s) = ka*Conc+kd. Observed rate constant (slope of ln(dR/dt) against t),
local.
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2.11.3.2. Definition of Heterogeneous Ligand (Parallel Reactions)
Model
The Heterogeneous Ligand (Parallel Reactions) model describes an interaction
between one analyte (A) and two independent ligands (B1 and B2), forming two
complexes (AB1 and AB2). The calculated fitted curve is simply the sum of the
two independent reactions. Heterogeneous ligand situations frequently occur in
practice due to heterogeneous immobilisation of ligand as well as through
heterogeneity in the ligand itself.
Reaction 1: A + B1↔ AB1
Reaction 2: A + B2↔ AB2
Parameters:
tOn – Sample injection start time (s), constant.
tOff – Sample injection end time (s), constant.
Conc – analyte concentration (M), constant.
Rmax – Maximum analyte binding capacity (Response Units), fit globally.
ka1 – Association rate constant for A+B1=AB1 (M-1s-1), fit globally.
kd1 – Dissociation rate constant for A+B1=AB1 (s-1), fit globally.
ka2 – Association rate constant for A+B2=AB2 (M-1s-1), fit globally.
kd2 – Dissociation rate constant for A+B1=AB2 (s-1), fit globally.
RI – Bulk refractive index contribution (Response Units), fit locally.
Rate Equations:
A = Conc
B1[0] = RMax1
dB1/dt = - (ka1*A*B1 - kd1*AB1)
B2[0] = RMax2
dB2/dt = - (ka2*A*B2 - kd2*AB2)
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AB1[0] = 0
dAB1/dt = (ka1*A*B1 - kd1*AB1)
AB2[0] = 0
dAB2/dt = (ka2*A*B2 - kd2*AB2)
Total response:
AB1 + AB2 + RI
Calculated Report Parameters:
KA1 (1/M) = ka1/kd1. Equilibrium binding (affinity) constant for A+B1, global.
KA2 (1/M) = ka2/kd2. Equilibrium binding (affinity) constant for A+B2, global.
2.12. Nuclear Magnetic Resonance Spectroscopy
2.12.1. Sample Preparation
Unless otherwise stated, the NMR buffer used was 25 mM sodium phosphate,
100 mM NaCl, 10% D2O, pH 6.5. This buffer was compatible with all BPTI and
PDI constructs and allowed for direct comparison with previous PDI spectra.
BPTI samples were resuspended with the NMR buffer directly from lyophilised
powder. This was centrifuged at 16,000 x g for 2 min to remove any precipitate
and the pH was checked. Protein concentrations were measured but varied
according to the solubility of each construct, which depended on each protein’s
stage through the folding pathway, and are specified for individual results.
Experiments observing BPTI used 180 μl sample inserted into 3 mm Bruker
Match NMR tubes.
Since bb’x alters due to lyophilisation, samples were prepared fresh and
concentrated to 1.0-1.5 mM in 25 mM sodium phosphate, 150 mM NaCl, 10%
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D2O, pH 6.5 using Centricon filter column (10 kDa MWCO). 330 μl of sample
were required for each experiment, which used 5 mm Shigemi tubes.
2.12.2. Data Acquisition of BPTI Samples
All BPTI experiments were performed on a Bruker AV II 700 spectrometer
operating with a 16.45 Tesla ultra shielded superconducting magnet (700 MHz
1H resonance frequency). It was operated using a TCI cryoprobe 1H/13C/15N with
Z gradients (Bruker). Operating temperatures varied and are specified for each
result. Results were acquired using TopSpin version 2.1 (Bruker). Locking was
performed against the deuterium signal. Shimming, matching and tuning were
performed automatically using the appropriate commands. Water suppression
was performed by using an excitation sculpting pulse sequence. The spectral
width was set to 16 ppm and the power level was 5.90 db for a proton signal.
The transmitter frequency offset, representing the precise chemical shift of the
bulk water, and pulse time parameters were optimised for each sample. The
centre of each spectrum was set to the transmitter frequency offset. A receiver
gain adjustment was performed prior to data acquisition so that the optimum
amount of signal would be detected by the receiver. For longer experiments,
auto-shimming was activated to ensure a homogenous magnetic field was
maintained. A 1D spectrum was acquired before and after longer experiments
and compared to ensure the sample remained unaltered.
2.12.3. Data Processing of BPTI Data
Raw NMR data were processed using TopSpin version 2.1 (Bruker). The free
induction decay (FID) signal was truncated using the qsin apodisation function,
to optimise the signal-to-noise ratio. Zero filling of the truncated signal was used
to avoid any degradation of the resolution. The FID was then Fourier
transformed to change the signal from the time domain into the frequency
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domain. Data were then phased and baseline corrected to optimise the
symmetry of the peaks. The water peak from solvent was used to calibrate each
spectra, with the precise ppm adjusted to account for variations in temperature
(Wishart, Bigam et al. 1995).
2.12.4. Data Acquisition and Processing of PDI Samples
All HSQC spectrometry of 15N labelled bb’x samples were performed alongside
colleagues from the University of Kent. Samples were prepared with assistance
from Dr. L. Byrne and Dr. R. Williamson by resuspending in NMR buffer and,
after measuring the stock concentration, creating samples of the appropriate
concentration. Data were acquired at 298 K (25°C) using a four channel Varian
Unitylnova NMR spectrometer operating at 14.1 Tesla (600 MHz 1H resonance
frequency), equipped with a 5 mm HCN z-pulse field gradient probe. All
experiments were solvent suppressed using WATERGATE (Piotto, Saudek et al.
1992) using a gradient field strength of 40-50 G cm-1. Data processing was
carried out by Dr. M. Rowe (University of Kent) using Varian and Bruker
software.
2.12.5. 2D 1H-1H TOCSY / 2D 1H-1H NOESY
Both 2D TOCSY and 2D NOESY experiments were performed using 4096 data
points in the F2 dimension (1H) and 512 data points in the F1 dimension (1H),
with a mixing time of 60-80 ms. Total acquisition time of either experiment was
approximately 8.5 hours. 2D TOCSY and 2D NOESY were normally run
sequentially with the same sample.
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2.12.6. 15N-1H HSQC
Unless otherwise stated, HSQC experiments were performed using 2048 data
points in the F2 dimension (1H) and 128 data points in the F1 dimension (15N).
Total acquisition time was approximately 15 min.
2.12.6.1. 15N-1H HSQC at Various Temperatures
Wherever HSQC spectra were collected at various temperatures, the lock signal
was allowed to stabilise before proceeding. Shimming, matching and tuning
were repeated at each new temperature.
2.12.6.2. 15N-1H HSQC of BPTI with PDI Titration
Titration experiments were performed with 15N labelled wild type BPTI, 15N
labelled (30-51, 5-14) BPTI and 15N labelled fully reduced BPTI at ratios ranging
from 200:1 BPTI:PDI to 1:1 BPTI:PDI. For wild type and (30-51, 5-14) BPTI,
HSQC spectra were obtained using 400 μM samples. Due to its limited solubility,
HSQC spectra of reduced BPTI were acquired using 100 μM samples. The
amino acid assignments from BPTI without PDI present were then mapped onto
spectra with increasing PDI, thus identifying those BPTI residues least affected
in the BPTI:PDI complex.
2.12.6.3. 15N-1H HSQC of bb’x with BPTI Titration
Separate titration experiments were performed for different BPTI constructs:
wild type BPTI, (30-51, 5-14) BPTI and fully reduced BPTI. For wild type BPTI
and (30-51, 5-14) BPTI, HSQC spectra were obtained using 250 μM bb’x, with
bb’x:BPTI ratios of 25:1, 5:1 and 1:1. Due to the limited solubility of reduced
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BPTI, HSQC spectra were obtained using 250 μM bb’x at bb’x:BPTI ratios of
25:1 and 8.3:1. An additional HSQC spectrum was obtained at a 2.3:1 ratio, but
this required using bb’x at just 100 μM. The amino acid assignments from bb’x
without BPTI were used to assign spectra with increasing BPTI, identifying
residues that were significantly perturbed in the presence of the substrate.
2.12.6.4. 15N-1H HSQC with Hydrogen Deuterium Exchange
15N-1H HSQC experiments rely on a proton resonance. If the protein is
resuspended in a deuterium oxide NMR buffer, the exchange of protons for
deuterium will result in a loss of signal. Hence, the most solvent exposed
regions of the protein will lose their HSQC peak first, whereas the buried regions
of the protein will persist for longer. By comparing a timecourse of different BPTI
constructs, the stability and extent of folding of each can be elucidated.
For hydrogen deuterium exchange, the NMR buffer was as before, except it now
used 100% D2O as the solvent (25 mM sodium phosphate, 100 mM NaCl, 100%
D2O, pH 6.5). 15N labelled samples were prepared for wild type, (30-51, 5-14)
and fully reduced BPTI. Since it is important to acquire HSQC spectra as quickly
as possible after resuspending in the buffer, a dummy sample of 15N labelled
wild type BPTI was used for locking, shimming, matching, tuning and
optimisation of parameters prior to the preparing the first experimental sample.
All experiments were performed at 278K (5°C). To allow a greater frequency of
HSQC spectra to be collected within the first hour of the timecourse, the
acquisition time was decreased by halving the number of data points per scan.
This decreased the HSQC acquisition time to approximately 5 min. Acquisition
of the initial HSQC spectrum for each sample was started 5 min after the
lyophilised protein was resuspended in the deuterium oxide NMR buffer.
Spectra were obtained every 5 min until 20 min had elapsed, then every 10 min
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until 1 hour had elapsed, then every hour until 7 hours elapsed time. Final
spectra were recorded after 24 hours.
2.12.7. Data Analysis
Analysis of NMR data for all BPTI experiments was performed using Sparky
version 3.1. Data analysis of bb’x experiments were carried out using CcpNMR
Analysis version 2 (Vranken, Boucher et al. 2005). Initial experiments with bb’x
alone were used as a control to analyse the effect of adding various BPTI
constructs.
2.12.7.1. Peak Assignment of NMR Spectra from Previous Data
Wild type BPTI has been studied extensively by NMR. Previous NMR spectral
data from Biological Magnetic Resonance Data Bank (BMRB) entry 5359
(Biamonti 1996) were used as a template for the assignment of initial spectra.
Likewise, a previous study of bb’x (Byrne, Sidhu et al. 2009) provided spectral
data for initial assignment of bb’x control spectra acquired in this study, using
BMRB entry 15974.
2.12.7.2. De Novo Assignment of (30-51, 5-14) BPTI Backbone
1H NMR analysis has been performed previously on the (30-51,5-14) non-native
two disulfide intermediate of BPTI (Vanmierlo, Darby et al. 1991a). However,
this was performed using different conditions, e.g. a pH of 4.6, so was not
comparable for this study. To assign the backbone resonances for the (30-51, 5-
14) BPTI, 3D HSQC-TOCSY and 3D HSQC-NOESY experiments were
performed. These were used to identify each residue then establish a sequential
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assignment. This data was then mapped to the corresponding peaks in a 15N-1H
HSQC spectrum.
2.12.7.3. Chemical Shift Mapping
Analysis of the chemical shift between peaks of two HSQC spectra was
performed by establishing a peak list for each spectrum, which identified the 1H
and 15N resonances for each peak. The chemical shift difference was calculated
as:
combined shift difference = | 1H shift | + 1/6 | 15N shift |
The 15N shift is divided by six because the chemical shift range of 15N is
approximately six times larger than for 1H. The justification of this approach has
been described in detail by previous studies (Garrett, Seok et al. 1997;
Williamson, Carr et al. 1997). Visual depiction of chemical shifts was illustrated
using MolMol version 2K.2.
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Chapter 3. Preparation and Characterisation of BPTI
Constructs
3.1. Introduction
The aim of this study was to investigate the structure of folding intermediates of
BPTI and their interaction with PDI. The first stage in this process was to
prepare all the appropriate constructs. Previous work in the Freedman group
laboratory had produced well established protocols for the expression and
purification of various PDI constructs. Details of expression of these constructs
to study interaction with BPTI are outlined in the relevant NMR results chapters.
Here, focus is on the expression and purification of the various BPTI constructs.
First, the expression system is explained. An outline of the mutations required
for each of the folding intermediates is shown. Small culture expressions reveal
which mutant constructs show sufficient expression. After some optimisation,
large scale expression and purification is pursued.
For each construct, initial purification was performed through a series of washes
designed to isolate inclusion bodies. Inclusion bodies were then solubilised
using denaturant and reducing agent. The protein was then desalted to buffer
exchange into 10 mM HCl. Where appropriate, the reduced protein was then
oxidised by dilution using a buffer that included both oxidising and reducing
agents, thus facilitating the processes of both oxidation and isomerisation. This
resulted in each construct refolding to its fullest extent. Solid phase extraction
was used to both concentrate the refolded protein and to remove the refolding
agents. Finally, each construct was lyophilised prior to storage at -20°C.
Chapter 3: Preparation and Characterisation of BPTI Constructs
87
Throughout this chapter, SDS-PAGE, chromatograms, mass spectra and
circular dichroism are used to identify and characterise each of the BPTI
constructs. Alkylation reactions were used prior to mass spectrometry to verify
the oxidation state of each protein.
3.1.1. Expression Vector of Wild Type BPTI
The expression vector containing the ORF for recombinant wild type BPTI was
kindly provided by Prof. Lloyd Ruddock from the University of Oulu, Finland. The
expression vector was pET23b, which is a frame-shifted version of pET23a
shown in Figure 3.1. The ORF for wild type mature BPTI was inserted into the
multiple cloning site of the vector as described in section 2.1.
Figure 3.1: Vector map of pET23a (Novagen). Vector pET23b is identical, except it is a
3665bp plasmid, with 1 base pair subtracted after BamHI at 198.
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3.1.2. BPTI Mutations to Trap Intermediates along the Folding
Pathway
In order to generate partly-folded intermediates that could be analysed to
elucidate their structure and interaction with PDI, mutations were performed to
the wild type DNA. Figure 1.12 illustrates the folding pathway of BPTI, showing
the combination of disulfide bonds used to define each intermediate. In order to
trap each of the partly folded intermediates and prevent further oxidation, any
thiol groups not involved in the disulfide bonds already formed were removed.
This was performed by mutating out the appropriate cysteine residues. Serine is
structurally very similar to cysteine, except that the thiol is replaced by a
hydroxyl group. This study was essentially reconstructing many of the partly
folded BPTI intermediates created by the Creighton group in the 1990s (see
section 1.12). Figure 3.2 illustrates the desired effect of mutations to produce
the (30-51, 5-14) intermediate, resulting in a folding intermediate similar to that
created in a previous study (Vanmierlo, Kemmink et al. 1994). The lack of thiol
groups at positions 38 and 55 prevent isomerisation to the (30-51, 5-55) or (30-
51, 5-38) species.
Figure 3.2: Double mutation of wild type BPTI. The mutations replaced cysteines with
serines at specified locations. This prevented the formation of certain disulfide bonds,
thus blocking the protein’s progression through the folding pathway. The example shown
has C38S and C55S mutations; when fully oxidised the (30-51, 5-14) non-native two
disulfide bonded intermediate is formed.
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The combinations of mutations required to trap each of the predominant species
of the BPTI refolding pathway are outlined in Table 3.1. Site directed
mutagenesis was performed for each single point mutation, changing guanine to
cytosine such that codon changes would be TGCTCC or TGTTCT.
Mutagenesis was performed in the Freedman group by Dr. Edward Jack, as
described in Section 2.1.
Table 3.1: Mutations required to establish BPTI at various stages along its folding
pathway. Non-native disulfide bonds are in italics.
Mutants
(Cys to Ser)
Disulfides
Produced
Stage of Folding Pathway
Wild Type (30-51, 5-55, 14-38) Native Protein
C14S C38S (30-51, 5-55)
2 Disulfide
Native Intermediate
C14S C55S (30-51, 5-38)
2 Disulfide
Non-native Intermediate
C38S C55S (30-51, 5-14)
2 Disulfide
Non-native Intermediate
C5S C14S
C38S C55S
(30-51)
1 Disulfide
Native Intermediate
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3.2. Results
3.2.1. Verification by DNA Sequencing
Purified plasmids were sent for DNA sequencing for all BPTI constructs. The T7
promoter primer was used to sequence the BPTI insert in each case. This
confirmed that all inserts contained the correct sequence needed to express the
desired BPTI mutant.
3.2.2. Test Expression of BPTI Constructs
Small cultures were used to test the expression of each of the BPTI constructs
specified in Table 3.1. The procedure was as specified in section 2.3.1, except
that only 5 ml cultures were used for expression. After 4 hours expression,
samples were centrifuged and the cell pellets were resuspended in buffer.
These were frozen, thawed and sonicated to lyse cells. An aliquot of each
sample was analysed by SDS-PAGE (Figure 3.3). Clear bands are observed for
BPTI at 6 kDa for wild type BPTI and for the C38S C55S mutant.
All of the mutants of BPTI that did not express contain the C14S mutation.
Although the DNA inserted into the expression vector of these constructs has
been confirmed by sequencing, it is suspected that during mutagenesis of
cysteine 14 to serine, using the PfuUltra high fidelity polymerase, another
mutation occurred elsewhere in the vector that has prevented expression of
these constructs. Some attempts were made to sub-clone these inserts into
fresh pET23b vectors, which may have permitted expression of these constructs.
However, these attempts were unsuccessful.
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Figure 3.3: SDS-PAGE for test expression of various BPTI constructs. Lane 1, SeeBlue
marker; lane 2, wild type BPTI; lane 3, C14S, C38S mutant BPTI; lane 4, C14S, C55S
mutant BPTI; lane 5, C38S, C55S mutant BPTI; lane 6, C5S, C14S, C38S, C55S mutant
BPTI (quad mutant). A distinct band can be seen at 6.6 kDa for both the wild type BPTI
and for the C38S C55S mutant BPTI, but not for any of the constructs containing the
C14S mutation.
3.2.3. Optimisation of Expression
To test if expression of BPTI constructs was induced with IPTG, two small
cultures of wild type BPTI were grown to an OD600 = 0.4. At this stage, one
culture was induced with 1 mM IPTG while the other culture remained without
IPTG. Each culture was incubated at 37°C, with aliquots removed every hour
between 3 and 6 hours, plus a final aliquot removed after overnight incubation.
SDS-PAGE analysis of each aliquot is shown in Figure 3.4. It clearly shows
increased expression in the culture induced with IPTG, with similar levels of
protein expression occurring between 3-6 hours post-induction.
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Figure 3.4: SDS-PAGE of a timecourse of wild type BPTI cultures expressed both in the
absence and presence of IPTG. Lane 1, SeeBlue marker; Lanes 2-6, uninduced culture;
lanes 7-11, culture induced with 1 mM IPTG. Aliquots of each culture were taken at
various times after induction of the appropriate sample: 3 hours (lanes 2 and 7); 4 hours
(lanes 3 and 8); 5 hours (lanes 4 and 9); 6 hours (lanes 5 and 10); overnight (lanes 6 and
11). As a control, a sample was prepared containing 5 μg of BPTI plus 5 μg of insulin.
Since expression cultures did not express proteins below the molecular weight of BPTI,
insulin, which gets reduced to separate α and β chains of approximately 3 kDa each, was
used to verify that the bands observed at 6 kDa were BPTI, rather than a mixture of
smaller proteins that were unable to be resolved in the gel. Clearly, the culture induced
with IPTG shows larger levels of BPTI expression than the uninduced culture. However,
small levels of BPTI expression are observed even in the uninduced sample. In the
induced sample, there is little difference in amount of BPTI produced between 3-6 hours
post-induction (lanes 7-10), with protein degradation occurring if the culture is left
overnight (lane 11).
To further optimise their expression, small cultures of wild type BPTI and the
C38S C55S mutant were expressed and analysed as described earlier, except
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that the optical density at which cultures were induced with IPTG was varied.
The SDS-PAGE (Figure 3.5) shows that both constructs had very similar levels
of expression, irrespective of the OD600 at induction, between values of 0.3 to
0.6.
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Figure 3.5: SDS-PAGE of cultures expressed after induction with IPTG at various optical
densities. Lane 1, SeeBlue marker; lanes 3-6, wild type BPTI induced with IPTG at OD600
of 0.3 (lane 3), 0.4 (lane 4), 0.5 (lane 5) and 0.6 (lane 6). Lanes 8-11, C38S C55S mutant
BPTI induced with IPTG at OD600 of 0.3 (lane 8), 0.4 (lane 9), 0.5 (lane 10) and 0.6 (lane 11).
This indicates very similar expression levels at all of the different optical densities.
3.2.4. Isolation of Inclusion Bodies
All BPTI constructs were expressed as inclusion bodies. The protocol for
expression and isolation of inclusion bodies was developed by the lab of Lloyd
Ruddock (University of Oulu, Finland). Protocols for each purification step were
developed as part of this study.
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Figure 3.6: SDS-PAGE for isolation of wild type BPTI inclusion bodies. Lane 1, SeeBlue
marker; lane 3, total expressed protein; lane 4, total soluble protein; lane 5, total
insoluble protein; lane 6, supernatant after 1st wash; lane 7, pellet after 1st wash; lane 8,
supernatant after 2nd wash; lane 9, pellet after 2nd wash; lane 10, supernatant after water
rinse; lane 11, pellet after water rinse. Large bands are seen around 6.6 kDa in each of the
pellet samples, indicating that the BPTI inclusion bodies have been successfully isolated.
Once expressed, the insoluble inclusion bodies needed to be purified from other
insoluble cell debris. This followed the protocol defined in section 2.4.1. Figure
3.6 shows SDS-PAGE analysis of the isolation of inclusion bodies for wild type
BPTI. All samples containing total expressed protein or pellet (after
resuspension) show clear bands representing the desired protein, whereas
samples containing the discarded supernatant (soluble proteins) show only very
small amounts of BPTI. After sonication and centrifugation, the insoluble protein
pellet was resuspended in a buffer containing detergent. This assisted in
breaking up and solubilising lipid membranes and membrane proteins, thus
separating them from the insoluble inclusion bodies during centrifugation.
Although most detergent was discarded in the supernatant after centrifugation, it
was important to ensure any trace detergent that may have remained in the
inclusion body pellet was removed before proceeding, since the detergent could
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bind to exposed hydrophobic regions of BPTI and interfere with downstream
folding of the protein. To ensure all traces of detergent were removed, the
inclusion bodies were resuspended in water twice, pelleting the inclusion bodies
by centrifugation after each resuspension and discarding the supernatant. The
isolated inclusion bodies mostly consist of BPTI, but some impurities persist.
3.2.5. Solubilisation of Inclusion Bodies and Desalting of BPTI
Once isolated, the inclusion bodies were solubilised using denaturant and
reducing agent, as described in section 2.4.2. This caused the protein
molecules to separate into monomers of reduced BPTI. The protein would have
degraded rapidly if left in strong denaturing conditions, so it was buffer
exchanged to 10 mM HCl using a desalting column. The low pH of this solution
retained the protein in a reduced state. Figure 3.7 shows a typical
chromatogram from the desalting of the solubilised inclusion bodies. Protein
elution was detected by a peak in absorbance at 280 nm, with corresponding
fractions being pooled. The salt is eluted later and is detected in the
chromatogram by a peak in conductivity. SDS-PAGE was used to confirm the
desired molecular weight of the protein (Figure 3.7, inset).
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Figure 3.7: Chromatogram showing desalting of wild type BPTI using HiTrap desalting
column. Absorbance at 280 nm (blue) indicates protein elution; high conductivity (brown)
indicates the elution of salt. Inset: SDS-PAGE of eluted protein. Lane 1, SeeBlue marker;
lane 2, pooled fractions 4 and 5 corresponding to A280 peak of the chromatogram.
3.2.6. Verification of Reduced BPTI by Mass Spectrometry
In order to confirm the protein was reduced BPTI, aliquots were analysed using
ESI mass spectrometry. Based on the primary sequence of the protein, the
molecular mass of the reduced protein was calculated as 6649 Da (using
ProtParam, http://www.expasy.ch/tools/protparam.html). Standard mass
spectrometry techniques can be used to identify if the main species is of the
correct mass.
Once fully oxidised, the thiol groups of six cysteine residues would be involved
in the formation of three disulfide bonds, resulting in the removal of six hydrogen
atoms. Thus, the molecular mass of fully oxidised BPTI would be expected to be
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six Daltons less than fully reduced wild type BPTI. Intermediates, which are
partially oxidised, will have a difference of just two Daltons for each disulfide
bond. Since this difference in mass is relatively small, it may be difficult to
resolve peaks in a spectrum using standard mass spectrometry. To get a
clearer idea of the success of reduction and oxidation reactions, an alkylation
reaction adds to the overall mass for each free thiol present. Here,
iodoacetamide was used for the alkylation process. The reaction is illustrated in
Figure 3.8. Details are outline in Section 2.7.
Figure 3.8: Iodoacetamide alkylation reaction.
Iodoacetamide has a molecular mass of 185.0 Da. When reacted with a free
thiol group, iodine plus one hydrogen are removed. The addition in mass for
each thiol group will be 185.0 Da – 126.9 Da (iodine) – 1 Da (hydrogen) = 57.1
Da. So, for fully reduced wild type BPTI, six free thiols will result in 57.1 Da x 6 =
342.6 Da added to the overall mass of the protein. Figure 3.9 shows mass
spectra for aliquots of fully reduced wild type BPTI both unreacted (black) and
after the iodoacetamide reaction (green). The correct difference in mass
indicates that the majority of the protein has been fully reduced, with a small
amount appearing to have only four free thiols.
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Figure 3.9: Deconvoluted ESI mass spectra of fully reduced wild type BPTI. The
unreacted WT (black) is overlaid with a spectrum after an iodoacetamide reaction (green),
confirming the reduced state of the protein.
3.2.7. Oxidation and Refolding of BPTI
Once reduced protein had been eluted from the desalting column, it was ready
to be oxidised. The details of the oxidation reaction are specified in section 2.4.4.
Since this reaction was performed in the presence of reducing as well as
oxidising reagent, the process of isomerisation could also take place. This
allowed refolding of each BPTI construct to continue until it could go no further
along the folding pathway (see Figure 1.12). In the case of wild type BPTI, it
refolded to the native structure. Figure 3.10 shows SDS-PAGE analysis of wild
type BPTI before and after refolding. In this case, the reduced protein had been
stored at -20°C, so needed to be thawed before use. Some aggregation of BPTI
occurred during the refolding reaction, but this process had the advantage of
causing remaining impurities also to aggregate, such that only very pure, fully
oxidised BPTI remained. Centrifugation was used to pellet any aggregated
protein and the supernatant (lane 7) was then taken forward.
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Figure 3.10: SDS-PAGE of wild type BPTI before and after refolding. Lane 1, SeeBlue
marker; lane 2, total reduced; lane 3, reduced pellet; lane 4, reduced supernatant; lane 5,
total refolded; lane 6, refolded pellet; lane 7, refolded supernatant.
By removing aliquots of the refolding reaction at different times, the progress of
refolding was monitored. An alkylation reaction was used to prevent further
oxidation and identify the oxidation state of each sample (section 0). Figure 3.11
shows mass spectra of wild type BPTI at various times through the refolding
reaction. After 1 hour of oxidation, about 60% of the protein was completely
oxidised (three disulfides), with most of the rest in the two disulfide state. This
two disulfide species diminished and the fully oxidised species became
increasingly dominant at later time intervals. After 4 hours, the two disulfide
species disappeared completely (not shown). Allowing the oxidation reaction to
proceed overnight at 4°C resulted in full oxidation of the protein.
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Figure 3.11: Deconvoluted ESI mass spectra of wild type BPTI at different stages of
oxidation, after iodoacetamide reaction. The protein is fully reduced (top, green) at the
start. After 1 hour, some protein has fully oxidised (top, black), but a significant
proportion of the two disulfide species remains. When incubated overnight, all of the
protein has fully oxidised (bottom).
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3.2.8. Post-refolding Purification Using Solid Phase Extraction
Chromatography
The refolded BPTI was further purified using solid phase extraction (SPE)
chromatography. This served the following purpose:
 Removal of oxidising and reducing agents
 Concentrating of diluted protein
 Preparation for lyophilisation
 Further purification
The procedure was carried out as specified in section 2.4.5. Protein was eluted
in 50% acteonitrile, which is suitable for downstream lyophilisation. SDS-PAGE
analysis of steps through the purification process of wild type BPTI is shown in
Figure 3.12. BPTI is observed before loading onto SPE column (lane 2) and
again in the first elution fraction during SPE purification (lane 5).
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Figure 3.12: SDS-PAGE of SPE purification of refolded wild type BPTI. Lane 1, SeeBlue
marker; lane 2, supernatant of refolded BPTI; lane 3, flow through from SPE; lane 4, rinse
from SPE; lane 5, 1st elute from SPE; lane 6, 2nd elute from SPE; lane 7, 3rd elute from SPE.
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Since different experiments require different solvent conditions and to avoid loss
through the freeze/thaw cycle, BPTI was lyophilised prior to storage at -20°C. It
has previously been shown that native BPTI can be lyophilised and
resuspended without adverse affect on its structure (Desai, Osterhout et al.
1994). Samples from SPE elution were vacuum evaporated to remove the
acteonitrile then lyophilised as described in section 2.4.6. Mass spectrometry of
lyophilised samples verified that neither SPE nor lyophilisation affect the
integrity of the samples (Figure 3.17).
3.2.9. Comparison of Recombinant Wild Type BPTI with
Commercial BPTI
Before studying modified versions of BPTI it was important to establish if the
recombinant wild type protein was similar to the commercially available product.
Circular dichroism was performed with both commercially available trypsin
inhibitor (purified from bovine pancreas) (Sigma) and with the recombinant wild
type BPTI, which had been lyophilised as explained above.
Figure 3.13 shows that the commercial and recombinant proteins have very
similar spectra. Dichroweb analysis showed the commercial product containing
0.28 α-helix; 0.33 β-sheet; 0.39 random coil (K2D method, NRMSD = 0.070).
Likewise the recombinant protein contained 0.27 α-helix; 0.33 β-sheet; 0.41
random coil (K2D method, NRMSD = 0.114) (Whitmore and Wallace 2008).
These results are also very similar to previous CD studies of native and refolded
BPTI, as shown in Figure 3.14.
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Figure 3.13: Far-UV circular dichroism of commercial (blue) and recombinant (red) wild
type BPTI.
Figure 3.14: Far-UV circular dichroism of BPTI, showing the native protein (open circles)
and the refolded protein (closed circles) (Kosen, Creighton et al. 1981).
The structure of recombinant wild type BPTI was also compared against
commercial BPTI using NMR spectroscopy, see section 4.2.2 for details.
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3.2.10. Expression and Purification of 15N Labelled BPTI
Expression and purification of 15N labelled wild type BPTI was identical to the
processes for unlabelled protein, except that the cultures were grown in minimal
medium using 15N labelled ammonium sulphate (section 2.3.2).
Wild type BPTI contains 85 nitrogen atoms, so the overall mass would be
expected to be approximately 85 Da larger than the unlabelled protein. Figure
3.15 shows ESI mass spectra of 15N labelled wild type BPTI before oxidation,
with and without alkylation. The unalkylated and alkylated samples show
dominant species of molecular masses that are 82.5 Da and 83.0 Da
respectively larger than the unlabelled protein (compare with Figure 3.9). This
suggested that the protein was approximately 98% 15N isotopically labelled, as
expected.
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0
Figure 3.15: ESI mass spectra of reduced 15N labelled wild type BPTI. Reacted (black) and
unreacted (green) with iodoacetamide.
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3.2.11. Trapping of Wild Type BPTI in the Reduced State
Fully reduced proteins are useful in the study of folding pathways, since they
represent the starting point from which folding intermediates are derived, and
are expected to have a high affinity to folding enzymes. Following desalting of
solubilised inclusion bodies, wild type BPTI was trapped in the fully reduced
state by alkylation of free thiol groups. Iodoacetamide was used as the
alkylating agent in a process similar to that used for mass spectrometry analysis.
However, conditions were optimised for preparative scale alkylation of the
reduced BPTI (section 2.7.1). Since oxidation was not required, the alkylated
reduced BPTI was then purified directly using solid phase extraction (section
2.4.5), then lyophilised (section 2.4.6) in the same manner as oxidised BPTI. 15N
labelled reduced BPTI followed the same process as the unlabelled protein,
except that it was prepared using 15N labelled wild type BPTI. Success of the
preparation of samples was confirmed using mass spectrometry (data not
shown).
One problem identified when lyophilised reduced BPTI was resuspended was
the low solubility of the protein. It had a maximum solubility of just 100 μM in the
NMR buffer, compared to the fully oxidised wild type which is still soluble at >1
mM. Significantly lower solubility is expected for a fully reduced protein, since it
will have many more exposed hydrophobic regions and thus a higher tendency
to aggregate.
3.2.12. Expression and Purification of (30-51, 5-14) BPTI
Intermediate
Expression and purification of (30-51, 5-14) BPTI followed the same protocol as
for wild type BPTI (sections 2.1 and 2.4). Likewise 15N labelled protein was
prepared using minimal medium.
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Figure 3.16 shows a chromatogram for the desalting of 15N labelled (30-51, 5-14)
BPTI from solubilised inclusion bodies. The A280 signal indicates the early
elution of the protein, possibly in several different conformations due to multiple
peaks. The denaturant, indicated by high conductance, is eluted later along with
the DTT reducing agent and small molecule contaminants.
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Figure 3.16: Chromatogram from desalting of 15N labelled (30-51, 5-14) BPTI. Blue,
absorbance at 280 nm; brown, conductance; red, eluted fractions.
The refolding of (30-51, 5-14) BPTI followed the same protocol as for wild type
BPTI, but due to the reduced number of free thiol groups available (due to Cys
to Ser mutations), the oxidation (and hence the refolding) can only proceed to a
certain level, as defined by the folding pathway (Figure 1.12). Mass
spectrometry confirmed successful oxidation and purification of the mutant
sample, both unlabelled (Figure 3.17) and 15N labelled (not shown).
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Figure 3.17: ESI mass spectra of fully oxidised BPTI. A) Wild type BPTI; B) (30-51, 5-14)
BPTI, which contains C38S and C55S mutations.
3.2.13. Comparison of Different Constructs
As well as analysing BPTI constructs in isolation, it was also useful to compare
the different constructs, so that any expected differences are observed. Figure
3.17 shows mass spectra for both wild type and (30-51, 5-14) BPTI after being
fully oxidised. A difference of 30 Da is observed between the dominant peaks of
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each spectrum. In the (30-51, 5-14) protein, two Cys to Ser mutations were
made. At an atomic level, each Cys to Ser mutation is effectively equivalent to
replacing a sulfur atom (32 Da) with an oxygen atom (16 Da). For two such
mutations, this would result in a difference of 2 x 16 = 32 Da. However, in the
fully oxidised protein, disulfide bond formation results in a single hydrogen atom
being removed from each of the Cys involved, resulting in a reduction of 2 Da in
mass for each disulfide bond. So the expected mass difference between wild
type BPTI (3 disulfides) and (30-51, 5-14) BPTI (2 disulfides) was 30 Da, just as
was observed from the mass spectra.
A comparison of secondary structure content between the various BPTI
constructs can be observed using circular dichroism. Figure 3.18 shows CD
spectra for the three constructs of BPTI. Some differences between the spectra
are visible. However, quantitative analysis of secondary structure was unreliable,
since reference data for unfolded proteins is not available (data not shown). This
indicates that far-UV CD is not very useful for detecting differences between the
different BPTI constructs, since large amounts of random coil secondary
structure in this small protein make differences difficult to discriminate.
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Figure 3.18: Far-UV circular dichroism of BPTI constructs at various stages of the folding
pathway, all acquired at 25°C. Blue, fully oxidised wild type BPTI; red, (30-51, 5-14)
mutant BPTI; green, reduced and alkylated wild type BPTI.
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Circular dichroism of 15N labelled proteins showed no significant difference in
secondary structure compared to the unlabelled equivalent proteins, indicating
that labelling did not significantly affect secondary structure (data not shown).
3.3. Discussion
This chapter has outlined the processes involved in the preparation of BPTI
samples. The mutations required to produce various partly-folded intermediates
were explained. Test expressions revealed that the (30-51, 5-14) two disulfide
was the only one which showed acceptable levels of expression.
A protocol was established for both pre- and post-refolding purification of BPTI
from inclusion bodies. The concentration and volumes of denaturant and
reducing agent were optimised to ensure solubilisation of inclusion bodies in as
small a volume as required. After exploring different purification techniques,
including reverse phase purification using high performance liquid
chromatography (HPLC), it was found that a desalting column provided the best
option for further purification of the reduced constructs. Refolding was
performed by dilution into a refolding buffer with oxidising and reducing agents.
A number of options were also explored for treatment of the protein after
refolding. Solid phase extraction is relatively uncommon for the purification of
macromolecules such as proteins, but a suitable column and procedure was
developed for the purification of BPTI. Volatile solvent was removed from the
eluted protein by vacuum evaporation, before finally the protein could be
lyophilised and stored at -20°C. Although the protocol was initially developed
using the wild type protein, it was also sufficient for the purification of both (30-
51, 5-14) and fully reduced BPTI.
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The correct molecular masses of purified constructs were verified using ESI
mass spectrometry. The oxidation state was confirmed by alkylation of free
thiols with iodoacetamide prior to mass spectrometry.
3.3.1. Summary of Purified BPTI Constructs
This chapter has outlined the expression, refolding (where appropriate) and
purification of three BPTI constructs representing different stages along this
protein’s folding pathway:
 Wild type BPTI, representing the natively folded mature protein, with
three disulfide bonds. This will be referred to as wild type BPTI.
 A partly-folded BPTI, specifically the (30-51, 5-14) two disulfide bonded
intermediate, which contains one native and one non-native disulfide
bond. This will be referred to as (30-51, 5-14) BPTI.
 Fully unfolded BPTI, represented by the fully reduced and alkylated wild
type mature protein. This will be referred to as reduced BPTI.
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Chapter 4. NMR Spectroscopy of BPTI Constructs
4.1. Introduction
Before analyses of the interaction of each BPTI construct with PDI, a study of
the structural characteristics of each recombinant construct in isolation was
performed. Several NMR studies have already been performed with BPTI, with
entries in the PDB data bank (Berndt, Guntert et al. 1992) and the Biological
Magnetic Resonance Data Bank (BMRB) (Biamonti 1996). First, the
recombinant wild type BPTI was compared to commercially available wild type
BPTI. This allowed us to verify if the recombinant protein is indeed
representative of the naturally occurring mature protein. Full assignment of the
wild type protein was then performed. The compatibility of BPTI to conditions
under which PDI has been studied was also investigated, so that interaction
studies would be viable. NMR characterisation of (30-51, 5-14) BPTI and
reduced BPTI followed in a similar manner, optimising conditions so that they
are most informative for each construct. All NMR spectra shown focus on the
fingerprint region, at 1H between 6-11 ppm, where most information about the
protein backbone can be elucidated.
4.2. NMR of Wild Type BPTI
4.2.1. TOCSY/NOESY NMR of Commercial BPTI at 36°C
The first stage in the process was to run 1H-1H TOCSY and 1H-1H NOESY NMR
experiments of commercially available native mature BPTI. These experiments
served as a suitable starting point since they observe only proton resonances
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and do not require any isotopic labelling of samples. NMR data was available
from a previous study of commercially available mature BPTI, submitted to the
BMRB data bank (Entry 5359) (Biamonti 1996). This study used 750 μM of BPTI
solvated in 25 mM calcium chloride, 3 mM sodium azide, 90% H2O, 10% D2O,
pH 5.8. Commercial BPTI used for this study was resuspended in the same
solvent at the same pH so that results could be directly compared. Figure 4.1
shows an overlay of TOCSY and NOESY spectra recorded for commercial BPTI.
In order to facilitate assignment of peaks, the appropriate 1H data for
assignments from the previous study were imported into the corresponding
spectra. Since prolines do not have amide protons, these residues were not
detected. The first residue, Arg1, was not available in the imported data.
Interestingly, there is one residue that is not within the fingerprint region at all.
The amide 1H resonance for Gly37 is actually found at approximately 4 ppm.
Inspection of the published structure of BPTI revealed that Gly37 is strongly
shielded by the aromatic side chain of Tyr35, resulting in a chemical shift far
upfield from where it may usually be expected. Visual inspection of individual
peaks in the acquired spectra showed the close proximity of the imported
assignments in the majority of cases. This allowed efficient assignment of peaks
in both the acquired TOCSY and NOESY spectra. N-terminal residues up to
Phe4 were not identified from the spectra. Likewise, residues Thr11, Arg39 and
Lys46 were not identified. All other residues were identified in both the TOCSY
and NOESY spectra. An assignment table from TOCSY and NOESY spectra is
available in Appendix A.
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Figure 4.1: Overlay of TOCSY and NOESY spectra for commercial wild type BPTI. Green,
TOCSY spectrum; blue, NOESY spectrum. NOESY assignments are labelled.
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4.2.2. TOCSY/NOESY NMR of Recombinant Wild Type BPTI at
36°C
To ensure the recombinantly expressed wild type BPTI truly reflects the
structure of the natural mature protein, its NMR spectra were compared with
commercially available BPTI. This also confirmed that the purification and
lyophilisation processes did not alter the protein conformation.
1H-1H TOCSY and 1H-1H NOESY NMR experiments were performed using the
same solvent and with the same acquisition parameters as for the commercial
protein.
Figure 4.2 shows an overlay of the recombinant and commercial TOCSY
spectra. It shows a high degree of agreement between the two spectra, with all
assigned peaks in the commercial protein spectrum also observed in the
recombinant protein. This clearly indicates that the recombinant protein adopted
the native state after purification and refolding and that its structure was not
altered by any post-refolding treatment. Interestingly, some peaks that were not
present in the commercial protein spectrum now appear, with relatively low
intensity, in the spectrum for the recombinant protein. Comparing these peaks to
assignments from previous NMR data of the mature protein allowed
assignments of Asp3, Phe4, Thr11, Arg39 and Lys46. Overlay of commercial
and recombinant BPTI NOESY spectra showed a similar pattern to the TOCSY
spectra, with the same additional residues having their peaks assigned (not
shown). This meant that only the prolines and Arg1 (plus the N-terminal Met
used as a start codon) remained unassigned, with Gly37 outside the fingerprint
region, as in the assignments of BMRB entry 5359 (Biamonti 1996). An
assignment table from TOCSY and NOESY spectra is available in Appendix A.
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Figure 4.2: Overlay of TOCSY spectra from commercial (green) and recombinant (red)
wild type BPTI samples. Assignments for the recombinant protein are labelled.
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4.2.3. NMR Conditions Compatible with PDI
Since the main aim of this study was to investigate the structural interaction of
PDI with BPTI it was important to establish a single NMR buffer that would be
compatible with both proteins. Recent work with various PDI constructs used a
buffer that gave optimal NMR spectra for these constructs (Nguyen, Wallis et al.
2008). The NMR buffer was 100 mM sodium chloride, 25 mM sodium phosphate,
90% H2O, 10% D2O, pH 6.5. This was used as the new buffer for NMR
experiments with wild type BPTI, to observe if this protein was stable and
yielded high quality NMR data under these conditions.
4.2.4. HSQC of Recombinant Wild Type BPTI at 36°C
1H-15N heteronuclear single quantum coherence (HSQC) NMR experiments
show interactions between the 15N amide nitrogen atoms of the protein
backbone and the hydrogen atoms that are covalently bonded to them. For a
standard protein, this essentially results in a single resonance peak for each
amino acid residue (except prolines), provided they remain in a single chemical
environment. Some protein side chains that contain amide groups will also be
visible.
15N isotopically labelled wild type BPTI was prepared as outlined in section 2.3.2.
An HSQC spectrum was then acquired using the parameters specified in
section 2.12.6. Figure 4.3 shows the HSQC spectrum for wild type BPTI at 36°C.
Chapter 4: NMR Spectroscopy of BPTI Constructs
117
Figure 4.3: HSQC of recombinant wild type BPTI at 36°C.
The peaks of the spectrum are very well dispersed throughout the fingerprint
region, with well resolved chemical shifts. This is indicative of a protein that is
fully folded, whereby each residue is stable in a well defined and distinct
chemical environment (Pascal 2008). Using both 15N and 1H data from previous
NMR assignment of BPTI, BMRB entry 5359 (Biamonti 1996), assignment of
peaks was performed. All residues were assigned except for the Arg1 and the
prolines. Amides from side chains appear at a 15N chemical shift of
approximately 112 ppm and display a characteristic ‘tear-drop’ shape. A full list
of these HSQC assignments is available in Appendix C.
4.3. NMR of (30-51, 5-14) BPTI Intermediate at Various
Temperatures
NMR of wild type BPTI showed that the recombinantly expressed protein
construct displays an almost identical structure to that of native mature BPTI.
This further demonstrated that the expression, purification and refolding
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processes yield the desired product, providing confidence that proteins
representing alternative positions in the BPTI folding pathway will reflect the true
structure of the folding intermediate.
Since a key aspect of this study is the interaction of BPTI with a folding enzyme,
it is more desirable to investigate the structure of partly-folded or fully unfolded
proteins, since they are the natural substrates of PDI. Using the same
conditions as for the wild type, a 1H-15N HSQC was performed with (30-51, 5-14)
BPTI, which is believed to be partly-folded. Figure 4.4 shows the HSQC
spectrum for (30-51, 5-14) BPTI at 36°C. It shows much poorer dispersion of
peaks, with most in the narrow range of 7.4-8.6 ppm. The accumulation of
peaks in a narrow chemical shift range compared to the wild type spectrum of
Figure 4.3 indicates that many of the residues are now in a very similar chemical
environment. This is indicative of a less folded protein, whereby instead of strict
positions in a well-defined structure, each residue is highly flexible and therefore
able to experience many different chemical environments. On the NMR
timescale, often only the average of these environments is observed,
representing a single peak in the HSQC spectrum. In a completely unfolded and
flexible protein, the averaged chemical shifts observed may be slightly different
for each residue, due to the type of amino acid and its position in the
polypeptide chain, which may impose certain steric hindrances. This results in a
region of overlapping, poorly dispersed peaks that are impossible to distinguish.
For (30-51, 5-14) BPTI, much of the spectrum in Figure 4.4 shows these
characteristics of an unfolded protein. However, some peaks within the
spectrum are clearly distinguishable, indicating that some residues have
retained a unique chemical environment. This implies that some part or parts of
(30-51, 5-14) BPTI remain folded, suggesting that the overall protein is indeed
partly folded.
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Figure 4.4: HSQC spectrum of (30-51, 5-14) BPTI at 36°C.
While Figure 4.4 shows strong evidence that (30-51, 5-14) BPTI represents a
partly folded protein, it is not feasible to attempt to assign each of the peaks.
However, such assignments are necessary in order to break down the
behaviour of the protein to specific regions or key residues.
At first, this may seem to be an intractable problem. However, a previous study
of similar partly folded BPTI constructs showed that increased resolution could
be obtained for one dimensional 1H NMR spectra by lowering the temperature
(Vanmierlo, Kemmink et al. 1994). They proposed that lines broaden on
increasing the temperature because of exchange between folded and unfolded
molecules with an intermediate rate on the chemical shift timescale (Vanmierlo,
Kemmink et al. 1994).
To explore the effect of temperature, a series of 1H-15N HSQC spectra were
acquired for (30-51, 5-14) BPTI using the same parameters as before, except
varying the temperature. Initially an HSQC spectrum was acquired at 36°C
before the temperature was gradually lowered to acquire spectra at 30°C, 25°C,
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20°C, 15°C, 10°C and 5°C. An increase in dispersion is clearly observed as
temperature is reduced. Figure 4.5A shows that even at 20°C there is a
significant gain in dispersion, with more distinct peaks visible. At 5°C, the HSQC
spectrum displays peaks with good resolution, well dispersed over 7-10 ppm
(Figure 4.5B). Indeed, this spectrum is much more characteristic of a folded
protein, suggesting that the (30-51, 5-14) non-native two disulfide intermediate
of BPTI has significant structure at 5°C.
Chapter 4: NMR Spectroscopy of BPTI Constructs
121
Figure 4.5: HSQC spectra of (30-51, 5-14) BPTI. A) 20°C; B) 5°C.
The effect of a change in temperature on secondary structure of (30-51, 5-14)
BPTI was also observed using far-UV CD. Figure 4.6 shows that the protein has
a very similar secondary structure profile at all temperatures. This suggests that
the changes observed by NMR at various temperatures are due to flexibility and
stability of the tertiary structure, rather than a change in secondary structure.
A
B
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Figure 4.6: Far-UV circular dichroism of (30-51, 5-14) BPTI at various temperatures. Blue,
5°C; red, 25°C; green, 36°C.
To compare the (30-51, 5-14) BPTI HSQC spectrum acquired at 5°C with the
wild type protein, a series of HSQC spectra was also acquired for wild type BPTI
at various temperatures. These showed very little change in the wild type at
lower temperatures (data not shown). This is not surprising since the wild type
already displays stable native structure at 36°C, so lowering the temperature
has little effect.
4.3.1. De Novo Assignment of (30-51, 5-14) BPTI NMR Spectra
Despite showing significant regions that appear to be folded, when overlaid with
the wild type protein the HSQC spectrum of (30-51, 5-14) BPTI intermediate at
5°C displays a different overall structure to wild type BPTI (see Figure 4.10).
Given this significant difference in spectra, the backbone of (30-51, 5-14) BPTI
could not reliably be assigned through a simple comparison. Instead, separate
NMR experiments were required for de novo assignment of the (30-51, 5-14)
Chapter 4: NMR Spectroscopy of BPTI Constructs
123
BPTI spectrum. A 15N labelled (30-51, 5-14) BPTI sample was used to perform
3D 15N-1H-1H TOCSY and 3D 15N-1H-1H NOESY experiments at 5°C. These
experiments provide information similar to unlabelled samples used for 2D
TOCSY and 2D NOESY, but have the additional 15N dimension, thus making
them much more informative and allowing distinction between peaks that
overlap in the 1H-1H dimensions. Since there is a general characteristic pattern
of chemical shifts associated with each amino acid (Roberts 1993), the 3D
TOCSY spectrum was used to identify the amino acid residues in (30-51, 5-14)
BPTI. A sequential walk across the “through space” interactions of the 3D
NOESY spectrum identified the relative position of each amino acid in the
primary sequence. These processes were performed iteratively so that as many
peaks as possible could be assigned correctly. Figure 4.7 shows a strip plot for
Arg53 to Gly56, a series of strips showing the sections of the 3D NOESY and
3D TOCSY spectra relevant to each residue, displayed at the appropriate 15N
chemical shift. Once the amino acid has been identified from the 3D TOCSY
spectrum, the 3D NOESY is used to assign cross correlating peaks to establish
the sequential assignment.
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Figure 4.7: Strip plots of (30-51, 5-14) BPTI 3D spectra illustrating the process of
sequential assignment of the protein backbone. Residues Arg53 to Gly56 are represented
showing three NOESY cross-peaks. For each residue, the 3D NOESY is represented in
green and 3D TOCSY is represented in red. The relevant assigned peaks are labelled in
each spectrum.
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In order to facilitate and visualise the assignment process, 2D 1H-1H TOCSY
and 1H-1H NOESY spectra were also acquired. Figure 4.8 shows an overlay of
the 2D TOCSY and 2D NOESY spectra after assigned peaks from the 3D data
had been mapped onto the corresponding peaks in the 1H-1H dimensions. In
cases where assignments were unable to be identified in the 3D spectra, the 2D
spectra were often able to highlight or clarify the relevant peaks. A previous
study that assigned 1H chemical shifts to a similar (30-51, 5-14) BPTI construct,
under NMR conditions different to this study, was also used as a rough guide for
assignment of resonances (Vanmierlo, Kemmink et al. 1994).
Figure 4.8: Overlay of 2D TOCSY (red) and 2D NOESY (green) spectra of (30-51, 5-14)
BPTI at 5°C. Assignments of NOESY peaks are labelled.
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4.3.2. Mapping 3D HQSC-TOCSY/ 3D HSQC-NOESY
Assignments to HSQC Spectrum
Once peaks were defined in the 3D HSQC-TOCSY spectrum, labelling of the
corresponding HSQC spectrum of (30-51, 5-14) BPTI was a straightforward
process. The chemical shifts of the 3D HSQC-TOCSY correlated directly with
those of the HSQC spectrum. Figure 4.9 shows the HSQC spectrum of (30-51,
5-14) BPTI, with labelled assignments.
Figure 4.9: HSQC spectrum of (30-51, 5-14) BPTI at 5°C showing assigned peaks.
One of the most interesting features identified from the assignment of peaks is
that all of the first 14 residues at the N-terminus of the protein are missing,
except for Gly12. This indicates that this region of the protein is still very flexible,
resulting in peak broadening and implying that the N-terminus of this mutant
remains unfolded.
Chapter 4: NMR Spectroscopy of BPTI Constructs
127
Native BPTI contains disulfides bonds between cysteines 30-51, 14-38 and 5-55.
The 30-51 disulfide bond is typically the first to form and is buried within the core
of the molecule. The other disulfide bonds assist in tethering more solvent
exposed regions, restricting their flexibility (Figure 1.11). However, the (30-51,
5-14) BPTI intermediate does not contain the 14-38 or 5-55 native disulfide
bonds, leaving much of the N-terminus in particular very flexible. Instead (30-51,
5-14) BPTI contains the non-native 5-14 disulfide bond, which is internal to the
N-terminal region, creating a loop that may sterically hinder potentially
stabilising interactions between the N-terminus and the rest of the molecule. In
addition, it should be noted that even in native wild type BPTI, all but three of
the first 17 N-terminal residues do not adopt regular secondary structure,
making this region of the protein inherently more flexible.
In contrast, the C-terminal end produces the most intense and clearly defined
peaks, suggesting a more clearly defined chemical environment for this region
of the protein. Interestingly, the last residue on the C-terminus, Ala58, shows
two clear peaks representing two distinct chemical environments for this residue.
A full list of assignments for all spectra of (30-51, 5-14) BPTI at 5°C is available
in Appendix B.
The difference between wild type and (30-51, 5-14) BPTI at 5°C can be
visualised using an overlay of both HSQC spectra (Figure 4.10). Despite
showing characteristics of a folded protein, the (30-51, 5-14) BPTI spectrum is
still significantly different than the wild type spectrum at 5°C. The unfolded
regions are large enough to affect the global structure of the protein, resulting in
a different chemical environment for each residue.
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Figure 4.10: Overlay of HSQC spectra of wild type (green) and (30-51, 5-14) BPTI (red) at
5°C. Assignments of wild type BPTI are labelled.
In an effort to quantify the differences between the wild type and (30-51, 5-14)
BPTI HSQCs, a chemical shift map was created comparing the chemical shifts
of the two spectra (Figure 4.11). The process of calculating chemical shift
changes was as outlined in section 2.12.7.3. Only residues with peaks assigned
in both spectra were used in this analysis.
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Figure 4.11: Change in chemical shift between wild type and (30-51, 5-14) BPTI HSQC
spectra. The secondary structure associated with each residue is illustrated graphically.
Residues not applicable to this analysis are represented as follows: P, proline; *,
assigned in wild type but not in (30-51, 5-14) BPTI; +, assigned in (30-51, 5-14) but not in
wild type BPTI. Arg1 was not detected in either HSQC spectra.
No obvious global pattern emerges, although the largest shifts occur in a coil
region and a row of four small shifts correspond closely to the β-turn region of
the protein, suggesting the environment of this structure may be least effected
by the mutations from the wild type. As previously observed, only Gly12 of the
first 14 residues at the N-terminus is assigned in (30-51, 5-14) BPTI. In wild type
BPTI, Gly37 was observed upfield of the fingerprint region in the TOCSY
spectrum due to chemical shielding by Tyr35 (see section 4.2.1), so it was not
observed within the spectral range of the HSQC spectrum. Interestingly,
however, Gly37 was observed in the HSQC spectrum of (30-51, 5-14) BPTI,
suggesting that its NH proton was not shielded by Tyr35 in the partly-folded
intermediate.
4.3.3. Mapping HSQC Assignments to Higher Temperatures
Once assignments had been made for (30-51, 5-14) BPTI at 5°C, this spectrum
could be used as a template for mapping to less well defined spectra at higher
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temperatures. The 5°C spectrum was used to assign available peaks in the
HSQC spectrum acquired at 10°C. This in turn was used to assign the spectrum
at 15°C, which was used to assign the spectrum at 20°C and so on until
assignments were made, where possible, to the original spectrum at 36°C. No
clear pattern emerges from the assigned residues, although most are towards
the C-terminal region of the protein, with Ala58 still showing two clear peaks
representing two distinct chemical environments for this residue. A full list of
assignments for HSQC spectra of (30-51, 5-14) BPTI at 20°C and 36°C is
available in Appendix C.
Figure 4.12: HSQC spectrum for (30-51, 5-14) BPTI at 36°C showing peak assignments.
4.4. NMR of Reduced Alkylated BPTI
So far both wild type, representing the fully folded protein, and (30-51, 5-14)
BPTI, representing a folding intermediate, have been observed by NMR.
However, by trapping wild type BPTI in a fully reduced state, a construct that
would be a close representation to a fully unfolded BPTI should result. Together,
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these constructs provide three distinct stages in the folding pathway of BPTI.
Reduced BPTI was prepared by alkylation of the free thiol groups after reduction
of wild type BPTI as specified in section 2.7.1.
4.4.1. NMR of Reduced Alkylated BPTI at 5°C
Since the partly-folded (30-51, 5-14) BPTI only showed good resolution of peaks
at 5°C, this seemed a logical starting point for acquisition of an HSQC spectrum
for reduced BPTI. Unfortunately, the solubility of reduced BPTI was limited to
just 100 μM. Presumably this is due to large exposed hydrophobic regions of the
unfolded protein causing aggregation even at relatively low molar
concentrations. Initially, the same parameters were used to acquire an HSQC
spectrum as for both wild type and (30-51, 5-14) BPTI at 5°C. However, tError!
Reference source not found.he resulting HSQC spectrum showed a relatively
weak signal-to-noise ratio (not shown).
Since the molar concentration of the reduced BPTI sample was significantly
lower than other BPTI constructs, the HSQC experiment was repeated, but with
an increae in acquisition time. This was done by increasing the number of scans
from 4 scans per experiment to 20 scans per experiment, resulting in a five fold
increase in acquisition time. Figure 4.13 shows the improved signal-to-noise
ratio that results from this enhanced spectrum. Even at 5°C, all visible peaks are
contained within a narrow range of 8-9 ppm, plus a couple of small clusters
around 112 ppm where aromatic side chains are usually visible.
As with (30-51, 5-14) BPTI at 36°C, this results from highly flexible residues of a
largely unfolded protein experiencing very similar average chemical
environments. Unlike (30-51, 5-14) BPTI, however, the unfolded nature of the
protein remains even at low temperatures. For completeness, HSQC spectra
were also acquired at 20°C and 36°C, but as expected this produced very
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similar spectra, showing that it is also unfolded at higher temperatures (not
shown).
Figure 4.13: HSQC spectrum of reduced alkylated BPTI at 5°C, enhanced using longer
data acquisition time.
4.5. Comparison of HSQC Spectra from BPTI Constructs
The differences between each of the BPTI constructs become clearly visible
when the HSQC spectra of all three constructs at 5°C are overlaid (Figure 4.14).
The well dispersed and well resolved peaks of the fully folded wild type BPTI
(green) show a very different spectrum to the merged peaks of the unfolded
reduced BPTI (blue). (30-51, 5-14) BPTI (red) shows a spectrum that lies
somewhere in between the others, indicating an intermediate, partly-folded state.
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Figure 4.14: Overlay of HSQC spectra for BPTI constructs representing different stages
along the protein folding pathway. Green, wild type BPTI; red, (30-51, 5-14) BPTI; blue,
reduced BPTI. All spectra were acquired at 5°C. Assignments for wild type BPTI are
labelled.
4.6. Hydrogen Deuterium Exchange of BPTI
Since HSQC experiments rely on signals from amide protons, once the protein
is dissolved in a deuterium oxide NMR buffer, the exchange of these protons for
deuterium will result in a loss of signal. Hence, the most solvent exposed
regions of the protein will lose their HSQC peaks first, whereas peaks
associated with the buried regions of the protein will persist. A timecourse of
HSQCs were acquired for each BPTI construct in order to observe the effect of
exposure to a D2O solvent. By comparing the timecourses of different BPTI
constructs, we can see how relatively stably folded or unfolded each construct is.
Since the greatest distinction between structures occurs at 5°C, all hydrogen
deuterium exchange experiments were also performed at 5°C. The NMR buffer
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was identical to that used in previous HSQC experiments, except that the
solvent is 100% D2O, rather than 90% H2O:10% D2O. Each experiment was
performed at a pH meter reading of 6.5, which equates to a pD of 6.9 (Glasoe
and Long 1960). In order to minimise the time before data acquisition of a
deuterated sample, a “dummy sample” was used to optimise instrument
parameters, including locking, shimming, matching and tuning. Details of the
experiment are outlined in section 2.12.6.4.
An overlay of HSQC spectra for hydrogen/deuterium exchange of wild type
BPTI after 5 min and 24 hours is shown in Figure 4.15, along with a spectrum of
wild type BPTI in 90% H2O buffer. After 5 min, 35% of the residues have
disappeared compared to those seen in H2O solvent, but the majority remain
visible in the HSQC spectra. After 24 hours, only 24% of the original peaks
remain, nearly all of which are in helix or β-strand regions. Since random coil
regions are inherently more flexible it is not surprising that these residues
become surface exposed more easily.
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Figure 4.15: HSQC spectra for wild type BPTI with and without hydrogen deuterium
exchange. A) in H2O NMR buffer, with no deuterium exchange; B) after 5 min in D2O NMR
buffer; C) after 24 hours in D2O NMR buffer; D) overlay of A, B and C spectra, illustrating
residues that exchange rapidly, with assigned peaks for the non-exchanged spectrum
labelled (green).
C
D
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Figure 4.16: HSQC spectra for (30-51, 5-14) BPTI with and without hydrogen deuterium
exchange. A) in H2O NMR buffer, with no deuterium exchange; B) after 5 min in D2O NMR
buffer; C) after 24 hours in D2O NMR buffer; D) overlay of A, B and C spectra, illustrating
the rapid exchange of the majority of residues, with assigned peaks for the non-
exchanged spectrum labelled (green).
C
D
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An overlay of HSQC spectra for hydrogen/deuterium exchange of (30-51, 5-14)
BPTI after 5 min and 24 hours is shown in Figure 4.16, along with a spectrum of
(30-51, 5-14) BPTI in H2O buffer. After 5 min, only 53% of the residues remain
visible compared to those in the H2O buffer and after 24 hours, this is reduced to
just 29% of residues.
The assigned peaks of both wild type and (30-51, 5-14) BPTI were analysed to
quantify their intensity for each of the HSQC spectra shown in Figure 4.15 and
Figure 4.16. In each case, the peak height was identified and normalised to
account for different levels of noise baseline (see Appendix D). The normalised
peak heights were plotted against residue number for each spectrum. The
resulting charts are shown in Figure 4.17, with a pictorial representation of the
secondary structure shown below each.
Several observations can be made from Figure 4.17. First, the peak heights are
generally a little higher for wild type than (30-51, 5-14) BPTI in the spectra
before H/D exchange, and peaks of N-terminus of (30-51, 5-14) BPTI are
missing. After 5 min of H/D exchange, many residues are no longer detected in
the wild type. It may seem surprising that much of the natively folded protein
exchanges so rapidly, but approximately one third of the protein lacks
secondary structure (Kabsch and Sander 1983), and inspection of the remaining
assigned peaks shows that most lie in helix or β-strand regions of the protein.
Indeed, even after 24 hours, many of the helix and β-strand regions remain
resistant to H/D exchange, suggesting they are in a stable position buried within
the core of the molecule. Leu29 in particular seems to persist with relatively high
peak intensity. This is located next to the Cys30-Cys51 disulfide bond, which is
the most stable disulfide bond since it is buried in the core of the molecule.
After 5 min H/D exchange, fewer assigned peaks are identified in (30-51, 5-14)
BPTI compared to the wild type, and nearly all that are present have a much
lower peak height. This indicates that this partly-folded intermediate allows
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much greater exposure of the core of the molecule to the deuterium solvent.
This could be either due to its structure being less compact or the molecule
being more flexible. Interestingly, although signal from C-terminal residues of
the natively folded wild type BPTI appears to disappear after just 5 minutes in
D2O buffer, some signal from the C-terminal region of the mutant persists even
after 24 hours in D2O buffer, despite the signal from other residues disappearing.
This suggests that in this particular partly-folded intermediate of BPTI, the C-
terminal region has become buried into the central region of the protein.
In native BPTI, the 5-55 disulfide bond is the most surface exposed, hence is
usually the last disulfide to be formed in the folding pathway (Figure 1.12).
Typically, this would form a stable conformation whereby both the N- and C-
termini are surface exposed in the native protein, see Figure 1.11. However, in
the (30-51, 5-14) BPTI intermediate the native 5-55 disulfide bond is not present,
leaving the C-terminus untethered. Additionally, this intermediate forms the non-
native 5-14 disulfide bond, which is likely to sterically inhibit movement of the N-
terminus into the vicinity of the C-terminus (hence the need for isomerisation to
form the 14-38 native disulfide before the final 5-55 disulfide can be formed).
Thus, the C-terminus of (30-51, 5-14) BPTI is free to explore its local
environment and may become more stable by forming weak interactions with
residues near the core of the protein.
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Figure 4.17: Comparison of peak heights for assigned residues of BPTI constructs. Left,
wild type BPTI; right, (30-51, 5-14) BPTI intermediate. Top, in 90% H2O buffer (effectively 0
min in D2O buffer); middle, after 5 min in 100% D2O buffer; bottom, after 24 hours in 100%
D2O buffer.
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Figure 4.18 shows the HSQC spectrum of reduced BPTI after 5 min in D2O
NMR buffer. No clear peaks are observed, with nothing visible until the noise
level of the spectrum is reached. This clearly indicates that the whole of the
reduced alkylated BPTI molecule is fully exposed to solvent and is, therefore,
fully unfolded.
Figure 4.18: HSQC spectrum for reduced alkylated BPTI after 5 min in D2O NMR buffer.
4.7. Discussion
The diagrammatic representation of the BPTI folding pathway (Figure 1.12)
shows a general progression from the fully reduced protein, through
intermediates with one or two disulfide bonds until the native, three disulfide
bonded protein is reached. However, two keys points should be noted. First, the
pathway is not a simple one way process. Rather, at any stage, including the
native protein, there is always a certain amount of exchange between different
disulfide bonding configurations. This is represented by the double-headed
nature of each arrow showing a transition. It is the general increase in stability of
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more folded intermediates that allows the protein to progress through each
stage of the folding pathway. Secondly, within each stage of the pathway,
represented by a particular disulfide bond configuration, there will exist a large
range of valid structures. Instead of a single static structure, each stage is more
accurately thought of as a dynamic ensemble of structures where one particular
species may dominate. The results of this chapter have shown the dynamic
nature of each of the three BPTI constructs.
The manner in which the dynamic nature of each construct is observed by NMR
depends on the rate of exchange between chemical environments compared to
the rate of acquisition of NMR data. Figure 4.19 illustrates this relationship in the
simple case where two equally populated environments are in chemical
exchange. If the rate of exchange is slow on the NMR timescale, both
environments are observed as distinct peaks in the spectrum. If they are in fast
exchange, only a single peak, representing an average of the two environments
is observed. If exchange is on an intermediate timescale, coalescence occurs
resulting in a broad peak with a large linewidth and reduced intensity (Roberts
1993).
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Figure 4.19: The effects of chemical exchange on NMR spectra at various exchange rates.
modified from (Prestegard 2010).
Since wild type BPTI appears to be natively folded at all temperatures, the
molecule is stable in a single conformation. Any changes from the native
conformation would be transient and represent an insignificant proportion of the
total population at any time, so are not effected by the chemical exchange rate.
However, when comparing the HSQC spectra between 5 min and 24 hours of
hydrogen deuterium exchange (Figure 4.15) some peaks disappear, implying
that even in the fully folded protein non-native states are explored long enough
to allow hydrogen deuterium exchange to take place.
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The example shown in Figure 4.19 shows a simple case of chemical exchange
between two equally weighted chemical environments. On the intermediate
timescale, coalescence occurs resulting in line broadening and a small
reduction in the amplitude of the signal. However, in the case of a very flexible
molecule, such as the 14 N-terminal residues of (30-51, 5-14) BPTI, each amino
group will experience many different chemical environments. The coalescence
of all of these environments, if exchange is on the intermediate time scale, will
result in line broadening and a reduction in amplitude so large that it is below
the signal-to-noise ratio, thus no signal is detected from these residues.
The rest of the (30-51, 5-14) BPTI protein shows a distinctly different pattern. At
36°C, most peaks are displayed within a very narrow range of chemical shifts,
implying that fast exchange is occurring, which is averaging many different
environments of a largely unfolded protein. However, at 5°C peaks are much
more disperse and well resolved, indicating they have a unique chemical
environment. The lower temperature increases the stability of the dominant
conformation, effectively slowing the exchange rate so that mostly a single
chemical environment is observed for each residue (except at the N-terminus).
Interestingly, there is one exception to this observation, which is the last residue
at the C-terminal end of the protein, Ala58. Here, two distinct peaks are
observed for the residue. This implies that Ala58 exists in two conformations in
slow exchange. This behaviour is not observed in wild type BPTI.
The fully reduced BPTI, which was completely or almost completely unfolded,
shows many poorly resolved peaks. Like (30-51, 5-14) BPTI, the protein
appears unfolded at 36°C. At 5°C, however, (30-51, 5-14) BPTI shows
significant portions of folded protein, whereas reduced BPTI remains unfolded.
Residues of the unfolded protein will experience many different chemical
environments, occurring on a much faster timescale than for (30-51, 5-14) BPTI,
resulting in peaks that represent an average of those environments for each
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residue. Hydrogen deuterium exchange showed that all of the protein is surface
exposed, confirming the unfolded nature of the protein.
This chapter has shown that recombinant wild type BPTI is extremely similar to
commercially available natural mature BPTI through comparison of TOCSY and
NOESY experiments. Analysis of HSQC spectra from 15N isotopically labelled
samples of wild type, (30-51, 5-14) and reduced BPTI has provided strong
evidence that they represent natively folded, partly-folded and unfolded proteins
respectively. Thus the available constructs act as good representations of
substrates at different stages of folding for the study of binding with the PDI
protein folding enzyme.
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Chapter 5. NMR Spectroscopy of BPTI in the Presence
of PDI
5.1. Introduction
So far, this study has focused on the expression, purification and
characterisation of various BPTI constructs in isolation. Various NMR
experiments demonstrated that wild type BPTI, (30-51, 5-14) BPTI and reduced
BPTI represent native, partly-folded and unfolded proteins respectively.
However the main interest of the study is to investigate how these constructs
interact as substrates with the PDI folding enzyme.
In this chapter, further HSQC experiments were used to study 15N labelled BPTI
constructs. Here, however, changes were observed when increasing quantities
of PDI were added to the substrate protein. By using 15N labelled BPTI but
unlabelled PDI, only resonances from the BPTI nuclei were observed, since
each HSQC detects correlations with 15N nuclei. Because PDI is a folding
enzyme, it seemed reasonable to hypothesise that an unfolded protein, such as
reduced BPTI, would bind much more readily than a fully folded protein, such as
wild type BPTI. (30-51, 5-14) BPTI, being a partly-folded intermediate, would lie
somewhere in between. The effects of PDI binding on the BPTI substrates were
observed by NMR spectroscopy via HSQC experiments. Since (30-51, 5-14)
BPTI was best observed at lower temperature, all HSQC experiments were
performed at 5°C.
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5.2. Expression and Purification of PDI
The expression and purification of each BPTI construct was shown in Chapter 3.
Full length His-tagged PDI was expressed as outlined in section 2.1. Details of
the purification protocols are given in section 2.5.
5.2.1. IMAC Purification
Since PDI constructs contain an N-terminal His-tag, purification can be
performed using immobilised metal affinity chromatography (IMAC). Figure 5.1
shows SDS-PAGE analysis of IMAC purification for full length PDI. The total
soluble protein applied to the IMAC column is shown in lane 3, showing good
expression of PDI. It is very similar to the overall protein (including insoluble
proteins), indicating that most of the protein is soluble (lane 2). Although a small
amount does not bind (lane 4), the vast majority is eluted with the nickel when
the column is washed with EDTA (lane 7). Only small amounts of PDI are
observed in the wash steps (lanes 5 and 6).
5.2.2. Ion Exchange Purification
Since the protein was eluted from the IMAC column with nickel and EDTA, the
eluted sample was dialysed overnight into 20 mM sodium phosphate (section
2.5.2). This was then loaded onto an anion exchange column. In a low salt
environment, the protein will bind to the column. A gradient is then applied to
gradually increase the salt content of the mobile phase, eventually resulting in
the dissociation of PDI from the stationary phase. Figure 5.2 shows a typical
chromatogram for ion exchange chromatography of PDI. The A280 signal shows
PDI eluting at about 350 mM NaCl (70% of the salt gradient). The corresponding
fractions were pooled and analysed using SDS-PAGE to confirm the correct
molecular mass for PDI (Figure 5.1, lane 10).
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Figure 5.1: SDS-PAGE of PDI purification. Lane 1, LMW marker; lane 2, total expressed
protein; lane 3, soluble protein; lane 4, IMAC flow through; lane 5, IMAC wash; lane 6,
IMAC low salt; lane 7, IMAC elute; lane 8, dialysed into 20 mM sodium phosphate; lane 9,
ion exchange flow through; lane 10, pooled fractions from ion exchange elute.
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Figure 5.2: Chromatogram from ion exchange purification of full length PDI. Blue,
absorbance at 280 nm; green, concentration of high salt buffer; brown, conductance; red,
eluted fractions. At a low salt concentration, the protein is bound to the column; the
protein is eluted at 70% of the salt gradient, corresponding to a 350 mM NaCl buffer.
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5.2.3. Lyophilisation of PDI
Since all BPTI constructs were stored by lyophilisation, it was also desirable to
store PDI in this manner. The protein eluted from the ion exchange column was
in a high salt solution and was buffer exchanged into 10 mM ammonium
bicarbonate. Since ammonium bicarbonate is a volatile salt, it was able to
sublimate during the lyophilisation process. A native PAGE of samples before
and after lyophilisation was run to observe if PDI was affected by this process
(Figure 5.3). It shows that PDI is mainly monomeric, but with a small amount of
dimer present at all stages through the process. SDS-PAGE analysis was also
preformed and showed no signs of protein degradation from lyophilisation (data
not shown).
87654321
Monomer
Dimer
Figure 5.3: Native PAGE of PDI. Lane 1, dialysed into 20 mM sodium phosphate; lanes 2-5,
fractions from ion exchange; lane 6, PDI buffer exchanged to 10 mM ammonium
bicarbonate (before lyophilisation); lane 8, lyophilised PDI resuspended in NMR buffer.
This indicates that PDI was not affected by the lyophilisation process. Whenever large
samples are loaded, some dimer is observed, but the vast majority remains in the
monomer state.
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5.3. Titration of Full Length PDI into BPTI
It was important to make sure that conditions were compatible for both BPTI and
PDI and that the two proteins did not aggregate after mixing. This possibility was
already minimised by testing BPTI constructs in an NMR buffer previously used
for NMR with PDI constructs.
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Figure 5.4: SDS-PAGE of (30-51, 5-14) BPTI, PDI and (30-51, 5-14) BPTI/PDI combined
samples. Lane 1, SeeBlue marker; lanes 2-4, (30-51, 5-14) BPTI samples; lane 6, (30-51, 5-
14) BPTI:PDI 5:1 (30 μM BPTI, 6 μM PDI); lane 7, (30-51, 5-14) BPTI:PDI 1:1 (30 μM each),
lane 9, PDI ion exchange elute; lane 10, flow through from buffer exchange of PDI sample;
lane 11, PDI after buffer exchange to 10 mM ammonium bicarbonate; lane 12, PDI after
lyophilisation and resuspension in NMR buffer.
Figure 5.4 shows SDS-PAGE analysis of (30-51, 5-14) BPTI intermediate, PDI
and a mixture of samples at different molar concentrations. It clearly shows
monomeric PDI which can be purified, lyophilised and resuspended in NMR
buffer without dimerisation or degradation occurring (lanes 9-12). As previously
shown, BPTI samples were also prepared successfully in NMR buffer (lanes 2-
4). The two proteins were also mixed successfully at different molar
concentrations (lanes 6-7). Note that PDI (56 kDa) is more than 8 times larger in
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molecular mass than BPTI (6.6 kDa), therefore will show up as a much larger
band when at the same molar concentration (lane 7). Only at a 5 times higher
molar concentration of BPTI does the PDI band appear a similar size (lane 6).
5.4. (30-51, 5-14) BPTI interaction with PDI
Since a partly-folded protein would be more likely to interact with PDI than one
that is natively folded, it seemed logical to begin interaction studies using (30-51,
5-14) BPTI.
Before the addition of PDI, an HSQC spectrum was acquired with (30-51, 5-14)
BPTI only. Since no prior knowledge was available with regard to the binding of
PDI to a partly folded protein, initially the enzyme was added at a 1:1 molar ratio
of BPTI:PDI. However, at this ratio it was found that very little was detected in
the HSQC spectrum (data not shown). With a second sample, a sub-
stoichiometric amount of PDI was added, at a BPTI:PDI ratio of 5:1. Surprisingly,
even at this low sub-stoichiometric level of enzyme only a few peaks were
visible in the HSQC spectrum, Figure 5.5. Overlay of the (30-51, 5-14) BPTI
HSQC spectrum without PDI enabled the remaining peaks to be identified. Two
clear peaks are visible for Ala58, with Gly57 and Gly36 also visible.
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Figure 5.5: HSQC spectrum of (30-51, 5-14) BPTI in the presence of PDI at a BPTI:PDI ratio
of 5:1.
Since BPTI is a relatively small protein (6.6 kDa), it is well suited to investigation
using various NMR techniques, since such a small protein will have relatively
fast molecular tumbling, enabling sharp peaks to be detected even at low
temperatures. By comparison, PDI is a relatively large protein (56 kDa),
resulting in a much slower molecular tumbling rate, making it too large to be
detected using standard NMR techniques. When combined with 15N labelled
BPTI, the BPTI/PDI complex reaches 62.6 kDa, so is too large to be detected in
the HSQC spectrum. So, generally speaking, peaks in the HSQC spectrum
using 15N labelled BPTI will only be visible for the unbound protein, but not when
bound to the PDI enzyme. However, even in the bound state, regions of BPTI
that remain flexible may still be observed, since they will still be able to show
fast motions locally.
Figure 5.5 shows that almost all BPTI peaks have disappeared from the HSQC
spectrum even at sub-stoichiometric concentrations of PDI. This suggests that
on the timescale of observation of the HSQC signal, nearly all of the BPTI
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molecules have been bound by PDI, despite the enzyme being present at only
one fifth of the molar concentration.
Theoretically, this could be explained if PDI had multiple binding sites. However,
previous studies suggest that PDI only has a single binding site (Pirneskoski,
Klappa et al. 2004). Rather, it seems that PDI is able to bind and unbind rapidly
from its partly-folded substrate, such that all (30-51, 5-14) BPTI will have been
bound within the NMR timescale. The drastic loss of signal even with PDI at one
fifth of the molar concentration of BPTI may suggest that the enzyme is binding
to at least 5 substrate molecules within the timescale of HSQC observation.
Alternatively, binding may be less rapid, but exchange between bound and
unbound BPTI may be on an intermediate timescale, resulting in some line
broadening even in the unbound state.
Interestingly, however, a few peaks remain visible in the HSQC spectrum of
Figure 5.5. This could simply be because these residues had a higher intensity
in the unbound BPTI intermediate, and so when only a small fraction of the
population remains in the unbound state, only these residues remain detected.
Gly57 and Ala58 in particular showed relatively high peak heights in the HSQC
spectrum of unbound (30-51, 5-14) BPTI at 5°C (see Appendix C).
Alternatively, those residues that remain visible may be able to experience
some “local tumbling”, independent of the rest of the molecule. Perhaps the
flexibility of the C-terminal region allows it to retain isotropy by moving
unhindered by the rest of the molecule, thus permitting detection of HSQC
signal from this region.
To get a better idea of the extent of PDI binding, HSQCs of 15N labelled (30-51,
5-14) BPTI were obtained again, but this time titrating in smaller quantities of
PDI enzyme. The enzyme was added at BPTI:PDI ratios of 200:1, 100:1, 50:1,
25:1, 10:1 and 5:1.
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Figure 5.6: HSQC spectra of (30-51, 5-14) BPTI interaction with PDI. A) (30-51, 5-14) BPTI
only; B) 50:1 ratio BPTI:PDI; C) 10:1 ratio BPTI:PDI; D) Overlay of spectra from A, B and C.
Assigned peaks from (30-51, 5-14) BPTI only spectrum are labelled.
Comparison of each spectrum with a (30-51, 5-14) BPTI only control (no
enzyme) showed very little difference at the 200:1 ratio (not shown). At 100:1
C
D
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ratio, all assigned peaks are still present, but a reduction in intensity is clear. At
50:1, a further reduction of peak intensity is clear, with some assigned peaks no
longer visible (Figure 5.6B). This trend continues as the molar concentration of
PDI is increased. At 10:1 ratio, most assigned peaks are no longer visible, and
most that remain are just above the noise level (Figure 5.6C). An overlay of
HSQC spectra with various quantities of PDI illustrates the peaks that disappear
most rapidly and those that persist even at higher concentrations (Figure 5.6D).
5.5. Wild Type BPTI interaction with PDI
Since PDI is a folding enzyme, it would be expected to have a much higher
affinity to an unfolded or partly-folded substrate protein than to a protein in its
native state. To investigate this, wild type BPTI was examined in a series of
HSQCs whereby the PDI enzyme was titrated in at increasing molar
concentrations. Since the partly-folded (30-51, 5-14) BPTI intermediate showed
significant disappearance of peaks at BPTI:PDI ratio of 10:1 and wild type BPTI
was expected to bind with less affinity, this seemed like a logical starting point.
As expected, the effect of PDI at BPTI:PDI 10:1 was much less than with (30-51,
5-14) BPTI (Figure 5.7B). All assigned peaks are still clearly present and well
resolved, although when compared to wild type BPTI alone (Figure 5.7A), a
reduction in peak intensity is evident. The assigned peaks are still present at a
5:1 ratio, with the intensities further reduced (not shown). It is not until a 1:1 ratio
is reached that a dramatic reduction of visible peaks is observed (Figure 5.7C).
The only remaining assigned peaks were for Asp3, Gly57 and Ala58. An overlay
of HSQC spectra of wild type BPTI with various concentrations of PDI highlights
the peaks that remain visible even at high concentrations (Figure 5.7D). As with
(30-51, 5-14) BPTI, the C-terminal Gly57 and Ala58 residues remain visible. In
addition, Asp3, the first residue detected at the N-terminus of the protein, also
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remains visible, but with significantly reduced intensity. Chemical shift
assignments for all BPTI with PDI titration spectra are shown in Appendix E.
B
A
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Figure 5.7: HSQC spectra of wild type BPTI interaction with PDI. A) BPTI only; B) 10:1
ratio BPTI:PDI; C) 1:1 ratio BPTI:PDI; D) Overlay of spectra from A, B and C. Assigned
peaks from BPTI only spectrum are labelled.
To examine closer the effects of adding PDI, the heights of each assigned peak
were plotted against sequence number of the mature protein. This was done for
both wild type and (30-51, 5-14) BPTI. Since the greatest distinction between
D
C
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constructs seems to occur at BPTI:PDI ratio of 10:1, these plots are shown and
compared to BPTI before the addition of PDI (Figure 5.8). A full list of all
normalised peak heights is available in Appendix F.
As expected, the spectra obtained before addition of PDI are very similar to
those obtained for control experiments before hydrogen deuterium exchange
(compare with Figure 4.17), showing good repeatability of this standard HSQC
experiment between separate 15N labelled sample preparations for both wild
type and (30-51, 5-14) BPTI.
With wild type BPTI, all assigned peaks remain at the 10:1 ratio, but all are
reduced in intensity. Interestingly, despite this reduction of intensity, due to
some binding with PDI, the peak heights remain of the same relative magnitude
throughout the protein. This is consistent with what may be expected, whereby
unbound BPTI molecules continue to contribute to the chemical shift resonance
signal for each peak, but the BPTI bound in the PDI/BPTI complex no longer
contribute, resulting in an overall weaker intensity.
Since wild type BPTI is supposed to be natively folded, why should it show any
signs of binding to PDI at all? As well as its primary role as a folding enzyme,
PDI can also function as a molecular chaperone (Cai, Wang et al. 1994). Even
though wild type BPTI exists predominantly in the native state, it is a dynamic
molecule and will explore different conformations, occasionally exposing
hydrophobic residues. This is especially true for BPTI, since it contains a high
level of random coil structure. These events may enable PDI to bind, and are
compatible with the results obtained for hydrogen deuterium exchange.
With the partly-folded (30-51, 5-14) BPTI intermediate, at a BPTI:PDI ratio of
10:1 most peaks have disappeared and the normalised peak height of most
peaks that remain is very low, not much above the noise level of the HSQC
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spectrum. This clearly shows that PDI has a much greater binding affinity for the
(30-51, 5-14) BPTI intermediate than for wild type BPTI.
Figure 5.8: Comparison of peak heights for assigned residues of BPTI constructs before
and after addition of PDI. Left, wild type BPTI; right, (30-51, 5-14) BPTI intermediate. Top,
before addition of PDI; bottom, after addition of PDI to BPTI:PDI ratio 10:1.
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5.6. Reduced BPTI interaction with PDI
Since reduced BPTI is almost completely unfolded even at 5°C, it may be
expected that this construct would have the largest affinity for PDI. HSQC
spectra were acquired at reduced BPTI:PDI ratios of 100:1, 50:1, 25:1, 10:1 and
5:1. Since reduced BPTI only had a solubility of 100 μM in NMR buffer,
acquisition times were increased five fold to maximise the number of visible
peaks, as outlined in section 4.4.1.
At 100:1 ratio, a few peaks disappear and the remaining peaks are lower in
intensity compared to the HSQC spectrum of reduced BPTI only. At 50:1 ratio,
the same peaks remain but the intensity is further reduced (Figure 5.9B). This is
comparable to the results for (30-51, 5-14) BPTI intermediate (Figure 5.6B).
Ratios of reduced BPTI:PDI of 25:1 and 10:1 see a further reduction in intensity
(not shown), but it is not until a 5:1 ratio before most of the original peaks
disappear from the spectrum completely (Figure 5.6C). An overlay of HSQC
spectra for reduced BPTI with various quantities of PDI is shown in Figure 5.6D.
It is interesting that most peaks are still visible at a reduced BPTI:PDI ratio of
10:1, whereas most have disappeared in the corresponding partly-folded (30-51,
5-14) BPTI spectrum. There could be a number of reasons for this. HSQC
spectra for reduced BPTI were acquired at the solubility limit of 100 μM for this
construct. At a BPTI:PDI ratio of 10:1, this means that only 10 μM of PDI was
present. In contrast, the HSQC spectra of both wild type and (30-51, 5-14) BPTI
were acquired at concentrations of 400 μM, resulting in 40 μM of PDI at the 10:1
ratio. However, both the rate of binding of BPTI to PDI and the fraction of BPTI
bound in BPTI/PDI complex would be likely to increase with concentration. The
more dilute reduced BPTI sample may require higher molar equivalents of PDI
in order for binding to occur at the same rate and to the same extent, thus
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compensating for the lower collision rate due to dilution. It could also be that the
longer acquisition times required to observe peaks of the reduced BPTI spectra
mean that lower intensity signals are able to be detected which would otherwise
be invisible under the same conditions of (30-51, 5-14) BPTI.
A
B
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Figure 5.9: HSQC spectra of reduced BPTI interaction with PDI. A) Reduced BPTI only; B)
50:1 ratio BPTI:PDI; C) 5:1 ratio BPTI:PDI; D) Overlay of spectra from A, B and C.
For a direct comparison of wild type and (30-51, 5-14) BPTI to reduced BPTI, all
experiments would need to be performed at 100 μM BPTI, so that both the
molar equivalent and absolute concentration of PDI would be the same for each
C
D
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construct. However, this would come at the cost of producing spectra with a
lower signal-to-noise ratio for the potentially more soluble samples.
5.7. Discussion
One of the limitations of NMR as a technique for elucidating the structure of
macromolecules is that standard methods are limited by the size of the molecule.
Higher molecular weight proteins have slower molecular tumbling, resulting in
faster relaxation of NMR signal (Yu 1999). A related phenomenon is chemical
shift anisotropy, which occurs due to the instantaneous chemical shift of the
nucleus depending on the orientation of the molecule. With small molecules, the
effect is normally averaged away in solution. However, nuclei still experience a
rapid variation of local field from this source, and this stimulates relaxation. This
effect is more significant for slowly tumbling molecules (Neuhaus and
Williamson 2000).
The introduction of isotopic labelling has enabled the structure of larger proteins
to be elucidated by NMR (Cooke 1997), with multidimensional approaches such
as HSQC allowing structures up to 35 kDa to be determined (Gronenborn and
Clore 1995). Some larger protein structures have been solved using a
segmentation approach, whereby isotopically labelled proteins are divided into
overlapping regions for NMR analysis (Otomo, Ito et al. 1999).
After PDI was titrated into the 15N labelled BPTI solution for the HSQC
experiments performed here, the BPTI in a bound BPTI/PDI complex was much
too large (~64.6 kDa), so slow tumbling of the complex results in the NMR signal
disappearing before 15N-1H coherence was allowed to occur. The tumbling rate
of the enzyme was slowed even further by the lower temperature at which the
HSQC experiments were performed. Thus, the formation of BPTI/PDI complex
could be determined by the reduction of peak intensity in the HSQC spectra.
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This chapter has shown that PDI binds to all three BPTI constructs. The
reduction of peak intensity correlates with the addition of PDI in a dose
dependent manner. For both reduced BPTI and (30-51, 5-14) BPTI, peak
intensity is significantly reduced at low sub-stoichiometric concentrations of PDI,
with the majority of peaks disappearing with only one fifth molar equivalent PDI.
This implies very rapid binding and unbinding of PDI on the NMR timescale.
Binding to wild type BPTI only produces a significant loss of assigned peaks at a
1:1 ratio with PDI, indicating a much lower binding affinity for the natively folded
protein.
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Chapter 6. NMR Spectroscopy of bb’x Region of PDI in
the Presence of BPTI
6.1. Introduction
In studying the interaction of PDI with substrate proteins at various stages along
the folding pathway, the previous chapter focused on HSQC observations of
each BPTI construct and showed the effects of adding PDI to each.
This chapter describes a similar investigation, but focuses on HSQC
observations of PDI, titrating in the different BPTI constructs to see their effect
on the enzyme. Since PDI is too large for direct NMR spectroscopy, it is
desirable to analyse bb’x, which is known to be the main binding region of this
enzyme (Klappa, Ruddock et al. 1998). By using 15N labelled bb’x but unlabelled
BPTI, only resonances from the bb’x nuclei were observed, since each HSQC
detects correlations with 15N nuclei. In contrast to BPTI, all HSQC spectra for
bb’x were acquired at 25°C, since the higher temperature produces higher
quality data for this larger protein construct.
In preparation, the expression and purification of 15N labelled bb’x samples are
described. An HSQC spectrum of bb’x alone was performed and analysed by
comparison with a spectrum from a previous study. Separate bb’x samples were
then prepared with increasing amounts of BPTI and their HSQC spectra were
analysed by comparison with the bb’x only sample. Since bb’x (27.5 kDa) is
significantly larger than BPTI (6.6 kDa), the effects of adding substrate were
much more subtle than adding PDI to BPTI, with less visible differences
between spectra.
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6.2. Expression and Purification of bb’x
Expression of His-tagged bb’x was identical to the protocol for PDI (section 2.1).
Since HSQC spectra were acquired, 15N isotope labelling of bb’x was performed
by growing cultures in minimal medium with 15N labelled ammonium sulphate
(section 2.3.2).
6.2.1. IMAC Purification of bb’x
The first step in the purification of His-tagged bb’x used IMAC purification. Using
the N-terminal His-tag, the protein bound well to the column and eluted as
expected once EDTA was added to the buffer. The collected fractions were
analysed using SDS-PAGE to confirm the presence of purified bb’x in the
elution (data not shown). The protein was then dialysed overnight into 20 mM
sodium phosphate in preparation for ion exchange chromatography.
6.2.2. Ion Exchange Purification of bb’x
The dialysed protein was applied to an anion exchange column for further
purification, just like full length PDI. However, unlike full length PDI, which was
almost entirely monomeric, Figure 6.1 shows two large overlapping peaks,
which were identified by native PAGE as monomer and dimer.
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Figure 6.1: Chromatogram from ion exchange purification of bb’x. Blue, absorbance at
280 nm; green, concentration of high salt buffer; brown, conductance; red, eluted
fractions. The monomer and dimer elute at slightly different salt concentrations, but there
is a very large overlap between peaks.
6.2.3. Size Exclusion to Isolate bb’x Monomer
For the purposes of substrate interaction, only the monomer of bb’x is desired.
To separate monomer and dimer, the appropriate fractions from ion exchange
elution were pooled and concentrated to 1 ml so that it could be injected onto a
gel filtration column. The protocol is detailed in section 2.5.4. The chromatogram
of Figure 6.2 clearly shows good separation of monomer and dimer species.
Native PAGE analysis of the fractions representing these peaks confirms them
to be predominantly monomer and dimer, respectively. Fractions 34-38,
containing bb’x monomer, were pooled and stored at 4°C.
Chapter 6: NMR Spectroscopy of bb’x Region of PDI in the Presence of BPTI
170
3938373635343332313029
Dimer Monomer
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
mAU
100 120 140 160 180 200 220 ml
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46
Monomer
Dimer
Figure 6.2: Chromatogram from gel filtration of bb’x. Blue, absorbance at 280 nm; red,
eluted fractions. The absorbance signal indicates good separation of the monomer and
dimer peaks. Inset: native PAGE of fractions eluted from gel filtration of bb’x. Fractions
29-32 show mainly dimer, whereas fractions 34-38 show mainly monomer.
6.2.4. Testing Lyophilisation using Fluorescence Spectroscopy
Since all BPTI constructs and full length PDI were stored by lyophilisation, the
same procedure was followed for an aliquot of the bb’x monomer. However,
other studies have shown that the freeze/thaw process resulted in dimerisation
of the shorter b’x construct, see Figure 3 in (Wallis, Sidhu et al. 2009).
bb’x contains only one tryptophan residue, which is contained in the x region. So,
intrinsic fluorescence was used to test if lyophilisation affects the conformation
of bb’x. A change in fluorescence would indicate a change in the environment of
the x region and hence a change in the conformation of bb’x. The change
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occurs since, in the monomer state, x binds to the exposed hydrophobic region
of the b’ domain, whereas in a dimer the exposed regions of b’ domains bind to
each other, leaving the x regions free in solution, hence a more hydrophilic
environment (Figure 6.3). The fluorescent emission spectra for purified capped
monomer and uncapped dimer were previously illustrated in Figure 4B from
(Wallis, Sidhu et al. 2009), which show maximum intensities at approximately
330 nm for the monomer and approximately 345 nm for the dimer.
Figure 6.3: Model of interchange between uncapped homodimer and capped monomer of
the b’x region of PDI, modified from (Byrne, Sidhu et al. 2009), caused by the exposed
hydrophobic regions of the b’ and x domains. The same model is valid with the addition
of the b domain, i.e. the bb’x region.
After testing the effects of lyophilisation on bb’x, Figure 6.4 shows that a
significant difference in fluorescence does occur. Before lyophilisation (blue),
maximum intensity was reached at 332 nm, showing the sample is mainly
monomeric. However, after lyophilisation there is a significant decrease in
intensity and the maximum intensity is red-shifted to 336 nm, indicating that
more dimer is present in the sample. This suggests that lyophilisation is not
appropriate for the preparation of bb’x. It must be prepared fresh, stored at 4°C,
and used before degrading.
Chapter 6: NMR Spectroscopy of bb’x Region of PDI in the Presence of BPTI
172
Mainly Capped Monomer
Hydrophobic environment
More Dimer
Hydrophilic
environment
Figure 6.4: Intrinsic fluorescence of bb’x before and after lyophilisation. Freshly purified
bb’x stored at 4°C (blue) shows fluorescence indicating the x-region of the protein is in a
hydrophobic environment, thus will mainly exist as a capped monomer. Lyophilised bb’x,
which was frozen during the lyophilisation process, when resuspended in buffer shows
fluorescence indicating the x-region of the protein is in a more hydrophilic environment,
suggesting some dimer formation of the protein.
6.3. HSQC Spectra of 15N labelled bb’x with Substrate Titrations
Acquisition of HSQC spectra of bb’x were performed as described in section
2.12.6.3. In contrast to HSQC spectra of BPTI, all bb’x NMR experiments were
performed at 25°C, since previous data showed this temperature to provide a
good balance between spectral resolution (better at higher temperatures) and
protein stability (better at lower temperatures) (Byrne, Sidhu et al. 2009).
As a control, an HSQC spectrum was acquired for bb’x alone (Figure 6.5A). This
was compared to a previously assigned HSQC experiment run under the same
conditions (Byrne, Sidhu et al. 2009). An overlay showed that the two spectra
were very similar, allowing rapid assignment of the control spectrum.
HSQC spectra could then be obtained for bb’x in the presence of various
concentrations of BPTI. No prior knowledge was available for the interaction of
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these proteins, apart from results for spectra of 15N labelled BPTI detailed in the
previous chapter. So, for both wild type and (30-51, 5-14) BPTI, separate
samples were prepared at bb’x:BPTI ratios of 25:1, 5:1 and 1:1. The
concentration of 15N labelled bb’x was the same for each sample (250 μM), but
the concentration of BPTI was varied at 10 μM, 50 μM and 250 μM respectively.
Figure 6.5 shows example spectra of these titrations at a bb’x:BPTI ratio of 5:1
for wild type (Figure 6.5B) and (30-51, 5-14) BPTI (Figure 6.5C).
Since bb’x is relatively large (27.5 kDa) compared to the BPTI substrate (6.6
kDa), the overall effect of adding substrate was not visibly apparent, with only
small differences observed when HSQC spectra of titrated samples were
overlaid onto the control spectrum (Figure 6.5D).
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Figure 6.5: HSQC spectra of 15N labelled bb’x at 25°C both in the absence of substrate
and at a bb’x:BPTI ratio of 5:1. A) bb’x only; B) bb’x with wild type BPTI; C) bb’x with (30-
51, 5-14) BPTI; D) Overlay of spectra from A, B and C. Peaks for indole resonances of
Trp347 are highlighted with a dashed box.
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6.4. Minimal Shift Mapping between bb’x with and without BPTI
Substrate
One way to closely analyse the subtle differences between bb’x spectra before
and after the addition of substrate is to estimate the perturbation of chemical
shifts from assigned peaks of bb’x alone to the unassigned peaks of bb’x with
the substrate added. Regions where large perturbations occur indicate a change
in chemical environment and imply a significant role in substrate binding for this
part of the protein. This technique has the advantage of being informative about
significant regions of the protein that show a change in environment without
having to go through laborious processes to accurately assign all chemical shifts
in the each sample with substrate added. Thus, it is a useful technique for
comparison of one control sample with many experimental spectra, as in the
comparison of bb’x alone with bb’x plus substrate.
First, peaks were picked in each HSQC spectrum automatically using CCPNmr
Analysis software and visual inspection ensured erroneous or duplicate peaks
were removed. Then lists of 1H and 15N resonances were exported for each
spectrum. These were compared with each assigned peak of the bb’x only
control spectrum and in each case the nearest peak was identified. The change
in chemical shift was then calculated for each assigned residue of bb’x, as
described in section 2.12.7.3.
Once minimal shift maps had been calculated for bb’x at all bb’x:BPTI ratios, the
maps of wild type and (30-51, 5-14) BPTI could be compared. At a 25:1 ratio,
the addition of either BPTI construct shows only low levels of chemical shift
perturbation. More interestingly, however, are the differences observed at the
intermediate bb’x:BPTI ratio of 5:1 (Figure 6.6).
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Figure 6.6: Chemical shift perturbations (to nearest peak) for bb’x alone compared to
bb’x:BPTI at a 5:1 ratio. A) (30-51, 5-14) BPTI; B) wild type BPTI. Shift perturbations
represent a change in chemical shift of an assigned peak in the bb’x only spectrum to the
nearest identified peak in the spectrum of bb’x in the presence of BPTI. Since the scale of
chemical shifts is larger in the 15N axis than in the 1H axis, chemical shift perturbations
were calculated as a weighted sum, 1/6|∆15N| + |∆1H|. Blue bars represent shifts of peaks
identified in the target spectrum; maroon bars represent shifts from peaks that were
unable to be identified in the target spectrum, presumed to be due to line broadening.
The graphic below each graph indicates visually the position of each domain in the bb’x
construct.
At this bb’x:BPTI ratio, the addition of wild type BPTI shows very little
perturbation of chemical shifts in any part of the protein, suggesting that very
little protein-substrate interaction is occurring. However, the addition of (30-51,
5-14) BPTI shows significant perturbation in some regions, suggesting bb’x
interaction with this folding intermediate alters the chemical environment of
these regions. Interestingly, the largest perturbations occur in the b’ domain, but
very little perturbation of chemical shifts occur in the b domain. This suggests
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that even with this full length protein substrate (albeit a small protein) the b’
domain dominates the binding of substrates with the b domain remaining largely
unaffected. Visual comparison between the bb’x only spectrum and the
spectrum of bb’x in the presence of (30-51, 5-14) BPTI indicated that many of
the residues showing a large chemical shift perturbation no longer showed a
visible peak after (30-51, 5-14) had been added, presumably due to line
broadening (Figure 6.6, maroon bars).
By contrast, at the 1:1 ratio, the addition of either BPTI construct shows high
levels of chemical shift perturbation (Figure 6.7), with the spectrum produced in
the presence of the partly folded (30-51, 5-14) BPTI still showing larger changes
in shift than the spectrum in the presence of wild type BPTI.
As with the addition of (30-51, 5-14) BPTI at lower concentration, the addition of
wild type BPTI at a 1:1 ratio shows the vast majority of perturbations occurring
in the b’ domain, with comparatively few residues perturbed in the b domain. As
before, when peaks between spectra were compared, many of the residues
showing a large chemical shift perturbation seemed to be no longer represented
by a visible peak in spectra containing BPTI (Figure 6.7, maroon bars). This is
most likely due to binding of the substrate causing line broadening to such an
extent that no peak is visible above the noise level, see Figure 6.8C. In
analysing shift perturbations of residues with peaks identified even in the
presence of BPTI (Figure 6.7, blue bars), it is interesting that of the two that are
above 0.1 ppm, one is in the b domain, Leu188, suggesting that this may have
an important role in substrate binding.
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Figure 6.7: Chemical shift perturbations (to nearest peak) for bb’x alone compared to
bb’x:BPTI at a 1:1 ratio. A) (30-51, 5-14) BPTI; B) wild type BPTI. Shift perturbations
represent a change in chemical shift of an assigned peak in the bb’x only spectrum to the
nearest identified peak in the spectrum of bb’x in the presence of BPTI. Since the scale of
chemical shifts is larger in the 15N axis than in the 1H axis, chemical shift perturbations
were calculated as a weighted sum, 1/6|∆15N| + |∆1H|. Blue bars represent shifts of peaks
identified in the target spectrum; maroon bars represent shifts from peaks that were
unable to be identified in the target spectrum, presumed to be due to line broadening.
The graphic below each graph indicates visually the position of each domain in the bb’x
construct.
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Figure 6.8: Chemical shifts of bb’x residues in the absence and presence of various
concentrations of (30-51, 5-14) BPTI. Purple, bb’x only; blue, bb’x:BPTI ratio of 25:1;
green, bb’x:BPTI ratio of 5:1; red, bb’x:BPTI ratio of 1:1. A) Lys333 shows no perturbation
of chemical shift, suggesting that the backbone of this residue is not affected by
substrate binding B) Leu188 shows increasing perturbation of chemical shift with
increasing concentration of BPTI substrate, suggesting this residue may have a role in
substrate binding. The extent of chemical shift perturbation is measured based on the
change in shift from the peak of the bb’x only spectrum (purple) to the corresponding
peak in the bb’x spectrum in the presence of substrate. An example is shown for bb’x in
the presence of (30-51, 5-14) BPTI at bb’x:BPTI ratio of 1:1 (red). The shift perturbations
are highlighted using dashed lines, showing the change in the 15N axis, ∆15N, and in the
1H axis, ∆1H. Since 15N shifts are much larger than 1H shifts and because the magnitude is
important but not the direction of change, the chemical shift perturbation is calculated as
a weighted sum: 1/6|∆15N| + |∆1H|. A reduction in signal intensity is also seen with
increasing concentration of substrate, probably due to line broadening. C) Line
broadening of Ile301 results in loss of signal below the noise level of the spectrum at
higher concentrations of BPTI substrate. Since minimal shift mapping detects the nearest
peak in the unassigned spectrum, this will cause a large chemical shift perturbation to be
calculated for this residue at higher concentrations (arrow).
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Average minimal shifts across the whole bb’x region were calculated for both
constructs at each bb’x:BPTI ratio, with residues showing the most significant
perturbations identified and summarised (Table 6.1). Most large shifts were
observed in the spectrum with a 1:1 ratio of (30-51, 5-14) BPTI and these were
mapped to the crystal structure of bb’, showing visually where the most
significant perturbations are occurring (Figure 6.9). This highlights the
significance of the b’ domain (right) compared to the b domain (left) in binding of
the (30-51, 5-14) BPTI substrate.
Table 6.1: Summary of minimal shift changes for bb’x in the presence of wild type and
(30-51, 5-14) BPTI. All HSQC spectra were acquired using 250 μM bb’x.
Wild Type
BPTI
(30-51, 5-14)
BPTI
Ratio of bb'x:BPTI Ratio of bb'x:BPTI
25:1 5:1 1:1 25:1 5:1 1:1
Average Minimal
Shift Change(ppm)
4.42E-03 6.80E-03 3.82E-02 5.42E-03 1.92E-02 5.67E-02
Total Shifts > 0.06 0 0 25 0 13 45
Total Shifts > 0.10 0 0 16 0 5 33
0.06 < Total Shifts < 0.10 0 0 9 0 8 12
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Figure 6.9: Illustration of bb’ mapping regions of chemical shift perturbation occurring
with the addition of (30-51, 5-14) BPTI, at bb’x:BPTI ratio of 1:1. Yellow, Perturbations >
0.06 ppm; red, perturbations > 0.1. Illustrated using structure of bb’ from PDB ID 2K18
(Denisov, Maattanen et al. 2009).
6.5. HSQC Spectra of 15N labelled bb’x with Titrations of
Reduced BPTI
Due to the limited solubility of reduced BPTI, the range of bb’x:BPTI ratios used
was different than for wild type or (30-51, 5-14) BPTI. As before, samples still
contained 250 μM bb’x, with HSQC spectra acquired at ratios of 25:1 and 8.3:1,
using reduced BPTI at concentrations of 10 μM and 30 μM respectively. To
investigate a bb’x sample with a larger ratio of reduced BPTI, a sample was
prepared at just 100 μM bb’x and 43 μM reduced BPTI (ratio 2.3:1). To
compensate for the reduced molar concentration, a longer acquisition time was
applied. Spectra for the 25:1 and 2.3:1 ratios are shown in Figure 6.10.
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Figure 6.10: HSQC spectra of 15N labelled bb’x at 25°C in the presence of reduced BPTI. A)
at bb’x:BPTI ratio of 25:1 using 250 μM bb’x; B) at bb’x:BPTI ratio of 2.3:1 using 100 μM
bb’x; C) Spectra from A and B overlaid on top of bb’x only spectrum (purple). Peaks for
indole resonances of Trp347 are highlighted with a dashed box.
Analysis of spectra containing reduced BPTI followed the same procedures as
for other BPTI constructs, but since the bb’x:BPTI ratio of 25:1 was the only ratio
matching wild type and (30-51, 5-14) BPTI HSQC spectra, this was the main
spectrum used for comparison with the other BPTI constructs.
Minimal shift maps of bb’x comparing before and after the addition of reduced
BPTI were generated as described earlier. For the 25:1 ratio, the shift maps in
the presence of reduced BPTI and (30-51, 5-14) BPTI were compared (Figure
6.11). Although the shift perturbations are small for both constructs, they are still
noticeably larger in the presence of reduced BPTI compared with the partly
folded protein, particularly towards the C-terminal end of the bb’x region. This
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would suggest that bb’x has a slightly greater affinity to reduced BPTI than to
the (30-51, 5-14) BPTI at this low concentration.
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Figure 6.11: Chemical shift perturbations (to nearest peak) for bb’x alone compared to
bb’x in the presence of BPTI at a bb’x:BPTI ratio of 25:1. A) using (30-51, 5-14) BPTI; B)
using reduced BPTI; C) comparison of average perturbations from A and B. Shift
perturbations represent a change in chemical shift of an assigned peak in the bb’x only
spectrum to the nearest identified peak in the spectrum of bb’x in the presence of
reduced BPTI. Since the scale of chemical shifts is larger in the 15N axis than in the 1H
axis, chemical shift perturbations were calculated as a weighted sum, 1/6|∆15N| + |∆1H|.
The graphic below each graph indicates visually the position of each domain in the bb’x
construct.
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The minimal shift changes for bb’x with reduced BPTI at bb’x:BPTI ratios of
8.3:1 and 2.3:1 were also analysed. The results of all minimal shift data using
reduced BPTI are summarised in Table 6.2.
Table 6.2: Summary of minimal shift changes for bb’x in the presence of reduced BPTI.
HSQC spectra of bb’x with a bb’x:BPTI ratio of 25:1 and 8.3:1 were acquired using 250 μM
bb’x, whereas the spectrum of 2.3:1 was acquired using 100 μM bb'x.
Reduced
BPTI
Ratio of bb'x:BPTI
25:1 8.3:1 2.3:1
Average Minimal
Shift Change(ppm)
8.81E-03 1.27E-02 3.22E-02
Total Shifts > 0.06 1 7 28
Total Shifts > 0.10 0 2 13
0.06 < Total Shifts < 0.10 1 5 15
Figure 6.12 illustrates the differences in minimal shift perturbations in bb’x after
addition of reduced BPTI at bb’x:BPTI ratios of 8.3:1 and 2.3:1. Generally,
regions of relatively large shift change are visible in the b’ domain, with only a
few residues in the b domain showing a shift change. This is similar to
observations seen in the presence of higher concentrations of wild type and (30-
51, 5-14) BPTI. Another similarity is that many of the larger shift perturbations
are for residues where peaks have not been identified in the spectrum
containing reduced BPTI (maroon bars), probably due to line broadening.
Leu188 shows the largest shift change in the b domain, just above 0.1 ppm for
the 2.3:1 ratio, which is the largest change of all residues that have been
identified in the spectrum containing reduced BPTI (blue bars). Although a
broad trend may occur within each of the minimal shift maps in Figure 6.12,
caution should be used when comparing then with each other, since spectra in
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the presence of reduced BPTI were obtained at different concentrations of bb’x,
due to the limited solubility of reduced BPTI, as explained above.
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Figure 6.12: Chemical shift perturbations (to nearest peak) for bb’x alone compared to
bb’x in the presence of reduced BPTI. A) bb’x:BPTI at 8.3:1 ratio using 250 μM bb’x; B)
bb’x:BPTI at 2.3:1 ratio using 100 μM bb’x. Shift perturbations represent a change in
chemical shift of an assigned peak in the bb’x only spectrum to the nearest identified
peak in the spectrum of bb’x in the presence of reduced BPTI. Since the scale of
chemical shifts is larger in the 15N axis than in the 1H axis, chemical shift perturbations
were calculated as a weighted sum, 1/6|∆15N| + |∆1H|. The graphic below each graph
indicates visually the position of each domain in the bb’x construct.
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6.6. Indole Resonances of Trp347 as Indicators of Substrate
Binding
A recent study investigating the binding of peptides to various PDI constructs
revealed that indole resonances of Trp347, identified as distinct peaks in HSQC
spectra, could be used to monitor the binding of substrate to the b’x region
(Byrne, Sidhu et al. 2009). In the absence of substrate, b’x and bb’x constructs
of PDI were found to exist in two distinct forms, either as ‘capped’ monomer,
whereby the x region binds to the b’ domain, or as ‘uncapped’ dimer whereby
dimerisation takes place via the interaction of b’ domains (Nguyen, Wallis et al.
2008), see Figure 6.3.
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Figure 6.13: Perturbation of indole resonances of Trp347 from bb’x in the presence of
various concentrations of BPTI construct. A) Wild type BPTI; B) (30-51, 5-14) BPTI
intermediate. Purple, bb’x only (no BPTI); blue, bb’x:BPTI at 25:1; green, bb’x:BPTI at 5:1;
red, bb’x:BPTI at 1:1. The change in proton chemical shift between bb’x only and bb’x in
the presence of BPTI at a 25:1 ratio is labelled for the ‘capped’ peak of Trp347.
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With Trp347, which is located in the x region, the two forms of bb’x can be
observed as separate peaks in the HSQC spectrum, see purple contours in
Figure 6.13. The downfield peak at 1H = 10.38 ppm arises from the indole NH
resonance of Trp347 in the monomeric capped conformer of bb’x; the upfield
peak at 1H = 10.11 ppm arises from the indole NH resonance of Trp347 in dimer
bb’x.
Despite isolating the monomer form of bb’x by gel filtration during sample
purification (see Section 6.2.3), the HSQC spectra show clear signs of both
monomer and dimer bb’x. This is due to a conversion of bb’x from monomer to
the dimer form before beginning the HSQC experiment (with sample stored at
4°C), during sample preparation and during acquisition of the HSQC data at
25°C.
The presence of two distinct peaks in the absence of substrate indicates that
interconversion between the two conformations is slow on the NMR timescale
(Byrne, Sidhu et al. 2009). However, substrates are able to displace the x region
of the capped monomer, resulting in bb’x conversion into the uncapped form
during substrate binding. Figure 6.13 suggests that for BPTI this interaction
occurs on an intermediate timescale, resulting in broadened peaks being
observed between the capped and uncapped states. The indole resonances of
Trp347 are highlighted by dashed boxes in Figure 6.5 and Figure 6.10.
At a bb’x:BPTI ratio of 25:1 (Figure 6.13, blue contours), the wild type BPTI
spectrum (Figure 6.13A) shows no sign of binding, since the uncapped
monomer peak remains unchanged. By contrast, the (30-51, 5-14) BPTI
spectrum (Figure 6.13B) indicates a monomer peak that has shifted slightly, with
a reduced intensity, indicating a small amount of binding. It is not until a 5:1 ratio
(Figure 6.13, green contours) that the wild type BPTI peak shifts slightly towards
uncapped form, indicating the higher concentration required for wild type binding.
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The (30-51, 5-14) BPTI spectrum at a 5:1 ratio shows almost no signal above
the noise level for monomer bb’x, except for a tiny peak barely visible at 1H =
10.31 ppm. Similarly, when the bb’x:BPTI ratio is increased to 1:1 (Figure 6.13,
red contours), only the peak for bb’x dimer remains visible in the spectrum
containing wild type BPTI. The disappearance of the bb’x monomer peaks are
probably due to line broadening, indicating that interaction is occurring on an
intermediate timescale.
Once the substrate unbinds from bb’x, it will presumably revert back to the
capped conformer. If the conversion between substrate bound (uncapped) and
unbound (capped) bb’x occurs on an intermediate timescale, this will result in
line broadening and a reduction in peak intensity. At certain concentrations of
wild type and (30-51, 5-14) BPTI, it appears that the NMR signal is reduced to
the noise level, so no peak is identified.
At a bb’x:BPTI ratio of 1:1 using the (30-51, 5-14) BPTI construct, a clear peak
is observed in the HSQC spectrum close to the uncapped species (Figure 6.13B,
red contours). This indicates that the majority of bb’x monomer is now
predominantly observed in the uncapped conformation, presumably due to
binding of the (30-51, 5-14) BPTI substrate. This provides further evidence of
the greater binding affinity to bb’x of this partly-folded substrate over natively
folded BPTI.
The perturbations of indole resonances of Trp347 in the presence of reduced
BPTI at various concentrations of bb’x are shown in Figure 6.14. Due to the
limited solubility of reduced BPTI, it should be noted that a different set of
bb’x:BPTI ratios were used. However, the lower ratio of 25:1 is comparable with
those of wild type and (30-51, 5-14) BPTI, and the bb’x spectrum with reduced
BPTI at this ratio shows a significant perturbation of the capped monomer peak
(Figure 6.14, blue contours). This perturbation (0.0240 ppm) is much larger than
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that observed with the same amount of (30-51, 5-14) BPTI, with very little
perturbation visible in corresponding wild type peak. This comparison suggests
that bb’x has a greater affinity for reduced BPTI than the more folded constructs.
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Figure 6.14: Perturbation of indole resonances of Trp347 from bb’x in the presence of
various concentrations of reduced BPTI. Purple, bb’x only (no reduced BPTI); blue, bb’x:
reduced BPTI at 25:1; green, bb’x: reduced BPTI at 8.3:1; red, bb’x:reduced BPTI at 2.3:1.
The change in proton chemical shift between bb’x only and bb’x in the presence of
reduced BPTI at a 25:1 ratio is labelled for the ‘capped’ peak of Trp347.
Although the effect of bb’x with reduced BPTI could only be measured up to a
bb’x:BPTI ratio of 2.3:1, it is still enough for some interesting observations.
Although some line broadening and a reduction of peak intensity is observed as
the concentration of reduced BPTI is increased, all of the indole Trp347 peaks
from the monomer still remain clearly visible in the spectrum. This contrasts with
the spectra containing (30-51, 5-14) BPTI, where at bb’x:BPTI ratio of 5:1 the
peak is barely visible. This suggests that reduced BPTI may have a faster
exchange rate with bb’x than the (30-51, 5-14) BPTI intermediate. However,
since the larger bb’x:BPTI ratio of 2.3:1 was performed using only 100 μM bb’x,
it is difficult make any concrete conclusions with the available data.
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6.7. Discussion
All BPTI substrates, at any stage along the folding pathway, indicate that
binding to bb’x is focused mainly in the b’x region, with few chemical shift
perturbations displayed in the b domain. This is in good agreement with
previous PDI binding studies, such as the binding of bb’ with peptides
mastoparan and somatostatin as well as unfolded protein RNase A by (Denisov,
Maattanen et al. 2009), as well as binding of ∆-somatostatin by (Byrne, Sidhu et
al. 2009). Although b’ has been known to be the primary binding domain of PDI
for some time, it has been suggested that other domains will be involved with
binding larger substrates (Klappa, Ruddock et al. 1998). Thus, it was anticipated
that BPTI, being a full length protein, may require more regions of the PDI
enzyme, including the b domain, for binding to take place. However, It was
surprising that this full length protein, albeit rather small (6.6 kDa), has very little
effect on the b domain of PDI upon binding, implying that this domain has little
influence on the binding of the BPTI substrate. In contrast, a recent study of
Ero1-Lα, a much larger substrate protein (approx 44 kDa), binding to PDI
indicated that the minimal elements required included the b’xa’ region of PDI
(Wang, Li et al. 2009), suggesting larger protein substrates require more
domains of the enzyme.
In order to compare and contrast more closely the effects of substrate binding
on bb’x, chemical shift perturbations seen in the b’x region due to substrate
binding from a variety of studies is shown in Figure 6.15. Since experiments
were performed under different conditions and using substrates with different
binding affinities, the criteria used to identify the most significant perturbations is
different in each case. Lower concentrations of bb’x were used in experiments
with BPTI substrates, hence smaller overall shift perturbations were observed.
Here, the emphasis is on identifying similarities or differences in the positions of
binding.
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Figure 6.15: Structural alignment of the b’ domain of human PDI (black) and yeast PDI
(blue) showing the ligand binding site as mapped by chemical shift perturbation. (a)
Comparison of bb’x with bb’ + Δ-somatostatin (yellow highlight > 0.13ppm; red highlight
> 0.2ppm). (b) Comparison of b’x with b’ + KFWWFS (yellow highlight > 0.15ppm; red
highlight > 0.2ppm). (c) Comparison of b’x with b’x + Δ-somatostatin (yellow highlight >
0.09ppm; red highlight > 0.15ppm). (d) Comparison of bb’x with bb’ as assigned by
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(Denisov, Maattanen et al. 2007) (yellow highlight >0.15ppm; red highlight >0.3ppm). (e)
Comparison of bb’ with bb’ + unfolded RNase (Denisov, Maattanen et al. 2009). (f)
Comparison of bb’x with bb’x:(30-51, 5-14) BPTI at 5:1 ratio (yellow highlight >0.02ppm;
red highlight >0.04ppm). (g) Comparison of bb’x with bb’x:wild type BPTI at 1:1 ratio
(yellow highlight >0.02ppm; red highlight >0.04ppm). (h) Comparison of bb’x with
bb’x:reduced BPTI at 8.3:1 ratio (yellow highlight >0.02ppm; red highlight >0.04ppm). (i)
Peaks that seem to disappear due to line broadening, when comparing bb’x with bb’x:(30-
51, 5-14) BPTI at 1:1 ratio (green highlight). Comparisons using BPTI substrates (f-i)
indicate residues not assigned in the bb’x control spectrum (grey lettering), thus no
chemical shift perturbation were calculated for these residues. (j) Hydrophobic ligand
binding site identified in the crystal structure of yeast PDI (grey highlight). The secondary
structure assignments for both the human and yeast structures are shown above and
below the sequences in the corresponding colour (h, α-helix; s, β-sheet). Modified from
Figure 6 in (Byrne, Sidhu et al. 2009) with assistance from Dr. Richard Williamson,
University of Kent.
Generally, the region spanning β1 to β2 shows the greatest perturbations in all
BPTI constructs, either via large minimal shifts or through line broadening
(highlighted green) in this region. This follows a similar trend seen in all of the
other bb’x ligand perturbations in Figure 6.15, emphasising the importance of
this region. The reduced BPTI perturbations together with the line broadening of
mutant BPTI at high concentrations suggest that the β4 to β5 region also acts
as a particular focus of binding, which is in general agreement with other shift
perturbation maps. Ligand binding does not appear to be localised to the small
hydrophobic pocket proposed previously using homology modelling (Pirneskoski,
Klappa et al. 2004), and this region has little overall influence on binding. A
more recent study suggested that a large hydrophobic binding site is an
effective way for PDI to bind a variety of substrates when unfolded and to
release them once they acquire their native conformation with fewer
hydrophobic residues exposed (Denisov, Maattanen et al. 2009).
Some subtle differences between the binding of BPTI constructs and others
substrates can be observed in Figure 6.15. The perturbation of Ile236 by all
BPTI constructs is only shared with the comparison of bb’ with bb’ + unfolded
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RNase. Other interesting residue are Asp275 and Leu290, which show line
broadening and large perturbation with all BPTI constructs, but were not
perturbed significantly in other studies. Glu316 is perturbed with all BPTI, and
also comparing bb’x to bb’ of Denisov, but not in any others.
At the C-terminal end of b’, Arg328 and Lys330 show perturbation, in good
agreement with other constructs. In the x region, Ile334 and Ser340 show
perturbation either side of βx.
An underlying assumption in the interpretation of chemical shift perturbations is
that the extent of perturbation directly correlates with the importance of that
residue or region in the binding process. This is not necessarily the case.
Although perturbations in the b domain may be small compared to the b’ domain,
they could still have a significant substrate binding role. For example, Leu188 in
the b domain of BPTI shows a noticeable chemical shift perturbation (Figure
6.8B), but this is still small compared to the large perturbations observed in the
b’ domain. Since the magnitude of shift perturbations caused by line broadening
are not meaningful, then if only the remaining shifts are considered Leu188
appears relatively large compared to many in the b’ domain. Leu188 also
showed similar perturbations in ∆-somatostatin (Byrne, Sidhu et al. 2009) and
may serve a key role in the substrate binding process.
Since HSQC spectra only observe backbone resonances of the protein or
peptide sample, only perturbations in these chemical shifts are observed. Such
a limitation may not fully reflect the role that amino acid side chains may have
upon substrate binding.
The limitations of the minimal shift mapping technique itself should also be
considered. Although it is a useful technique where the accurate assignments of
spectra are difficult, it has the underlying assumption that the nearest peak
represents the same residue. Visual inspection of minimal shift data indicates
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that many residues show very large perturbations in bb’x because the peak has
disappeared from the spectrum (due to line broadening). Thus the nearest peak
actually represents the peak of a different residue (see Figure 6.8C). This can
show up as extremely large perturbations in the minimal shift map, particularly if
the peak is far away from the next nearest peak in the HSQC spectrum.
Alternatively, in a very crowded region of the spectrum, a peak could have
shifted a long way, beyond the next nearest peak, in which case the shift
perturbation would be underestimated.
In this study, chemical shift perturbations that were likely to have been caused
due to peak disappearance have been highlighted, but this is not normally the
case in publications using the minimal shift approach. Thus, it is difficult to know
the extent to which line broadening has influenced the shift map. A certain
degree of subjectivity arises whenever very weak signals are detected. Deciding
if a peak assigned in one spectrum has disappeared in another spectrum may
depend on careful judgement about setting the noise level of the spectrum and
deciding how far above the noise level a signal has to be before it can be
designated as a genuine peak.
In this chapter, HSQC spectra of bb’x in the absence and presence of various
BPTI constructs have been acquired and analysed. They show that BPTI
binding generates largest perturbations in the b’ domain, suggesting that this
domain dominates binding of BPTI. Adding different concentrations of substrate
protein indicated that reduced BPTI showed the greatest binding affinity, with
(30-51, 5-14) BPTI showing clear signs of binding at lower concentrations than
the wild type substrate.
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Chapter 7. Binding Affinity of BPTI/PDI Interactions
7.1. Introduction
Previous chapters have focused on structural studies of the interaction between
the PDI folding enzyme and the BPTI substrate at various stages along the
folding pathway. In this chapter, insight was sought into the binding affinities
between PDI and each BPTI construct. How does BPTI’s affinity to PDI change
as it goes through its folding pathway?
While several studies have investigated the nature of substrate binding to PDI
(Pirneskoski, Klappa et al. 2004), specifically the role of domains in the binding
process (Klappa, Ruddock et al. 1998), very little is known about the binding
affinity or kinetics of binding with each substrate. There are few studies into the
binding affinity of PDI with unfolded or partly-folded substrates, probably due to
the difficulties associated with the stability of these proteins.
One technique for measuring protein-protein interactions is surface plasmon
resonance (SPR). This involves immobilising one protein onto a chip surface
and flowing the other in solution over the surface, allowing binding to occur and
be measured via a change in mass on the chip surface.
7.1.1. Protein Constructs Used In Binding Studies
For binding studies, interest is mainly focused on how BPTI at various stages of
folding interacts with the full length PDI enzyme. However, since NMR
observations of PDI focus on the main substrate binding region, bb’x, it is also of
interest to compare the binding to full length PDI with the binding to bb’x. This
will indicate if the observations of bb’x binding reflect the true nature of binding
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to the full length protein. PDI and bb’x were recombinantly expressed as
described previously.
As a control, a protein of similar molecular mass to full length PDI (56kDa) was
desired. Ovalbumin, after post-translational modifications, has a molecular
weight of 44.3 kDa (Tai, Yamashita et al. 1977). It is considered a member of
the serpin superfamily, but does not function as a serine protease inhibitor nor
show any enzymatic activity (Hu and Du 2000). Although its function is unknown,
it is presumed to be a storage protein (Gettins 2002). These characteristics
were thought to make ovalbumin a suitable control for BPTI binding experiments.
Ovalbumin purified from chicken egg white was used for immobilisation (Grade
VI, Sigma).
7.1.2. Temperature Studies
Throughout this study, NMR experiments were performed at three different
temperatures. Initially, NMR was performed at 36°C to compare the
recombinant wild type BPTI with previous studies of the commercial protein.
However, partly-folded BPTI required NMR at 5°C to get good resolution. In
contrast, NMR of the bb’x region of PDI is best performed at 25°C. Since
different temperatures were used for different types of experiment, it is desirable
to identify the effects of temperature on BPTI/PDI interaction at each stage of
the folding process. For this reason, separate sets of binding experiments were
performed at 5°C, 25°C and 36°C.
7.2. Immobilisation of Proteins by Amine Coupling
PDI/BPTI binding studies could be performed in two ways, immobilising either
the PDI or the BPTI constructs to the sensor chip. For this study, the PDI
Chapter 7: Binding Affinity of BPTI/PDI Interactions
199
constructs were immobilised, with various BPTI constructs used as the analyte.
Ideally, the same experiments would also be performed with BPTI constructs
immobilised and PDI as the analyte, to verify the results.
In order to be able to fully correlate binding experiments with the corresponding
NMR experiments, both the full length PDI and the bb’x region of PDI were
immobilised on the sensor chip surface.
Several different approaches are available for performing the immobilisation. By
far the most common is amine coupling, whereby the sensor chip is pre-treated
in a way that allows amine groups of the available protein to covalently bind to
the chip surface (section 2.11.1). For this study, PDI and bb’x were bound on
separate channels of the same chip, with another channel reserved as a blank.
The details of the procedure are outlined in section 2.11.1. Figure 7.1 shows the
sensorgram from bb’x immobilisation. After pre-treatment with EDC/NHS, bb’x
was successfully bound to the sensor chip. Ethanolamine was then reacted with
any remaining functional groups on the chip surface, displacing some bb’x that
may not have become covalently bound. bb’x immobilisation resulted in a final
value of 2582.2 response units (RU). Amine coupling of PDI was also
successful, resulting in a final immobilisation value of 5591.4 RU.
EDC/NHS
Pre-treatment
bb’x
binding
Ethanolamine
Figure 7.1: Sensorgram of bb’x immobilisation onto the sensor chip surface by amine
coupling.
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7.2.1. Preliminary Test to Check Binding to Immobilised
Proteins
Before performing large sets of binding experiments with several different BPTI
constructs, an initial test of binding was performed using (30-51, 5-14) BPTI as
analyte flowing over the sensor chip with immobilised PDI constructs. Figure 7.2
shows the sensorgram from various concentrations of (30-51, 5-14) BPTI
binding to the bb’x channel of the sensor chip. It shows very clear and distinct
association and dissociation phases, with the response increasing in a dose-
dependent manner. Also, it was crucially important to verify that the response
level returned to the baseline value after regeneration (data not shown).
Figure 7.2: Sensorgram of (30-51, 5-14) BPTI as analyte binding to bb’x at various
concentrations.
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7.3. Experimental Design
Three different proteins were immobilised onto the sensor chip (PDI, bb’x and
ovalbumin). Experiments were performed using three different analytes,
representing different stages of folding of BPTI (wild type BPTI, (30-51, 5-14)
BPTI, reduced BPTI). Binding analysis was performed at three different
temperatures (5°C, 25°C and 36°C). This provided a total of 27 different
experimental conditions.
There was little prior knowledge providing expected binding affinities for each
condition, except for the preliminary experiment shown above. This meant that a
wide range of different molar concentrations of analyte were used for each
interaction. This also allowed for a potentially large difference in affinities
between different interactions. In each case, lyophilised protein was
resuspended in the running buffer. A buffer only negative control was used that
did not contain analyte (0 μM). Six different molar concentrations of analyte
were used for each experiment, at 1 μM, 2.5 μM, 5 μM, 10 μM, 15 μM and 20
μM. Each set of injections was repeated once to gauge the repeatability of each
experiment.
7.4. Curve Fitting
The nature of the interactions between BPTI and PDI constructs were
elucidated through the fitting of curves to kinetic data from the sensorgram.
Using Biacore’s BIAevaluation software, various curve fitting options were
explored.
In all cases, simultaneous fitting of the association and dissociation phases of
the kinetic data was attempted, since any valid kinetic model should be able to
account for both aspects of binding. Curve fitting was also performed
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simultaneously using all concentrations of the analyte, since the underlying
processes by which binding occurs should be dose-independent. All parts of
each curve were used in the fitting, except for small regions near the inject start
and inject end, where perturbations often occur. For any model, the curve fitting
process attempts to find the values for parameters in the rate equation that best
fit the selected experimental data.
Since each lyophilised BPTI construct was resuspended directly into the running
buffer, no change in bulk refractive index between running buffer and analyte
was observed, so the refractive index difference parameter (RI) was set to a
constant of zero.
7.4.1. Assessing Goodness of Fit
How well the fitted curves represent the data can be assessed in a number of
ways. Firstly, visual inspection of the fitted curves can give an indication as to
how reasonable the model is and identify clear systematic problems where the
fitting may not match the data. Secondly, residual plots are provided, where
residuals represent the difference between the experimental data and the fitted
values for every point in the sensorgram. The scatter of residual plots indicates
the noise of the signal. It is often easier to detect small systematic deviations
from the residual plots than from the sensorgrams. Statistically, a chi2 value
represents the closeness of fit, where chi2 approximates to the average squared
residual per data point (Biacore 1997). However, the form of the fitted curve in
relation to the experimental data (i.e. the shape of the residual plot) is often
more valuable in assessing the goodness of fit (Biacore 1997).
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7.4.2. Curve Fitting Models
The most basic fitting model assumes a one to one binding between the
immobilised protein (ligand) and the analyte. With this model, single on (ka) and
off (kd) rate constants are given, allowing simple calculation of a single
dissociation constant (KD) for the interaction.
Another fitting model takes account of the possibility of heterogeneity of the
immobilised protein; it is referred to as “Heterogeneous ligand – Parallel
reactions” in the BIAevaluation software. This fitting process implies that there is
more than one mechanism by which the analyte (i.e. BPTI) can bind to the
immobilised proteins. With this model, two sets of on and off rate constants are
given, resulting in two separate dissociation constants. Since more parameters
are involved, any solution when applying this model is more sensitive to initial
parameters. The optimum solution for each BPTI binding was obtained by
iteration through the model, using the previous on and off rates as initial
parameters to the next iteration, until a minimum chi2 value was obtained.
Various reasons why such a model may be applicable to BPTI/PDI interaction
are explored in the discussion section.
7.4.3. Curve Fitting for BPTI Binding Analysis
Curve fitting was attempted for all experiments using these two different models.
Figure 7.3 shows a typical example of the results of fitting for each model.
Visually, the curve fitting appeared better using the heterogeneous ligand model.
However, this does not necessarily mean it is a more appropriate model, since
better fits would be expected from a model that has more parameters and
therefore more degrees of freedom. Indeed, recent reviews of biosensor
literature show that it is a common mistake for users to fit their data using
inappropriately complex models (Rich and Myszka 2008; Rich and Myszka
Chapter 7: Binding Affinity of BPTI/PDI Interactions
204
2010). Figure 7.4 summarises the dissociation constants obtained from two
different binding models at 36°C. Despite showing a much better fit to the data,
the model that assumes a heterogeneous ligand generally shows dissociation
constants that are very similar to each other in every case except reduced BPTI
binding to ovalbumin, where KD1 is so small it is not visible on this scale
(compare KD1 and KD2 in Figure 7.4B). A pattern of very similar KD pairs in this
model would suggest that the simpler one to one binding model may be more
appropriate. Indeed, the summary of dissociation constants for BPTI binding at
36°C using the one to one model shows a remarkable similarity to the pattern of
KD pairs using the heterogeneous ligand model, despite the seemingly poor fit of
individual curves (compare Figure 7.4A with Figure 7.4B).
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Figure 7.3: Example curve fitting to BPTI binding sensorgram data using different curve
fitting models. A) 1:1 (Langmuir) binding model; B) model assuming heterogeneous
ligand with parallel reactions.
A
B
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Figure 7.4: Different representations of BPTI binding at 36°C using different curve fitting
models. A) 1:1 (Langmuir) binding model; B) model assuming heterogeneous ligand with
parallel reactions.
7.5. BPTI Binding at Various Temperatures
The BPTI constructs representing different extents of folding were run over the
sensor chip at different temperatures, as described above (section 7.3). The
results after curve fitting assuming a 1:1 binding are summarised in Figure 7.5.
The detailed results of the curve fitting analysis are shown in Appendix G.
A
B
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Figure 7.5: Average dissociation constants for reduced, (30-51, 5-14) mutant and wild
type BPTI binding at various temperatures. BPTI was used as analyte and bound to
immobilised full length PDI, bb’x region of PDI and ovalbumin. A) 5°C; B) 25°C; C) 36°C.
A
B
C
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The curve fitting process provides separate global association and dissociation
rate constants that can be separately analysed to observe trends in these
kinetic rates. Figure 7.6 shows the association rate constants for the various
interactions of BPTI. It shows a general trend similar to the overall dissociation
constants shown in Figure 7.5, with the logarithmic axis reversed.
Figure 7.6: Average association rate constants for reduced, (30-51, 5-14) and wild type
BPTI binding at various temperatures. A) 5°C; B) 25°C; C) 36°C.
A
B
C
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Figure 7.7 shows the dissociation rate constants for the interactions. The
variation is much smaller, with an axis displayed on a linear scale. This
suggests that the majority of the differences observed between interactions are
due to different ‘on’ rates rather than different ‘off’ rates.
Figure 7.7: Average dissociation rate constants for reduced, (30-51, 5-14) and wild type
BPTI binding at various temperatures. A) 5°C; B) 25°C; C) 36°C.
A
B
C
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A general trend emerges at all temperatures that shows the reduced, unfolded
BPTI with the strongest binding (lowest dissociation constant), with the partly-
folded (30-51, 5-14) BTPI binding less well and the fully folded wild type BPTI
showing the weakest binding. This trend may be expected, since it is
reasonable to expect the less folded substrate to have a higher affinity to the
folding enzyme. Although the wild type protein exists in an equilibrium that is
heavily biased towards the native state, there will still be rare occasions when it
is partly-unfolded, thus some binding to PDI may be expected. These rare
unfolding events may take place more often at higher temperatures, as
indicated by the higher affinity of wild type BPTI to PDI at 36°C.
Interestingly, at all temperatures, binding of reduced BPTI has just as high an
affinity to ovalbumin as it does for PDI constructs. However, the partly folded
intermediate shows much weaker binding to ovalbumin than to the PDI
constructs. Since the partly-folded protein exposes only certain hydrophobic
regions, the PDI enzyme binding site may be preferentially attracted to these
regions, whereas ovalbumin is not. However, the fully unfolded, reduced BPTI
will have significant exposed hydrophobic regions throughout the protein. It may
be that such a protein has a tendency to bind to almost any protein.
There was no significant difference between binding of full length PDI and the
shorter bb’x region of PDI for fully unfolded or partly folded BPTI substrates.
This indicates that for this small protein, the bb’x region is sufficient for complete
binding of the substrate. This provides greater confidence in interpretation of
NMR results using the bb’x region of PDI, and that the observations likely reflect
the behaviour of the full length folding enzyme.
There is a general trend that shows binding gets stronger at higher
temperatures for all constructs binding to full length PDI or bb’x. Since proteins
become more dynamic at higher temperatures, configurations that expose extra
hydrophobic regions become more common, so hydrophobic interactions
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become more frequent. So an increase in binding affinity at higher temperatures
supports the theory that binding of PDI and substrate is primarily hydrophobic in
nature.
7.6. Discussion
Although the method of curve fitting that best describes BPTI/PDI interactions is
not clear, the general pattern that results from each model is consistent. The
most unfolded protein, BPTI in the fully reduced form, shows the strongest
affinity to PDI, with decreasing affinity the more folded the substrate becomes.
Below, some reasons for the observed binding behaviour are explored.
Suggestions are put forward for how the experimental process may be improved
and alternative methods of elucidating binding affinities are given.
7.6.1. Alternative Conformations of PDI May Influence Binding
One theory supporting parallel binding to a heterogeneous ligand is the role of
the x region of PDI in substrate binding. A recent study revealed that the x
region modulates the exposure of the binding site of PDI (Nguyen, Wallis et al.
2008), and distinct species of ‘capped’ and ‘uncapped’ bb’x have been isolated
(Wallis, Sidhu et al. 2009). These two species of PDI are likely to have different
binding affinities, supporting a parallel binding model, with the ‘uncapped’
species exposing the binding site, thus having a much greater binding affinity.
Such a model would be complicated by the ability of PDI to switch between the
‘capped’ and ‘uncapped’ states. Indeed, the rate of transition from ‘capped’ to
‘uncapped’ conformer may be determined by the difference in affinity for the b’
domain between the substrate and the x region.
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7.6.2. Non-specific Binding of Substrate Hydrophobic Regions
PDI is thought to have only a single binding region, focused around the b’
domain, with other domains influencing the binding process (Klappa, Ruddock
et al. 1998). However, since binding is mainly based on hydrophobic interaction
with its substrate, the region of binding on the substrate molecule will be based
on its exposed hydrophobic regions, rather than a specific binding site. If all
exposed hydrophobic regions had the same binding affinity, this would not be a
problem, since a single binding constant could still be established. However, if
different hydrophobic regions showed different affinities for PDI, a more complex
binding picture would emerge. The binding affinity of each region would perhaps
be proportional to its hydrophobicity. Such complex binding would be very
difficult to deconvolute.
7.6.3. Calculating Affinities from Steady State Binding
Establishing the binding affinities could be easier if the injections had been
allowed to proceed for longer, or at higher concentrations, such that steady-
state equilibrium was established (for higher analyte concentrations). In this way,
binding affinities could be calculated from the response units at steady state for
each concentration, independent of the kinetics required to reach the steady
state.
7.6.4. Alternative Form of Immobilisation
One of the major issues with the use of surface plasmon resonance as a
technique for studying binding kinetics is that it is difficult to be certain that the
process of immobilisation has not altered the protein’s ability to bind its
substrate. With amine coupling as an immobilisation strategy, the protein is
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immobilised based on exposed amine groups. As well as the N-terminus of the
protein, amine coupling could take place at various amino acid side chains.
Thus, heterogeneity may exist in the nature of immobilisation, which may, in turn
result in heterogeneity in binding due to different parts of the protein surface
being more exposed than others.
Since the PDI constructs used in this study are expressed with an N-terminal
His-tag, the SPR techniques used in this study could be improved by performing
immobilisation using the His-tag of the recombinant PDI constructs, rather than
by amine coupling. Using a sensor chip that has been functionalised with
nitrilotriacetic acid (NTA), the His-tag of the protein can be non-covalently
captured via nickel ions, see Figure 7.8 (Biacore 2003).
Figure 7.8: Immobilisation of ligand containing a His-tag via nickel chelated to NTA
(Biacore 2003).
With this technique, more certainty can be put on the location in which the
immobilisation takes place on the protein. Since the His-tag has only been
added to the recombinant protein to facilitate purification, its immobilisation is
much less likely to interfere with the natural binding properties of any PDI
construct.
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7.6.5. Alternative Methods of Probing Binding Interactions
7.6.5.1. Isothermal Titration Calorimetry
While SPR essentially detects binding based on a change of mass at the sensor
chip surface, calorimetric techniques observe binding based on changes in heat.
Isothermal Titration Calorimetry (ITC) is a technique which allows the progress
of a binding reaction to be followed thermodynamically. When two substances
bind, energy is either released or absorbed. ITC measures changes in binding
enthalpy and entropy as the binding reaction occurs, allowing the calculation of
binding constants and reaction stoichiometry.
No ITC studies have been performed between PDI and BPTI. However, ITC has
been used to show that the b’ domain of ERp57 binds calnexin with micromolar
affinity (Kozlov, Maattanen et al. 2006). A previous study used the related
isothermal microcalorimetry technique to study the thermodynamics of the
refolding of GAPDH assisted by PDI (Liang, Li et al. 2001). However, since
GAPDH does not form disulfide bonds, this study focused on PDI’s function as a
chaperone, preventing aggregation, rather than as a folding enzyme.
Several studies have used calorimetry to study BPTI binding, mostly studying its
interaction as an inhibitor of the trypsin enzyme. ITC was used to study the
effects of Y35G replacement in BPTI on enzyme-inhibitor interaction with trypsin
(Hanson, Domek et al. 2007) and it has also been used to study BPTI binding to
the chaperone SecB (Panse, Swaminathan et al. 2000). Another calorimetric
technique, differential scanning calorimetry (DSC), has also been used to study
the effects of various mutations in BPTI (Liu, Breslauer et al. 1997; Grzesiak,
Helland et al. 2000; Buczek, Krowarsch et al. 2002).
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The main advantage of ITC over SPR is that it does not require the
immobilisation of enzyme or substrate, thus eliminating any effects that
immobilisation might have on the binding process. However, ITC tends to
require larger volumes and higher concentrations of protein and can require
considerable trial and error to optimise. Non-specific binding of unfolded or
partly-folded BPTI to PDI could also become a problem, if different exposed
hydrophobic regions of the unfolded protein displayed different affinities to the
folding enzyme.
7.6.5.2. Estimating Binding Affinity from NMR Spectra
Another method of estimating the binding affinity between BPTI and PDI
constructs may be through using certain NMR techniques. This can often be by
observing ligand and titrating in the enzyme. Such experiments have recently
been performed to observe binding to bovine serum albumin, where either a
chemical shift or a linewidth is monitored as a function of changing solution
composition (Fielding 2007). It has also been used to provide a crude estimate
of peptide ∆-somatostatin binding affinity to the b’x region of PDI, focusing on
data from the indole resonances of Trp347 (Byrne, Sidhu et al. 2009). Similarly,
(Denisov, Maattanen et al. 2009) calculated dissociation constants for binding of
various substrates to the bb’ region of PDI by monitoring the chemical shift
changes as a function on ligand concentration using a simple binding model.
They performed a least-squares search by varying the values of KD and the
chemical shift of fully saturated protein. Standard deviations were derived by
comparing cross-peaks in the HSQC spectra. Saturation transfer methods can
also be employed, providing that the ligand is in fast exchange between free
and bound states on the NMR time-scale (Fielding 2007).
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7.6.6. Using Biosensors to Distinguish Substrate Specificity
between PDI Family Members
SPR and other biosensor techniques could be applied to other PDI family
members. Many PDI family members show distinct substrate specificity (Jessop,
Watkins et al. 2009). The differences in binding affinities with different unfolded
and partly-folded substrates could give insight into the different functions of
each family member. For example, PDI could be compared with PDIp using
both substrates that are ubiquitously expressed and those that are highly
expressed in the pancreas.
The binding of substrates to ERp57 and PDI could be compared. Since ERp57
is thought to preferentially bind to N-glycosylated substrates, analytes could
include both non-glycosylated and glycosylated protein substrates. However,
since ERp57 only binds to N-glycosylated substrates when a complex with lectin
partners calnexin or calreticulin, an affinity capturing mechanism could be
employed to form these complexes (Biacore 2003). A similar capturing
mechanism could be used to form a complex between ERdj5 and BiP, which
can then be used to observe binding with misfolded proteins normally
earmarked for the ERAD pathway.
One interesting comparison may be between PDI and ERp44. Since ERp44
has only one cysteine it has been speculated that a mixed disulfide with the
substrate may persist. Using conditions that allow a mixed disulfide to form may
provide a mechanism to test this hypothesis. If disulfides form and persist, the
sensorgram may show a typical association phase, but a much shallower
dissociation phase, since the substrate would remain covalently bound to the
immobilised enzyme. With this kind of comparison, the precise redox conditions
would become important and the effect of using running buffer in different pH
conditions could be explored. Indeed, a variety of chemicals could be added to
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the running buffer to observe the influence they have on the binding process,
such as oxidising and reducing agents, Ca2+ ions or ATP.
Techniques are also available to attach lipid membranes and vesicles to the
sensor chip surface (Biacore 2003), opening up the possibility that even
substrate binding to PDI members with transmembrane domains could be
investigated.
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Chapter 8. Discussion
8.1. Introduction
Protein disulfide isomerase (PDI) has been studied for many years, with most
emphasis put on its catalytic role in the oxidation and isomerisation of disulfide
bonds. However, in order to catalyse these processes PDI must first bind to the
substrate. Recently, more emphasis has been put on the nature of this binding.
The earliest binding studies identified the b’ domain of PDI as the primary
binding site of the enzyme, but it was suggested that all domains influenced
binding (Klappa, Ruddock et al. 1998). More recently, short peptides and a
small unfolded protein have been used to try and localise the binding site to
specific regions within the b’ domain (Byrne, Sidhu et al. 2009; Denisov,
Maattanen et al. 2009).
Although previous studies used a variety of different substrates to characterise
binding to PDI, this is the first study to compare binding of the same substrate
protein at different stages along its folding pathway. While previous studies
focused on fully unfolded proteins or peptides, this is the first study to
investigate the structural interaction of a partly-folded protein intermediate with
the PDI folding enzyme. While all nascent proteins produced by the ribosome
will initially be fully reduced, formation of initial disulfide bonds, where required,
is often rapid. However, in a protein requiring multiple disulfide bonds, the initial
configuration of disulfides is often incorrect, with disulfides often formed
between cysteine residues in close proximity, rather than in the stable
configuration required to establish the natively folded protein. In such
circumstances, isomerisation of disulfide bonds is required and this process is
often the rate limiting factor in protein folding (Huth, Perini et al. 1993; Land,
Zonneveld et al. 2003). Given these circumstances, partly folded, rather than
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completely unfolded proteins are likely to make up a large proportion, possibly
even the majority, of substrates for the PDI enzyme and the wider PDI family of
proteins.
For this study the protein bovine pancreatic trypsin inhibitor (BPTI) was chosen
as a suitable substrate for studies of binding with PDI. BPTI is a small, well
characterised protein containing three disulfide bonds (Deisenhofer and
Steigemann 1975). The native protein has a particular configuration of disulfide
bonds, but a folding pathway has been established that maps the order in which
these bonds typically form, which includes the formation of non-native disulfides
in folding intermediates (Darby, Morin et al. 1995), see Figure 1.12. This makes
BPTI an ideal candidate as a substrate for studying PDI binding, since partly-
folded intermediates, represented by their disulfide bond configuration, can be
recombinantly expressed (Creighton, Darby et al. 1996).
One interesting feature of this study is that it has sought to characterise binding
not only in terms of the changes to the PDI enzyme, but also in terms of the
effects on the substrate, at different stages of its folding pathway, i.e.
investigating how each BPTI substrate is affected by binding to PDI as well as
how PDI is affected by binding of each BPTI substrate.
The main aims of this project were i) to prepare various BPTI constructs
representing different stages along its folding pathway; ii) characterise each
BPTI construct, using NMR and other techniques to establish the extent of
folding; iii) observe changes in each BPTI construct upon addition of the PDI
enzyme; iv) observe changes in the binding region of PDI upon addition of each
BPTI construct; v) establish a binding affinity between PDI and each BPTI
construct.
Previous chapters in this study used different techniques and different
perspectives to investigate the nature of binding between PDI and various BPTI
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constructs representing different stages along its folding pathway. In this
chapter the results from all aspects of this study are brought together and used
to make conclusions about the interaction of PDI with BPTI during the protein
folding process. The findings from previous studies in this area are compared
and contrasted with the results of this study, with the hope that they can add a
valuable contribution to understanding of the processes involved in oxidative
protein folding in the endoplasmic reticulum. Improvements that could be made
to the experiments performed in this study are discussed. Different techniques
that could be used to further characterise the enzyme-substrate interface are
also suggested.
8.2. Preparation of Protein Samples
The first stage in this study was the mutagenesis of the mature wild type BPTI
construct, such that specific cysteine residues were mutated to serines. This
prevented the formation of disulfide bonds at mutated sites, thus arresting BPTI
folding at particular stages along its folding pathway. Expression studies
revealed that the (30-51, 5-14) two disulfide intermediate produced sufficient
yield of protein to enable this intermediate to be investigated (Figure 3.3). This
intermediate is particularly interesting because it contains one native disulfide
bond (30-51) and one non-native disulfide bond (5-14), so under normal
circumstances disulfide isomerisation would be required before folding to the
native state could be completed (Figure 1.12).
A protocol for expression and purification of both wild type BPTI and (30-51, 5-
14) BPTI were established and optimised. The constructs were expressed as
inclusion bodies. After incubation in denaturing and reducing agents, each BPTI
construct was desalted into 10 mM HCl to maintain the protein in reduced form.
The mass of each construct was verified by ESI mass spectrometry. Both
constructs were then refolded to their fullest extent by dilution into a refolding
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buffer containing oxidising and reducing agents. Other preparations of wild type
BPTI were alkylated via a reaction with iodoacetamide, resulting in a form of
BPTI lacking disulfide bonds and equivalent to a fully reduced state. 15N labelled
versions of all three constructs were prepared in the same manner, using 15N
labelled ammonium sulphate. Mass spectrometry was once again used to verify
the correct oxidation state and isotopic labelling of each construct.
Circular dichroism indicated that recombinant wild type BPTI had an almost
identical secondary structure profile to commercially available, purified mature
BPTI (Figure 3.13). However it was also important to compare their tertiary
structures via NMR, to ensure that the recombinant product reflected the actual
structure of BPTI. 2D TOCSY and 2D NOESY NMR confirmed that they have
very similar structures (Figure 4.2). An HSQC spectrum of recombinant wild
type BPTI was then acquired and assigned at 36°C (Figure 4.3).
Mature His-tagged PDI was prepared as specified in a previous study (Alanen,
Salo et al. 2003). A previously developed protocol was also used for the
preparation of bb’x (Byrne, Sidhu et al. 2009).
8.2.1. Soluble Expression of BPTI Constructs
In this study, all BPTI constructs were expressed as inclusion bodies, which
were subsequently isolated and purified. The resulting BPTI monomers required
refolding to reach the correct oxidative state and associated structure. This is in
line with most previous studies using recombinant BPTI, which also expressed
the protein as inclusion bodies.
However, recent developments in recombinant expression technology have
opened up the possibility of expressing partly-folded protein intermediates as
soluble proteins. This involves the use of specially adapted expression systems
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that allow oxidative folding and isomerisation in the cytosol, such as the
SHuffleTM competent cells recently developed by New England Biolabs.
SHuffleTM competent cells are E. coli cells capable of oxidising proteins in the
cytoplasm to promote correct disulfide bond formation. Normally, reductases in
the cytoplasm would reduce any disulfide bonds that have formed. However
SHuffleTM competent cells have been adapted with deletions of the genes for
these reductases (specifically glutaredoxin reductase and thioredoxin reductase)
(de Marco 2009) . Thus, disulfide bonds formed in the cytoplasm are able to
persist. Furthermore, the cells have also been modified to express an adapted
version of DsbC that lacks the signal sequence that would normally target the
enzyme towards the periplasm. Thus, DsbC is retained in the cytoplasm, where
it functions to catalyse isomerisation of multi-disulfide bonded proteins.
Cytoplasmic expression results in significantly higher yields of disulfide bonded
proteins compared to periplasmic expression (de Marco 2009).
8.3. Structural Dynamics of the (30-51, 5-14) BPTI Partly-folded
Intermediate
When an HSQC spectrum was acquired for (30-51, 5-14) BPTI at 36°C, it
revealed poorly resolved peaks, characteristic of a protein that was mainly
unfolded (Figure 4.4). However, when an HSQC spectrum of the same sample
was acquired at 5°C, it showed well dispersed peaks, indicative of a well folded
protein (Figure 4.5). This supported evidence from a previous study, which
showed an increased resolution in 1H NMR with BPTI intermediates as the
temperature was decreased (Vanmierlo, Kemmink et al. 1994). It also strongly
suggests that this construct was flexible at higher temperatures, but was
stabilised by a reduction in temperature. However, the HSQC spectrum of (30-
51, 5-14) BPTI at 5°C was still quite different from the wild type spectrum
(Figure 4.10). Since a structure of this intermediate had not been determined in
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the given conditions, a series of NMR experiments were performed to establish
the backbone assignments. Once the HSQC spectrum could be assigned, it was
clear that the N-terminal region of the protein was not visible. This was most
likely due to line broadening caused by the N-terminal region being highly
flexible, even at 5°C. This could be explained by the lack of a 5-55 disulfide
bond, which would normally keep the N-terminus tethered to the C-terminus of
the protein (see Figure 1.11). The non-native 5-14 disulfide creates a large
flexible N-terminal loop with very little secondary structure that is highly dynamic
and explores many different local chemical environments within the NMR
timescale, causing line broadening in the HSQC spectrum and hence no signal
is detected.
8.3.1. Is the C-terminus of (30-51, 5-14) BPTI Buried?
Hydrogen deuterium exchange experiments were performed on all BPTI
constructs to establish the extent to which different regions of the protein were
solvent exposed. As expected, the natively folded wild type protein displayed
much less solvent exposure compared with the partly-folded (30-51, 5-14) BPTI
intermediate (Figure 4.17). However, although signals from C-terminal residues
of wild type BPTI disappeared after just 5 minutes in D2O buffer, signals from
the two C-terminal residues of the (30-51, 5-14) persisted even after 24 hours in
D2O buffer, despite the signal from other residues disappearing (Figure 4.17).
This suggests that in this particular partly-folded intermediate of BPTI, the C-
terminus has become buried into the central region of the protein. These C-
terminal residues are also clearly distinguishable in the HSQC spectrum at 36°C
(Figure 4.12), implying a unique chemical environment which would result from
being buried in the centre of the molecule, even at a temperature where the rest
of the molecule shows high flexibility. Also, the C-terminal of (30-51, 5-14) BPTI
seems to be the one region of the HSQC spectrum that persists even after
relatively high concentrations of PDI have been added (Figure 5.6C), suggesting
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that even small amounts of unbound (30-51, 5-14) BPTI are enough to provide a
noticeable signal for these residues. Together, these experiments provide
evidence that the C-terminus of the (30-51, 5-14) BPTI partly-folded
intermediate may be buried within the core of the molecule. Such a model is
quite feasible, since the native 5-55 disulfide bond is missing, hence no longer
constraining the movement of this region of the protein. Similarly, the N-
terminus, which is in close proximity to the C-terminus in wild type BPTI, is kept
away from the C-terminal region by the 5-14 non-native disulfide, removing this
steric hindrance from the C-terminal. With such a reduction in restraints the C-
terminus may by expected to be very flexible, but perhaps it forms weak bonds
with proximal residues when able to bury within the core of the molecule.
8.4. Reduced Alkylated BPTI is Predominantly Unstructured
HSQC spectra were also acquired for 15N isotopically labelled fully reduced and
alkylated wild type BPTI. Despite complications due to the limited solubility of
this construct, enhanced HSQC spectra clearly showed that the protein was
predominantly unfolded and very dynamic even at low temperatures (Figure
4.13). This was supported by the hydrogen deuterium exchange experiment,
which showed complete disappearance of all HSQC signals before they could
be detected (after just 5 min) (Figure 4.18).
8.5. Recombinant BPTI Constructs Provide a Good
Representation of Different Stages along the Protein’s Folding
Pathway
Analysis of HSQC spectra from 15N isotopically labelled samples of wild type,
(30-51, 5-14) and reduced BPTI provided strong evidence that they represent
natively folded, partly-folded and unfolded proteins respectively (see overlay of
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spectra in Figure 4.14). Thus the available constructs acted as good
representations of substrates at different stages of folding for the study of
binding with the PDI protein folding enzyme.
8.6. Interaction of PDI with Wild Type BPTI
As expected, natively folded wild type BPTI showed much weaker binding to
PDI than the less folded BPTI constructs. However, an interaction was
nevertheless evident from observations of HSQC spectra, both from the
perspective of 15N labelled wild type BPTI (Figure 5.7) and the perspective of
the 15N labelled bb’x region of PDI (Figure 6.7). SPR experiments suggested a
dissociation constant of approximately 2.9 mM for binding between wild type
BPTI and full length PDI at 25°C (Figure 7.5), which is comparable to an
estimate of >2 mM for binding of folded RNase and bb’ from a recent study
(Denisov, Maattanen et al. 2009). Since PDI is primarily a folding enzyme
responsible for oxidation and isomerisation of disulfide bonds in proteins during
the folding process, it may seem unexpected that a natively folded protein, such
as wild type BPTI, with all disulfide bonds intact, would interact at all with PDI.
However, there are two main reasons why PDI interaction with a natively folded
protein would be feasible. Firstly, as well as its primary role as a folding enzyme,
PDI has been demonstrated to act as a chaperone (Cai, Wang et al. 1994; Song
and Wang 1995). In the natural ER environment of PDI, protein aggregation can
occur due to its very crowded environment, so the chaperone function of PDI,
even for natively folded proteins, may be underrated (Ellis 2001). Secondly,
even natively folded, highly stable proteins such as BPTI are dynamic and are
associated with an ensemble of different conformations. On occasions this will
include conformations that are partially unfolded and expose hydrophobic
regions of the molecule, allowing PDI to bind to it. This is demonstrated by the
hydrogen deuterium exchange experiment using wild type BPTI, which
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suggested that after 24 hours most of the molecule had become solvent
exposed (Figure 4.17).
8.7. Comparisons between Reduced BPTI and (30-51, 5-14)
BPTI Interactions with PDI
The HSQC spectrum of reduced BPTI shows substantial line broadening, even
in the presence of small concentrations of PDI (Figure 5.9). It seems to produce
marginally larger perturbations when present in HSQC spectra of bb’x compared
to the (30-51, 5-14) BPTI intermediate (Figure 6.11). However, due to the limited
solubility of reduced BPTI, it is difficult to judge if this difference is significant.
SPR binding analysis estimated dissociation constants of 3.0 μM for reduced
BPTI and 4.4 μM for (30-51, 5-14) BPTI when binding to full length PDI at 25°C.
Overall, the evidence suggests that fully reduced BPTI has a greater affinity to
PDI than the two disulfide species, but this difference is relatively small.
8.8. Binding Affinities to PDI Constructs
It is interesting to compare the binding of BPTI constructs to similar studies of
PDI binding. The dissociation constant for another full length protein, RNase A,
binding to the bb’ region of PDI was estimated to be 35 μM for the unfolded
protein, compared with at least 2 mM for folded RNase A (Denisov, Maattanen
et al. 2009). The same study estimated a KD of 35 μM for the peptide
somatostatin (similar to unfolded RNase) and an weaker binding of 130 μM for
peptide mastoparan (Denisov, Maattanen et al. 2009). A separate study of a
truncated version of somatostatin binding to the b’x region crudely estimated a
dissociation constant between 0.1-1.0 mM (Byrne, Sidhu et al. 2009). These
figures suggest that BPTI constructs bind much more tightly to the binding
region of PDI than any of these other constructs (except when fully folded), or
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they use multiple binding interactions with different regions of PDI. Perhaps the
low level of secondary structure in BPTI allows hydrophobic regions to be
readily exposed when it is in a partially folded state.
The affinity of PDI for substrates seems to be comparable to that of molecular
chaperones. For example, the molecular chaperone BiP binds synthetic
peptides with consensus motifs with 10–60 μM affinity (Blondelguindi, Cwirla et
al. 1993). The relatively weak binding of PDI even to unfolded or partly-folded
BPTI, along with the large size of the binding pocket in the b’ domain, is
consistent with a low degree of specificity for hydrophobic ligands (Denisov,
Maattanen et al. 2009). The identification of several low-affinity substrate
binding sites in PDI, rather than a single high-affinity site, could account for the
broad specificity of PDI for non-native proteins (Hatahet and Ruddock 2007). A
recent paper proposed that the b’ domain acts as a large, multivalent
hydrophobic binding site and is an effective way to bind a variety of substrates
when unfolded, then to release them once they have acquired their native
conformation, since fewer hydrophobic residues will be exposed in the native
state (Denisov, Maattanen et al. 2009). Likewise, a recent review suggested that
the combination of multiple low-affinity sites may be essential for the
physiological function of PDI (Hatahet and Ruddock 2009).
8.8.1. Dependence of Binding on Mixed Disulfide Formation
Some caution should be taken when interpreting the results of this study and
how accurately they reflect behaviour in the ER. The folding intermediate has
been prevented in proceeding along the BPTI folding pathway by mutation of
the cysteine residues not involved in its current disulfide bond configuration.
However, this is likely to impact on the protein’s binding to PDI, since the normal
processes of oxidation and isomerisation would involve the formation a mixed
disulfide with a least one of the cysteines that no longer exist (Hatahet and
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Ruddock 2007). This means that off rates in kinetic analysis of binding are likely
to be much higher for simple binding of an intermediate stuck at one point in the
folding pathway than for an intermediate that is actively undergoing oxidation or
isomerisation in the ER.
Likewise, in this study, wild type BPTI was trapped in the fully reduced state by
alkylation of the free thiols, preventing oxidation. In practise, binding to PDI
would result in a transient but important mixed disulfide in the process of
oxidising the reduced substrate (Morjana and Gilbert 1991).
An alternative approach might be to generate mutations in both PDI and BPTI
that would lead to the formation of a trapped mixed disulfide between the two
proteins. For example, a PDI construct whereby all but one of the active site
cysteines were mutated could be oxidised in the presence of a BPTI construct
that would only have a single C14S mutation. According to the BPTI folding
pathway, this would result in a (30-51, 5-55) intermediate, with the C38
remaining as a free thiol. When oxidised in the presence of the PDI mutant, a
PDI/BPTI complex would form with a mixed disulfide bond between the
remaining active site cysteine of PDI and the C38 of BPTI. To enable NMR of
PDI, a truncated construct, e.g. abb’x or bb’xa’, could be used. As performed in
this study, the PDI and BPTI constructs could be 15N labelled so that their
effects on each other could be observed from the perspective of both the folding
enzyme and the partly-folded substrate.
Another consideration with regard to the extent of substrate binding to PDI in
vivo is the role of glutathione, which can compete with substrate binding by PDI
(Lumb and Bulleid 2002).
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8.9. Approximation to Physiological Conditions
The pH of the endoplasmic reticulum at rest is approximately 7.1 (Kim,
Johannes et al. 1998), although it is highly permeable to H+ equivalents, so is
susceptible to alterations in the cytosolic pH. All NMR experiments in this study
were performed at pH 6.5, since this was the pH used for the acquisition of
previous PDI spectra. However, it is believed the structure would not alter with
the relatively small increase in pH to that of the ER.
It should be noted that during the folding process in vivo, BPTI would actually be
in the form of proBPTI, still containing N- and C-terminal extensions that are
cleaved after export from the cell. Despite this sequence containing an extra
cysteine residue which could theoretically result in an alternative protein folding
pathway, one previous study suggests that this residue does not significantly
alter the pathway of BPTI (Creighton, Bagley et al. 1993). This was contrary to
an earlier study, which found that both the rate and yield of natively folded BPTI
increased using proBPTI (Weissman and Kim 1992a). In any case, even if the
folding pathway of BPTI is unaltered by these extensions, this should not be
taken as a general rule and it remains plausible that the precursor of a protein
may result in a different folding pathway than with the study of mature protein.
All protein refolding in this study was performed in vitro by dilution into a
buffered solution with oxidising and reducing agents. This proved sufficient for
the successful refolding of BPTI. However, the endoplasmic reticulum is a very
crowded environment, and the effects of such protein crowding on the folding
process need to be considered before the pathway can be said to reflect the
folding pathway of BPTI in vivo (Ellis 2001).
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8.10. Alternative NMR Techniques to Characterise PDI/BPTI
Binding
8.10.1. Observing Substrate Folding in Real Time
Under certain conditions it may be possible to observe the refolding of BPTI in
real time by NMR. Starting with fully reduced, but not alkylated, BPTI, short
HSQC spectra could be acquired in quick succession to observe the refolding of
BPTI to its native state. This could theoretically be done in both the absence
and presence of PDI. However, the main obstacle would be the timescale of
refolding, which is normally very rapid. Conditions would have to be optimised
so that the folding process would be slowed considerably, perhaps by refolding
at a lower pH or with a lower concentration of oxidising agent. A previous study
used HSQC spectra to follow the kinetics of protein folding (Balbach, Forge et al.
1996). Here, the intensities and line shapes of the cross peaks in the spectrum
reflected the kinetic time course of the folding events that occurred during the
spectral accumulation.
8.10.2. Hydrogen Deuterium Exchange to Observe Enzyme-
Substrate Interactions
This study used HSQC spectra to investigate H/D exchange of each of the BPTI
construct in isolation (section 4.6). This was informative about both the structure
and dynamics of BPTI at different stages along its folding pathway. The same
technique could be used to study PDI/BPTI interactions by acquiring HSQC
spectra of BPTI in the presence of PDI (Mandell, Baerga-Ortiz et al. 2005). By
comparing the regions exchanged in the absence and presence of PDI, the
areas of BPTI buried by binding could be identified, since they will be less
solvent exposed when in the PDI/BPTI complex. Likewise, similar experiments
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could be performed with the bb’x region of PDI in the absence and presence of
BPTI constructs. Together, the data could reveal further detail about the
interaction interface. NMR data could be complemented with measurements
using mass spectrometry (Komives 2005).
8.10.3. Exchange-transferred NOE Spectroscopy
For a long time intramolecular NOEs have been used to aid the determination of
protein structures. However, NOEs can also be transferred from one molecule
to another in close proximity. Exchange-transferred NOE spectroscopy (et-
NOESY) can be used to probe the conformation of small molecule ligands in
association with high molecular weight proteins (Post 2003). The experiment is
capable of giving information on the conformation of bound ligands (Neuhaus
and Williamson 2000). It is applied to systems for which exchange is fast on the
chemical shift timescale, so that ligand protons show a single resonance peak
averaged over the free and bound states. An important consideration in all
applications of et-NOESY is the demonstration of specific binding and the
exclusion of nonspecific binding (Post 2003). The experiment relies on weakly
binding ligands that remain on the enzyme for a relatively short time, so that
NOEs between nuclei in the bound ligand are transferred to the more easily
detected nuclei in the ligand free in solution by virtue of chemical exchange
between the free and bound states (Evans 1995). However, ligands used in et-
NOESY need to be small enough so that cross-peaks observed in the bound
state are sufficiently larger than in the free state. This generally equates to an
upper limit of 5 kDa for the ligand (Post 2003), so at 6.6 kDa BPTI would be a
very challenging substrate.
Chapter 8: Discussion
232
8.10.4. Saturation Transfer Difference Spectroscopy
Another technique that exploits the intermolecular transfer of NOE is saturation
transfer difference spectroscopy (STD). This technique also allows the detection
of transient binding of ligands to macromolecular receptors, but does not have
the same restriction with regard to the size of the ligand, so protein-protein
interactions are more feasible (Post 2003). The STD method can be used to
determine which part of the ligand molecule is responsible for binding, since the
most strongly interacting groups of a ligand will show stronger STD effects. The
method relies on the ability to selectively saturate protons of the
macromolecular receptor by irradiating the spectral region containing “wings” of
broad resonances of the macromolecule, which is also free of any smaller
molecule signals (Mayer and Meyer 1999). Due to effective spin diffusion,
saturation quickly propagates across the entire receptor. If the ligand is bound to
the receptor, saturation will also spread onto the ligand. The result will be that
the intensity of the ligand signal will be attenuated. Subtraction of the resulting
spectrum from the reference spectrum (without saturation) yields the STD
spectrum containing only signals of the binding ligands (Klein, Meinecke et al.
1999). STD can be particularly effective at identifying the contact surface of a
protein-ligand interaction (Post 2003). As such, it could be a very useful
technique in identifying more precisely the PDI-BPTI binding interface for BPTI
at each stage along its folding pathway.
8.10.5. Water-Ligand Observed via Gradient Spectroscopy
(WaterLOGSY)
WaterLOGSY is a variant of STD NMR spectroscopy that utilises the bound
water at protein-ligand interfaces. It differs from STD spectroscopy in that the
water is magnetised then transferred to the protein, whereas with STD the
protein is magnetised directly (Meyer and Peters 2003). The WaterLOGSY
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experiment utilises water molecules present at the protein-ligand interface and
uses intermolecular NOE and chemical exchange to transfer magnetisation from
bulk water to the protein. The magnetisation is then transferred to the bound
ligand, which can leave the binding site carrying with it the magnetisation
acquired from binding (Dalvit, Fogliatto et al. 2001). The result is that the
resonances of non-binding ligands appear weaker than those of interacting
ligands. A comparison can then be performed with a WaterLOGSY experiment
of the ligand solution without the receptor protein present. Quantitative
estimates of KD can also be obtained (Fielding 2007). WaterLOGSY could
potentially be used to complement STD experiments in further characterisation
of the PDI-BPTI binding interface, comparing how each different BPTI construct
binds to the enzyme and possibly as a method for verifying binding constants
estimated using SPR.
8.11. Alternative Biophysical Approaches
8.11.1. Small Angle X-Ray Scattering
Small-angle X-ray scattering (SAXS) has been used to study properties of full
length human PDI free in solution (Solda, Garbi et al. 2006), as well as another
PDI family member (Kozlov, Maattanen et al. 2009). SAXS may be able to
confirm or extend knowledge of substrate binding through crude measurements
of the effect of binding a protein substrate. This technique has the advantage of
being unlimited by either the size of the enzyme or the size of the substrate, so
full length PDI could be observed in solution, both in the presence and absence
of BPTI. However, the technique lacks the high resolution available from NMR
or X-ray crystallography and it may be difficult to distinguish differences using
such a small substrate protein.
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8.12. Partly Folded Proteins in the Endoplasmic Reticulum
Nascent polypeptide chains often begin folding co-translationally and folding is
completed post-translationally. Hence, when studying protein folding in the ER,
most nascent proteins will be in a partly folded state, rather than being
completely unfolded. Thus, many ER resident folding enzymes and quality
control machinery will have partly folded proteins as their most predominant
substrate. Despite this, most previous studies investigating the interaction of a
substrate with folding enzymes have focused on using fully reduced, unfolded
proteins or peptides as substrates.
PDI is an ER resident enzyme that functions both as a folding catalyst, assisting
substrate proteins in reaching their native state, and as a chaperone, preventing
protein misfolding and misassembly.
This study investigated the interactions between PDI and BPTI at different
stages along its folding pathway. BPTI was prepared in both its natively folded
and fully reduced forms. However, it was the preparation of a partly folded BPTI,
representing an intermediate in the folding pathway of this protein, which was of
greatest interest.
Structural characterisation of the folding intermediate by NMR indicated that the
protein is highly flexible at physiological temperatures, indicating behaviour of a
mainly unfolded protein. Interestingly, however, the stability of the protein
increased markedly with a decrease in temperature. At 5°C, most of the protein
adopts a well folded conformation, but the N-terminal region remains flexible.
This verifies that at a low temperature the folding intermediate of BPTI is indeed
a partly folded protein, a finding supported by comparison with NMR
experiments of natively folded and fully reduced BPTI.
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Interaction of the partly folded substrate with PDI revealed their binding affinity
to be less than with the enzyme binding to a fully reduced protein, presumably
due to having fewer exposed hydrophobic regions. However, the binding was
still much stronger than PDI binding to the natively folded protein, which would
have very few exposed hydrophobic regions.
NMR analysis of the structural changes in PDI during binding with the partly
folded protein suggested that the regions of the enzyme affected by binding
were similar to those affected by binding of both the reduced and natively folded
substrate. These regions also broadly match the affects observed due to the
binding of other substrates from previous studies.
Together, these findings imply that although binding affinity with PDI generally
decreases as a substrate progresses along its folding pathway, the regions of
binding on the enzyme remain unchanged.
This study focused on the interaction of a partly folded protein with the folding
enzyme PDI. However, partly folded proteins will interact with many different
enzymes in the crowded environment of the ER. Without a greater
understanding of how partly folded proteins interact with the wide variety of
folding enzymes and chaperones available in the ER, a full picture of how they
are treated cannot be obtained. The outcomes of partly folded proteins are
determined by interactions with proteins of both the folding and quality control
machinery. The actions taken on partly-folded substrates by the ER machinery
will determine its fate, either as a natively folded protein that is exported from
the ER with appropriate signal sequence to reach its final destination or to
become misfolded, where it may become degraded or lead to aggregate
formation, Figure 8.1.
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Figure 8.1: General protein folding pathways and consequences in the ER. The outcomes
of partly-folded proteins are determined by interaction with proteins of the folding and
quality control machinery. If not tightly controlled, protein misfolding can occur and the
crowded environment of the ER can lead to aggregation. Misfolded proteins are often
degraded, but aggregate formation can lead to pathology. One multifunctional enzyme
that both assists protein folding to the native state (as an oxidoreductase) and prevents
protein misfolding or aggregation (as a chaperone) is protein disulfide isomerase (PDI).
In this study, the mechanisms through which PDI assists protein folding have been
investigated by studying its interaction with a protein substrate at different stages along
its folding pathway: in the fully reduced state, in a partly folded conformation and in the
natively folded state (depicted graphically in the diagram). Understanding the nature of
these interactions improves understanding of the general protein folding process and
thus provides knowledge for how protein misfolding or aggregation could be prevented.
Understanding how partly-folded proteins interact with the crowded environment
of the ER is crucial to understanding how proteins reach their native three
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dimensional conformations, or how they may end up in a misfolded or
aggregated state. This is the first study to investigate the structural interaction
of PDI with a partly-folded protein substrate. It is hoped that the findings of this
study will contribute to a general understanding of oxidative protein folding in the
endoplasmic reticulum.
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APPENDIX A – CHEMICAL SHIFT RESONANCES FOR
WILD TYPE BPTI ASSIGNMENTS AT 36°C
Chemical shift data (in ppm) are given for both commercial and recombinant
wild type BPTI at 36°C. Assignment tables are based on 1H-1H TOCSY and
1H-1H NOESY assignments.
Commercial BPTI Recombinant BPTI
Amino
Acid
NH CαH CβH CγH NH CαH CβH CγH
Arg1 - - - - - - - -
Pro2 - - - - - - - -
Asp3 - - - - 8.697 4.250 2.759 -
Phe4 - - - - 7.779 4.591 3.347 -
Cys5 7.477 4.348 2.859
2.742
- 7.509 4.354 2.843
2.770
-
Leu6 7.574 4.507 1.840 - 7.569 4.512 1.839
1.683
-
Glu7 7.526 4.584 2.252
2.168
- 7.528 4.586 2.257
2.165
2.569
Pro8 - - - - - - - -
Pro9 - - - - - - - -
Tyr10 7.808 4.933 2.954 - 7.802 4.930 2.955 -
Thr11 - - - - 8.953 4.527 4.048 1.387
Gly12 7.164 3.896
3.261
- - 7.160 3.895
3.260
- -
Cys14 8.702 4.559 3.460
2.794
- 8.697 4.558 3.461
2.798
-
Lys15 7.967 4.407 2.090
1.577
- 7.968 4.407 2.085
1.575
-
Ala16 8.221 4.294 1.172 - 8.210 4.296 1.171 -
Arg17 8.205 4.315 1.594 - 8.190 4.312 1.594
1.476
1.303
Ile18 8.130 4.196 1.865 - 8.116 4.195 1.867 0.963
Ile19 8.694 4.307 1.946 - 8.689 4.307 1.947 -
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Arg20 8.399 4.699 1.804
0.809
- 8.394 4.697 1.807
0.812
-
Tyr21 9.184 5.678 2.698 - 9.186 5.679 2.700 -
Phe22 9.778 5.269 2.906
2.818
- 9.777 5.271 2.906
2.816
-
Tyr23 10.560 4.294 3.459
2.731
- 10.570 4.297 3.463
2.738
-
Asn24 7.774 4.601 2.859
2.167
- 7.779 4.603 2.862
2.169
-
Ala25 8.794 3.761 1.554 - 8.789 3.760 1.554 -
Lys26 7.910 4.069 1.884 - 7.913 4.067 1.884 -
Ala27 6.822 4.290 1.181 - 6.817 4.292 1.184 -
Gly28 8.141 3.917
3.611
- - 8.143 3.919
3.628
- -
Leu29 6.828 4.743 1.728
1.427
- 6.828 4.755 1.730
1.429
-
Cys30 8.417 5.606 3.670
2.665
- 8.406 5.607 3.672
2.665
-
Gln31 8.771 4.824 2.180
1.729
- 8.763 4.824 2.223
1.729
-
Thr32 8.040 5.289 4.035 - 8.035 5.291 4.035 -
Phe33 9.373 4.862 3.084
2.951
- 9.375 4.867 3.088
2.949
-
Val34 8.386 3.915 1.949 - 8.368 3.915 1.947 -
Tyr35 9.389 4.879 2.662
2.500
- 9.388 4.874 2.664
2.501
-
Gly36 8.616 4.316
3.246
- - 8.616 4.317
3.241
- -
Gly37 4.334 4.225
2.907
- - 4.307 4.219
2.903
- -
Cys38 7.764 4.951 3.958
3.031
- 7.755 4.951 3.955
3.029
-
Arg39 - - - - 9.075 3.937 2.271
1.594
-
Ala40 7.422 4.085 1.203 - 7.422 4.080 1.200 -
Lys41 8.327 4.439 2.252
1.654
- 8.331 4.439 2.251
1.657
-
Arg42 8.366 3.664 1.025
0.364
- 8.358 3.658 1.014
0.341
-
Asn43 7.214 5.055 3.335
3.265
- 7.212 5.052 3.335
3.285
-
Asn44 6.776 4.897 2.774
2.504
- 6.762 4.898 2.775
2.503
-
Phe45 9.939 5.122 3.405 - 9.938 5.125 3.406 -
270
2.784 2.787
Lys46 - - - - 9.913 4.383 2.092
1.983
-
Ser47 7.468 4.533 4.124
3.861
- 7.466 4.531 4.124
3.862
-
Ala48 8.148 3.151 1.033 - 8.140 3.155 1.035 -
Glu49 8.613 3.865 2.007
1.830
- 8.603 3.858 2.005
1.834
2.334
2.184
Asp50 7.856 4.282 2.875
2.714
- 7.849 4.281 2.870
2.719
-
Cys51 6.992 1.687 3.172
2.881
- 6.985 1.687 3.175
2.892
-
Met52 8.593 4.163 2.052
1.963
- 8.581 4.170 2.052
1.963
2.692
Arg53 8.269 3.983 1.923
1.863
- 8.267 3.986 1.918
1.869
-
Thr54 7.392 4.072 4.000 - 7.398 4.078 4.005 1.615
Cys55 8.239 4.612 2.241
2.004
- 8.204 4.643 2.221
2.024
-
Gly56 7.998 3.849 - - 7.997 3.848 - -
Gly57 8.198 3.944
3.824
- - 8.211 3.950
3.842
- -
Ala58 7.923 4.023 1.301 - 7.919 4.025 1.303 -
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APPENDIX B – CHEMICAL SHIFT RESONANCES FOR
(30-51, 5-14) BPTI INTERMEDIATE ASSIGNMENTS AT
5°C
Chemical shift data (in ppm) are given for spectral assignments of (30-51, 5-14)
BPTI partly-folded intermediate at 5°C. The assignment table is derived from a
combination of 3D HSQC-TOCSY, 3D HSQC-NOESY, 2D 1H-1H TOCSY, 2D
1H-1H NOESY and 15N-1H HSQC spectra. Peak lists of the assignments for each
spectrum are provided on the accompanying CD.
Amino
Acid
N NH CαH CβH CγH CδH CεH
Gly12 110.8 8.602 4.051 - - - -
Lys15 120.0 8.175 4.316 1.722 - - -
Ala16 125.2 8.520 4.271 1.387 - - -
Arg17a 121.1 8.459 4.386 1.694
1.475
- - -
Arg17b 122.7 8.545 4.288 1.794 1.648
1.570
- -
Ile18 119.9 8.224 4.246 1.753 1.511
1.226
- -
Ile19 126.8 8.473 4.481 1.856 1.466
0.730
- -
Arg20 126.6 8.381 4.802 1.084 - - -
Tyr21 115.4 9.062 5.512 2.761
2.692
- 6.716 6.776
Phe22 119.4 9.717 5.430 3.202
3.025
- 7.180 7.204
Tyr23 123.1 9.713 4.520 3.013
2.735
- 7.097 6.571
272
Asn24 127.7 8.095 4.629 2.928
2.279
- - -
Ala25 127.0 8.580 3.707 1.578 - - -
Lys26 117.5 8.030 4.108 1.934 - - -
Ala27 118.6 7.021 4.299 1.240 - - -
Gly28 107.8 8.240 3.958
3.760
- - - -
Leu29 115.0 6.998 4.900 1.721
1.465
- - -
Cys30 119.2 8.923 5.632 3.727
2.702
- - -
Gln31 122.7 9.029 4.888 1.998
1.738
- - -
Thr32 110.3 8.299 4.938 4.047 - - -
Phe33 118.8 8.640 4.850 3.195
3.026
- - -
Val34 120.7 8.507 4.069 1.941 0.830
0.875
- -
Tyr35 129.1 8.772 4.388 2.821
2.504
- 6.940 -
Gly36 108.9 8.373 3.990
3.980
- - - -
Gly37 114.7 8.315 3.878
3.842
- - - -
Ser38 115.7 8.369 4.420 3.945
3.896
- - -
Arg39 121.0 8.362 4.434 1.785 - - -
Ala40 123.9 8.224 4.256 1.362 - - -
Lys41 124.0 8.920 4.297 1.771 - - -
Arg42 120.2 8.141 4.316 1.847 - - -
Asn43 119.8 8.660 4.623 2.795 - - -
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Asn44 117.7 7.962 5.384 - - - -
Phe45 117.1 9.316 5.108 2.766 - 7.294 -
Lys46 120.2 9.952 4.470 2.069 - - -
Ser47 109.4 7.506 4.553 4.134
3.874
- - -
Ala48 125.3 8.327 3.111 1.106 - - -
Glu49 117.6 8.748 3.865 2.019
1.852
- - -
Asp50 119.8 7.718 4.288 2.717
2.721
- - -
Cys51 118.5 7.110 - 2.992
2.657
- - -
Met52 121.3 8.666 4.120 2.045
2.051
- - -
Arg53 120.0 7.984 4.047 1.888 - - 7.795
Thr54 111.9 7.568 4.188 4.049 - - -
Ser55 115.5 7.764 4.136 3.240
3.133
- - -
Gly56 108.1 7.919 3.886 - - - -
Gly57 108.7 8.129 3.931
3.565
- - - -
Ala58a 128.9 7.947 4.194 1.372 - - -
Ala58b 129.2 8.045 4.183 1.381 - - -
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APPENDIX C – CHEMICAL SHIFT RESONANCES FOR
HSQC SPECTRA AT VARIOUS TEMPERATURES
Chemical shift data (in ppm) are given for 15N-1H HSQC assignments of both
wild type and (30-51, 5-14) BPTI partly-folded intermediate at various
temperatures.
Wild Type BPTI
5°C 36°C
Amino Acid N NH N NH
Arg1 - - - -
Pro2 - - - -
Asp3 123.630 8.764 123.360 8.509
Phe4 117.510 8.060 117.015 7.780
Cys5 121.612 7.609 121.564 7.428
Leu6 113.719 7.700 114.008 7.503
Glu7 120.326 7.587 120.645 7.436
Pro8 - - - -
Pro9 - - - -
Tyr10 123.596 7.971 123.573 7.758
Thr11 127.620 9.203 127.581 8.924
Gly12 107.590 7.347 107.517 7.110
Pro13 - - - -
Cys14 120.471 8.844 120.312 8.645
Lys15 115.610 8.145 115.778 7.922
Ala16 123.711 8.287 123.796 8.130
Arg17 118.742 8.449 118.744 8.173
Ile18 125.958 8.262 125.966 8.067
Ile19 128.352 8.927 128.452 8.662
Arg20 130.263 8.495 130.181 8.314
Tyr21 115.202 9.307 115.489 9.124
Phe22 119.902 9.863 120.056 9.699
Tyr23 124.867 10.702 125.050 10.506
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Asn24 125.282 7.773 125.474 7.650
Ala25 126.191 9.043 126.478 8.769
Lys26 117.459 8.109 117.350 7.854
Ala27 118.658 6.917 118.744 6.740
Gly28 107.326 8.265 107.295 8.074
Leu29 114.922 6.938 114.957 6.754
Cys30 118.304 8.580 118.578 8.353
Gln31 122.928 8.856 123.126 8.689
Thr32 108.526 8.198 108.653 7.982
Phe33 119.153 9.461 119.310 9.297
Val34 118.848 8.590 118.956 8.330
Tyr35 129.711 9.568 129.866 9.345
Gly36 114.361 8.766 114.431 8.553
Gly37 - - - -
Cys38 115.000 7.804 115.214 7.656
Arg39 113.264 9.285 113.597 9.058
Ala40 118.225 7.553 118.335 7.361
Lys41 121.204 8.464 121.293 8.268
Arg42 116.143 8.565 116.067 8.323
Asn43 116.159 7.277 116.296 7.118
Asn44 120.730 6.856 120.972 6.690
Phe45 122.714 10.054 122.787 9.865
Lys46 120.370 10.139 120.610 9.892
Ser47 108.942 7.541 109.027 7.387
Ala48 125.414 8.297 125.591 8.097
Glu49 117.583 8.721 117.800 8.533
Asp50 120.698 8.019 120.586 7.796
Cys51 119.771 7.073 119.886 6.899
Met52 120.550 8.687 120.855 8.495
Arg53 122.057 8.333 121.704 8.183
Thr54 113.427 7.493 113.506 7.325
Cys55 115.027 8.388 115.029 8.156
Gly56 108.082 8.203 108.018 7.942
Gly57 109.635 8.459 109.541 8.194
Ala58 128.702 8.026 128.895 7.754
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(30-51, 5-14) BPTI Intermediate
5°C 20°C 36°C
Amino Acid N NH N NH N NH
Gly12 110.755 8.594 110.738 8.506 - -
Lys15 119.976 8.164 119.713 8.058 119.710 7.995
Ala16 125.236 8.518 124.965 8.384 124.573 8.251
Arg17a 121.038 8.453 120.867 8.340 120.571 8.227
Arg17b 122.658 8.544 - - - -
Ile18 119.872 8.217 119.819 8.104 - -
Ile19 126.807 8.468 126.865 8.437 - -
Arg20 126.682 8.373 126.528 8.332 - -
Tyr21 115.357 9.057 115.659 8.997 - -
Phe22 119.361 9.709 119.593 9.677 - -
Tyr23 123.151 9.708 - - - -
Asn24 127.715 8.089 127.754 8.081 - -
Ala25 127.026 8.576 127.210 8.494 - -
Lys26 117.525 8.023 117.469 7.964 - -
Ala27 118.636 7.012 118.729 6.974 - -
Gly28 107.703 8.232 107.669 8.194 107.626 8.152
Leu29 115.073 6.991 115.118 6.963 - -
Cys30a 119.165 8.919 119.303 8.827 - -
Cys30b - - 119.023 8.755 119.088 8.625
Gln31 122.550 9.024 122.732 8.988 - -
Thr32 110.296 8.289 110.347 8.214 - -
Phe33 118.844 8.641 118.816 8.569 118.781 8.480
Val34 120.659 8.506 120.734 8.408 - -
Tyr35 129.100 8.761 - - - -
Gly36 109.058 8.367 109.026 8.296 - -
Gly37 114.758 8.312 114.355 8.256 - -
Ser38 115.701 8.366 115.689 8.277 - -
Arg39 121.096 8.366 121.134 8.278 121.211 8.184
Ala40 123.874 8.215 123.861 8.118 123.757 8.037
Lys41 123.878 8.922 123.669 8.806 - -
Arg42 120.224 8.113 - - - -
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Asn43 119.841 8.657 119.658 8.555 - -
Asn44 117.769 7.963 119.346 7.946 119.428 7.891
Phe45 117.061 9.293 123.415 8.745 123.424 8.658
Lys46 120.163 9.946 - - - -
Ser47 109.444 7.499 - - - -
Ala48 125.362 8.318 125.543 8.278 - -
Glu49 117.595 8.743 117.778 8.698 - -
Asp50 119.813 7.913 119.684 7.845 - -
Cys51 118.549 7.100 118.506 7.068 - -
Met52 121.269 8.658 121.159 8.589 - -
Arg53 120.040 7.974 119.927 7.956 120.034 7.957
Thr54 111.834 7.559 112.119 7.521 111.908 7.442
Ser55 115.480 7.755 115.676 7.722 - -
Gly56 108.128 7.915 108.222 7.875 - -
Gly57 108.633 8.123 108.742 8.064 - -
Ala58a 128.862 7.941 128.994 7.856 129.151 7.785
Ala58b 129.062 8.038 129.157 7.937 129.285 7.832
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APPENDIX D – HSQC ASSIGNED PEAK HEIGHTS FROM
HYDROGEN DEUTERIUM EXCHANGE
Summary of peaks assigned in 15N-1H HSQC spectra of wild type BPTI and (30-
51, 5-14) BPTI intermediate in NMR buffer using solvents of 90% H2O, 100%
D2O after 5 min and 100% D2O buffer after 24 hours. Data show the height of
each assigned peak, after normalisation to account for the signal-to-noise ratio
of each spectrum.
Height of Assigned Peaks (Normalised)
Wild Type (30-51,5-14) Intermediate
Amino
Acid
Secondary
Structure
Disulfides
90% H2O
Buffer
D2O After
5 min
D2O After
24 hours
90% H2O
Buffer
D2O After
5 min
D2O After
24 hours
Arg1 coil
Pro2 coil
Asp3 coil 16.683
Phe4 310 helix 19.093 0.586
Cys5 310 helix 5-55 10.837 6.804
Leu6 310 helix 10.779 9.456 0.966
Glu7 coil 11.808 7.822 7.063
Pro8 coil
Pro9 coil
Tyr10 coil 4.159 2.907
Thr11 coil 8.739
Gly12 coil 8.030 2.029 0.297
Pro13 coil
Cys14 coil 14-38 3.436 2.899
Lys15 coil 5.117 5.039
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Ala16 coil 11.776 8.020 2.872 0.499
Arg17 coil 12.418 11.811 0.553 0.089
Ile18 β-strand 7.847 7.053 5.041 11.482 0.263 0.594
Ile19 β-strand 11.448 0.419 3.052
Arg20 β-strand 7.169 5.493 4.721 5.156 -0.042
Tyr21 β-strand 5.721 3.343 2.756 2.611
Phe22 β-strand 6.262 4.085 4.167 3.676 0.008 0.163
Tyr23 β-strand 5.333 3.291 2.832 3.712
Asn24 β-strand 6.904 4.674 4.257 3.896
Ala25 β-turn 11.551 4.936
Lys26 β-turn 11.687 9.280
Ala27 β-turn 14.251 0.161 9.535 0.776 0.641
Gly28 β-turn 11.264 5.701 10.654 0.607 -0.070
Leu29 β-strand 17.494 13.417 13.762 9.104 0.181
Cys30 β-strand 30-51 9.574 9.388
Gln31 β-strand 6.580 4.101 4.201 4.152
Thr32 β-strand 13.012 1.694 8.638
Phe33 β-strand 9.338 5.727 6.499 2.483
Val34 β-strand 8.930 1.270 4.413
Tyr35 β-strand 6.286 3.411 4.021 2.686 0.079
Gly36 coil 5.865 3.889 3.660 6.424 0.855 0.456
Gly37 coil 2.998
Cys38 coil 14-38 7.807 7.066
Arg39 coil 7.693 4.367 0.382
Ala40 coil 15.024 21.096 1.096 0.930
Lys41 coil 4.317 4.576 0.754 2.342
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Arg42 coil 6.373 7.275 0.544 0.262
Asn43 coil 7.441 0.133 4.272 0.175
Asn44 coil 7.866 5.141 5.325 3.309
Phe45 β-strand 4.877 2.471 3.025 0.776
Lys46 coil 9.938 2.780
Ser47 coil 10.382 4.622 0.104
Ala48 α-helix 14.787 0.750 7.990 0.097 0.078
Glu49 α-helix 17.460 9.939 0.381
Asp50 α-helix 11.536 8.479
Cys51 α-helix 30-51 9.164 6.326 4.474 3.226 0.137 -0.013
Met52 α-helix 9.138 6.297 2.629 5.840
Arg53 α-helix 13.612 8.373 3.031 10.894 0.344
Thr54 α-helix 9.907 6.816 5.262 0.430
Cys55 α-helix 5-55 7.270 4.175 2.937 8.333
Gly56 coil 6.933 4.738 10.693 0.607 0.083
Gly57 coil 15.140 21.087 1.569 0.683
Ala58 coil 28.425 59.920 5.323 1.248
Total Peaks Identified 52 34 20 45 24 13
% of Total Amino Acids 89.7 58.6 34.5 77.6 41.4 22.4
% of Amino Acids in H2O Buffer 100.0 65.4 38.5 100.0 53.3 28.9
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APPENDIX E – CHEMICAL SHIFT RESONANCES FOR
HSQC SPECTRA OF BPTI CONSTRUCTS WITH PDI
TITRATIONS
Chemical shift data (in ppm) are given for 15N-1H HSQC assignments of both
wild type and (30-51, 5-14) BPTI partly-folded intermediate with various molar
equivalent concentrations of PDI.
Wild Type BPTI:PDI
1:1 Ratio
Amino Acid N NH
Asp3 123.725 8.758
Gly57 109.616 8.464
Ala58 128.692 8.027
(30-51, 5-14) BPTI:PDI
50:1 Ratio 10:1 Ratio
Amino Acid N NH N NH
Gly12 110.754 8.590 110.796 8.611
Lys15 120.089 8.163
Ala16 125.259 8.520
Arg17 121.049 8.457 121.187 8.444
Ile18 119.878 8.223 119.874 8.228
Ile19 126.875 8.465
Arg20 126.710 8.375
Tyr21 115.346 9.067
Phe22 119.387 9.711
Tyr23 123.170 9.707
Asn24 127.800 8.094
Ala25 127.044 8.579 126.994 8.578
Lys26 117.455 8.020 117.478 8.025
Ala27 118.661 7.010 118.782 7.017
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Gly28 107.651 8.231 107.661 8.242
Leu29 115.041 6.986
Cys30 119.110 8.921
Gln31 122.562 9.028
Thr32 110.282 8.295
Phe33 118.840 8.648
Val34 120.644 8.503 121.109 8.489
Gly36 109.042 8.368 109.072 8.374
Gly37 114.741 8.320 114.529 8.367
Ser38 115.638 8.362 115.645 8.368
Arg39 121.144 8.361 121.073 8.370
Ala40 123.864 8.215 123.767 8.223
Lys41 123.874 8.922
Arg42 120.181 8.120 120.182 8.131
Asn43 119.828 8.665 119.877 8.670
Asn44 119.244 7.988
Phe45 123.409 8.820 123.436 8.822
Lys46 120.151 9.940
Ser47 109.454 7.498
Ala48 125.333 8.320
Glu49 117.576 8.747 117.626 8.751
Asp50 119.789 7.915
Cys51 118.637 7.097
Met52 121.233 8.657 121.172 8.646
Arg53 120.048 7.965 120.035 7.980
Thr54 111.829 7.554 111.847 7.562
Ser55 115.479 7.761 115.559 7.759
Gly56 108.098 7.917 108.125 7.914
Gly57 108.630 8.124 108.644 8.127
Ala58a 128.852 7.940 128.856 7.941
Ala58b 129.085 8.040 129.079 8.043
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APPENDIX F – HSQC ASSIGNED PEAK HEIGHTS FROM
BPTI WITH PDI TITRATIONS
Summary of peaks assigned in 15N-1H HSQC spectra of wild type BPTI and (30-
51, 5-14) BPTI intermediate with and without the addition of PDI. Data show the
height of each assigned peak, after normalisation to account for the signal-to-
noise ratio of each spectrum.
Height of Assigned Peaks (Normalised)
Wild Type
(30-51,5-14)
Intermediate
Amino
Acid
Secondary
Structure Disulfides
Without
PDI
BPTI:PDI
10:1
Without
PDI
BPTI:PDI
10:1
Arg1 coil
Pro2 coil
Asp3 coil 18.770 9.432
Phe4 310 helix 21.362 12.243
Cys5 310 helix 5-55 12.874 6.177
Leu6 310 helix 12.824 7.910
Glu7 coil 12.417 6.874
Pro8 coil
Pro9 coil
Tyr10 coil 5.000 1.017
Thr11 coil 10.217 4.922
Gly12 coil 9.548 4.740 3.206 1.463
Pro13 coil
Cys14 coil 14-38 4.056 1.747
Lys15 coil 6.117 1.192 8.033
Ala16 coil 13.774 6.095 4.600
Arg17 coil 14.484 8.097 5.998 0.759
Ile18 β-strand 9.331 4.621 18.074 1.371
Ile19 β-strand 12.973 6.080 4.028
Arg20 β-strand 8.434 3.330 7.608
Tyr21 β-strand 6.919 2.883 3.850
Phe22 β-strand 6.873 3.857 6.718
Tyr23 β-strand 6.026 2.843 5.268
Asn24 β-strand 8.293 4.278 6.555
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Ala25 β-turn 12.226 6.354 6.929 0.933
Lys26 β-turn 13.468 7.618 9.793 1.512
Ala27 β-turn 16.550 9.214 13.737 0.499
Gly28 β-turn 12.654 7.610 16.365 1.082
Leu29 β-strand 19.471 11.117 13.253
Cys30 β-strand 30-51 11.336 7.118 13.200
Gln31 β-strand 7.202 4.026 6.454
Thr32 β-strand 15.114 8.236 11.661
Phe33 β-strand 10.362 5.060 4.959
Val34 β-strand 10.878 5.134 6.842 1.102
Tyr35 β-strand 7.264 2.939 5.217
Gly36 coil 7.003 3.154 7.686 3.877
Gly37 coil 5.623 0.813
Cys38 coil 14-38 8.246 2.856 11.791 0.968
Arg39 coil 8.541 3.580 7.249 0.979
Ala40 coil 17.537 7.206 30.115 1.952
Lys41 coil 5.082 2.039 3.461
Arg42 coil 8.135 2.945 12.428 0.769
Asn43 coil 8.693 4.398 8.396 0.672
Asn44 coil 9.292 5.370 5.228
Phe45 β-strand 5.449 2.795 5.237 0.632
Lys46 coil 11.491 5.329 4.708
Ser47 coil 11.664 7.192 5.439
Ala48 α-helix 16.993 8.084 12.505
Glu49 α-helix 19.847 10.579 14.826 0.969
Asp50 α-helix 13.676 6.572 13.072
Cys51 α-helix 30-51 10.920 6.073 6.249
Met52 α-helix 10.719 5.558 8.142 0.744
Arg53 α-helix 15.673 8.255 14.210 0.523
Thr54 α-helix 11.057 6.566 8.669 0.432
Cys55 α-helix 5-55 8.422 4.485 11.531 1.241
Gly56 coil 7.885 4.212 15.558 1.860
Gly57 coil 16.643 11.380 33.376 10.420
Ala58 coil 31.721 25.726 70.255 31.454
Total Peaks Identified: 52 52 45 24
% of Total Amino Acids: 89.7 89.7 77.6 41.4
% of Amino Acids in Sample without PDI: 100.0 100.0 100.0 53.3
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APPENDIX G – SURFACE PLASMON RESONANCE
CURVE FITTING FOR PDI/BPTI INTERACTIONS
Analysis data from surface plasmon resonance of various BPTI constructs
binding to immobilised proteins after curve fitting using 1:1 (Langmuir) binding
model. Kinetic data was fitted simultaneously to association and dissociation
phases of the sensorgram data using BIAevaluation analysis software (Biacore).
Reduced BPTI at 5°C
Immobilised Protein
FL PDI bb'x Ovalbumin
Replicate
ka (1/Ms)1st 1830 1870 754
2nd 1830 1910 715
Average 1830 1890 734.5
kd (1/s) 1st 5.94E-03 5.95E-03 4.58E-03
2nd 6.01E-03 6.16E-03 4.77E-03
Average 5.98E-03 6.06E-03 4.68E-03
KD (M) 1st 3.24E-06 3.17E-06 6.07E-06
2nd 3.29E-06 3.22E-06 6.67E-06
Average 3.27E-06 3.20E-06 6.37E-06
Standard Deviation 3.54E-08 3.54E-08 4.24E-07
Standard Error 2.50E-08 2.50E-08 3.00E-07
Chi2 1st 15300 3670 10300
2nd 11800 2350 9280
Average 13550 3010 9790
Rmax 1st 2520 1240 2760
2nd 2370 1160 2830
286
(30-51, 5-14) BPTI at 5°C
Immobilised Protein
FL PDI bb'x Ovalbumin
Replicate
ka (1/Ms)1st 336 492 126
2nd 354 431 305
Average 345 461.5 215.5
kd (1/s) 1st 4.57E-03 6.40E-03 7.03E-03
2nd 5.11E-03 6.89E-03 6.95E-03
Average 4.84E-03 6.65E-03 6.99E-03
KD (M) 1st 1.36E-05 1.30E-05 5.57E-05
2nd 1.44E-05 1.60E-05 2.28E-05
Average 1.40E-05 1.45E-05 3.93E-05
Standard Deviation 5.66E-07 2.12E-06 2.33E-05
Standard Error 4.00E-07 1.50E-06 1.65E-05
Chi2 1st 10700 2250 3130
2nd 6030 1320 1300
Average 8365 1785 2215
Rmax 1st 3910 1420 4920
2nd 3620 1540 2100
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Wild Type BPTI at 5°C
Immobilised Protein
FL PDI bb'x Ovalbumin
Replicate
ka (1/Ms)1st 21 88.4 42.8
2nd 6.09 23.6 8.87
Average 13.545 56 25.835
kd (1/s) 1st 8.29E-03 8.95E-03 9.15E-03
2nd 8.97E-03 9.91E-03 1.02E-02
Average 8.63E-03 9.43E-03 9.68E-03
KD (M) 1st 3.94E-04 1.01E-04 2.14E-04
2nd 1.47E-03 4.20E-04 1.15E-03
Average 9.32E-04 2.61E-04 6.82E-04
Standard Deviation 7.61E-04 2.26E-04 6.62E-04
Standard Error 5.38E-04 1.60E-04 4.68E-04
Chi2 1st 5660 1760 1650
2nd 3210 939 813
Average 4435 1349.5 1231.5
Rmax 1st 27700 3850 8140
2nd 90800 13800 37700
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Reduced BPTI at 25°C
Immobilised Protein
FL PDI bb'x Ovalbumin
Replicate
ka (1/Ms)1st 1630 2090 1260
2nd 1690 2210 1260
Average 1660 2150 1260
kd (1/s) 1st 4.89E-03 3.98E-03 2.39E-03
2nd 5.07E-03 4.20E-03 2.43E-03
Average 4.98E-03 4.09E-03 2.41E-03
KD (M) 1st 3.00E-06 1.90E-06 1.90E-06
2nd 3.00E-06 1.90E-06 1.93E-06
Average 3.00E-06 1.90E-06 1.92E-06
Standard Deviation 0.00E+00 0.00E+00 2.12E-08
Standard Error 0.00E+00 0.00E+00 1.50E-08
Chi2 1st 13700 2260 14900
2nd 11800 1670 13600
Average 12750 1965 14250
Rmax 1st 2590 1170 2220
2nd 2430 1070 2180
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(30-51, 5-14) BPTI at 25°C
Immobilised Protein
FL PDI bb'x Ovalbumin
Replicate
ka (1/Ms)1st 615 692 7.36
2nd 757 745 22.9
Average 686 718.5 15.13
kd (1/s) 1st 2.87E-03 4.69E-03 5.74E-03
2nd 3.08E-03 4.71E-03 5.86E-03
Average 2.98E-03 4.70E-03 5.80E-03
KD (M) 1st 4.67E-06 6.78E-06 7.79E-04
2nd 4.08E-06 6.33E-06 2.57E-04
Average 4.38E-06 6.56E-06 5.18E-04
Standard Deviation 4.17E-07 3.18E-07 3.69E-04
Standard Error 2.95E-07 2.25E-07 2.61E-04
Chi2 1st 14400 2160 5840
2nd 7270 1380 4620
Average 10835 1770 5230
Rmax 1st 3120 1070 71700
2nd 2340 940 22100
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Wild Type BPTI at 25°C
Immobilised Protein
FL PDI bb'x Ovalbumin
Replicate
ka (1/Ms) 1st 1.13 94.4 9.66
2nd 36.7 142 2.05
Average 18.915 118.2 5.855
kd (1/s) 1st 6.40E-03 8.48E-03 7.66E-03
2nd 6.17E-03 8.44E-03 8.29E-03
Average 6.29E-03 8.46E-03 7.98E-03
KD (M) 1st 5.66E-03 8.98E-05 7.93E-04
2nd 1.68E-04 5.96E-05 4.05E-03
Average 2.91E-03 7.47E-05 2.42E-03
Standard Deviation 3.88E-03 2.14E-05 2.30E-03
Standard Error 2.75E-03 1.51E-05 1.63E-03
Chi2 1st 4050 990 2930
2nd 3460 861 2630
Average 3755 925.5 2780
Rmax 1st 358000 2690 37600
2nd 10400 1740 184000
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Reduced BPTI at 36°C
Immobilised Protein
FL PDI bb'x Ovalbumin
Replicate
ka (1/Ms) 1st 2150 1790 2110
2nd 2040 1750 1840
Average 2095 1770 1975
kd (1/s) 1st 3.27E-03 3.35E-03 1.99E-03
2nd 3.81E-03 3.87E-03 2.59E-03
Average 3.54E-03 3.61E-03 2.29E-03
KD (M) 1st 1.52E-06 1.88E-06 9.47E-07
2nd 1.87E-06 2.21E-06 1.41E-06
Average 1.70E-06 2.05E-06 1.18E-06
Standard Deviation 2.47E-07 2.33E-07 3.27E-07
Standard Error 1.75E-07 1.65E-07 2.32E-07
Chi2 1st 8950 2250 10900
2nd 7580 1880 7200
Average 8265 2065 9050
Rmax 1st 1700 955 1180
2nd 1830 1010 1320
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(30-51, 5-14) BPTI at 36°C
Immobilised Protein
FL PDI bb'x Ovalbumin
Replicate
ka (1/Ms) 1st 420 438 1.82
2nd 590 564 3.43
Average 505 501 2.625
kd (1/s) 1st 2.40E-03 2.79E-03 3.44E-03
2nd 2.40E-03 2.83E-03 3.70E-03
Average 2.40E-03 2.81E-03 3.57E-03
KD (M) 1st 5.72E-06 6.37E-06 1.89E-03
2nd 4.07E-06 5.02E-06 1.08E-03
Average 4.90E-06 5.70E-06 1.49E-03
Standard Deviation 1.17E-06 9.55E-07 5.73E-04
Standard Error 8.25E-07 6.75E-07 4.05E-04
Chi2 1st 16500 4690 8740
2nd 10000 2970 2260
Average 13250 3830 5500
Rmax 1st 4400 2140 262000
2nd 3130 1630 116000
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Wild Type BPTI at 36°C
Immobilised Protein
FL PDI bb'x Ovalbumin
Replicate
ka (1/Ms) 1st 216 371 2.6
2nd 357 441 1.77
Average 286.5 406 2.185
kd (1/s) 1st 4.06E-03 4.12E-03 5.27E-03
2nd 4.13E-03 4.62E-03 5.39E-03
Average 4.10E-03 4.37E-03 5.33E-03
KD (M) 1st 1.88E-05 1.11E-05 2.02E-03
2nd 1.16E-05 1.05E-05 3.05E-03
Average 1.52E-05 1.08E-05 2.54E-03
Standard Deviation 5.09E-06 4.24E-07 7.28E-04
Standard Error 3.60E-06 3.00E-07 5.15E-04
Chi2 1st 16500 3690 4900
2nd 7800 2180 3980
Average 12150 2935 4440
Rmax 1st 4890 1770 146000
2nd 3050 1470 222000
